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ABSTRACT 
Background. In Finland, the incidence of type 1 diabetes mellitus (T1DM) is the highest in the 
world, and it continues to increase steadily. No effective preventative interventions exist either 
for individuals at high risk or for the population as a whole. In addition to problems with daily 
lifelong insulin replacement therapy, T1DM patients with long-lasting disease suffer from 
various diabetes related complications. The complications can lead to severe impairments and 
reductions in functional capacity and quality of life and in the worst case they can be fatal.  
Longitudinal studies on the costs of T1DM are extremely rare, especially in Finland. Typically, 
in these studies, distinctions between the various types of diabetes have not been made, and costs 
have not been calculated separately for the sexes.  
Aims. The aim of this study was to describe inpatient hospital care and costs of inpatient care in 
a cohort of 5,166 T1DM patients by sex during 1973-1998 in Finland. Inpatient care and costs of 
care due to T1DM without complications, due to T1DM with complications and due to other 
causes were calculated separately.  
Material and Methods. The study population consisted of all Finnish T1DM patients diagnosed 
before the age of 18 years between January 1st in 1965 and December 31st in 1979 and derived 
from the Finnish population–based T1DM register (N=5,120 in 1979 and N=4,701 in 1997). 
Data on hospitalisations were obtained from the Finnish Hospital Discharge Register.  
Results. In the early stages of T1DM, the majority of the use of inpatient care was due to the 
treatment of T1DM without complications. There were enormous increases in the use of 
inpatient care for certain complications when T1DM lasted longer (from 9.5 years to 16.5 years). 
For women, the yearly number of bed-days for renal complications increased 4.8-fold, for 
peripheral vascular disease 4.3-fold and for ophthalmic complications 2.5-fold. For men, the 
corresponding increases were as follows: 5-fold, 6.9-fold and 2.5-fold. The yearly bed-days for 
glaucoma increased 8-fold, nephropathy 7-fold and microangiopathy 6-fold in the total 
population. During these 7 years, the yearly numbers of bed-days for T1DM without 
complications dropped dramatically.  
 
  
 
 
The length of stay in inpatient care decreased notably, but hospital visits became more frequent 
when the length of duration of T1DM increased from 9.5 years to 16.5 years.  
The costs of treatments due to complications increased when T1DM lasted longer. Costs due to 
inpatient care of complications in the cohort 2.5-folded as duration of T1DM increased from 9.5 
years to 16.5 years, while the total costs of inpatient care in the cohort dropped by 22% due to an 
80% decrease in the costs of care of T1DM without complications. 
Treating complications of female patients was more expensive than treating complications of 
men when T1DM had lasted 9.5 years; the mean annual costs for inpatient care of a female 
diabetic (any cause) were 1,642 €, and the yearly costs of care of complications were 237 €. The 
corresponding yearly mean costs for a male patient were 1,198 € and 167 €. Treating 
complications of female patients was more expensive than that of male patients also when the 
duration of diabetes was 16.5 years, although the difference in average annual costs between 
sexes was somewhat smaller. 
Total annual inpatient costs (any cause) in the cohort were 7,163,989 € when T1DM had lasted 
9.5 years and 5,555,855 €, when T1DM had lasted 16.5 years.  
Conclusions. In the early phases of T1DM, the treatment of T1DM without complications 
causes a considerable amount of hospital bed-days. The use of inpatient care due to 
complications of T1DM strongly increases with ageing of patients. The economic burden of 
inpatient care of T1DM is substantial.  
Keywords: T1DM, Diabetes, Hospital use, Inpatient use, Inpatient costs, Finland  
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TIIVISTELMÄ 
Tausta. Tyypin 1 diabetes mellituksen (T1DM) esiintyminen on Suomessa maailman suurin 
kasvaen jatkuvasti. Kasvu on ollut tasaista, eikä tehokkaita ehkäisyohjelmia ole näköpiirissä 
korkean riskin yksilöille tai väestöille. Päivittäisen, elinikäisen insuliinikäytön lisäksi ongelmia 
ja kärsimystä aiheutuu potilaille taudin edetessä diabetekseen liittyvistä erilaisista 
komplikaatioista. Komplikaatiot voivat johtaa vakaviin toimintakyvyn puutteisiin ja 
elämänlaadun heikkenemiseen, ja ne voivat muodostua kohtalokkaiksi. 
T1DM:n kustannuksiin liittyvät pitkittäistutkimukset ovat varsinkin Suomessa erittäin 
harvinaisia. Yleensä näissä tutkimuksissa ei ole erotettu diabeteksen eri tyyppejä, eikä 
kustannuksia ole laskettu erikseen sukupuolille. 
Tavoitteet. Tämän tutkimuksen tavoitteena oli kuvata sairaalakäyttöä ja -kustannuksia 5,166:n 
T1DM-potilaan kohortissa sukupuolittain Suomessa vuosina 1973–1998. T1DM:n hoidon 
sairaalakäyttö ja -kustannukset ilman taudin komplikaatioita ja komplikaatioista sekä muista 
syistä kuin T1DM:stä johtuva sairaalakäyttö kustannuksineen laskettiin erikseen. 
Aineisto ja menetelmät. Aineisto muodostettiin kaikista alle 18-vuotiaista suomalaisista T1DM-
potilaista, jotka oli diagnosoitu välillä 1.1.1965-31.12.1979 ja jotka saatiin suomalaisesta 
väestöpohjaisesta T1DM-rekisteristä (N=5,120 1979, N=4,701 1997). Tiedot sairaalakäytöstä 
saatiin hoitoilmoitusrekisteristä.  
Tulokset. T1DM:n keston alkuvaiheissa suurin osa sairaalakäytöstä johtui T1DM:n hoidosta, 
johon ei liittynyt komplikaatioita. T1DM:n keston pidentyessä (9.5:stä vuodesta 16.5:een) 
eräiden komplikaatioiden sairaalahoito kasvoi voimakkaasti. Naisilla vuosittaisten hoitopäivien 
määrä johtuen munuaiskomplikaatioista kasvoi 4.8-kertaiseksi, ääreisverenkierron 
komplikaatioiden määrä 4.3-kertaiseksi ja silmäkomplikaatioiden määrä 2.5-kertaiseksi. Miehillä 
vastaavat hoitopäivät em. komplikaatioille kasvoivat 5-, 6.9-, ja 2.5-kertaisiksi. Viherkaihin 
hoitopäivien määrä kasvoi 8-kertaiseksi, nefropatian 7-kertaiseksi ja mikroangiopatian 6-
kertaiseksi koko tutkimusväestössä. Kyseisenä ajanjaksona (7 vuotta) vuosittaisten hoitopäivien 
määrä liittyen T1DM:ään ilman komplikaatioita putosi dramaattisesti. 
 
  
 
 
T1DM:n keston pidentyessä 9.5:stä vuodesta 16.5:een vuoteen keskimääräinen hoitoaika lyheni 
selvästi, kun taas potilaat olivat sairaalahoidossa aikaisempaa tiheämmin. 
Komplikaatioiden hoidon kustannukset kasvoivat T1DM:n keston pidentyessä. 
Komplikaatioiden sairaalahoidon kustannukset kasvoivat kohortissa 2.5-kertaisiksi, kun taas 
hoidon kokonaiskustannukset vähenivät 22%, sillä hoitokustannukset liittyen T1DM:ään ilman 
komplikaatioita vähenivät 80% T1DM:n keston pidentyessä 9.5:stä vuodesta 16.5:een vuoteen. 
Naisten komplikaatioiden hoitaminen oli kalliimpaa kuin miesten. T1DM:n keston ollessa 9.5 
vuotta, keskimääräinen naisdiabeetikon sairaalahoitokustannus vuodessa oli 1,642 € ja 
komplikaatioiden keskimääräinen hoito maksoi 237 €. Vastaavasti, miesten hoito vuodessa 
maksoi 1,198 € ja 167 €. T1DM:n keston ollessa 16.5 vuotta, naisten komplikaatioiden 
hoitokustannukset olivat yhä miehiä suuremmat, mutta ero miehiin keskimääräisissä 
vuosikustannuksissa pieneni. 
Vuosittaiset kokonaissairaalahoitokustannukset kohortissa olivat 7 163 989 € (T1DM:n kesto 9.5 
vuotta) ja 5 555 855 € (T1DM:n kesto 16.5 vuotta).  
Johtopäätökset. T1DM:n hoito ennen komplikaatioiden puhkeamista aiheuttaa huomattavasti 
sairaalahoitopäiviä. Potilaiden ikääntyessä komplikaatioiden sairaalahoidon määrä kasvaa 
voimakkaasti. T1DM:n sairaalahoito aiheuttaa huomattavia taloudellisia kustannuksia.  
Asiasanat: T1DM, diabetes, sairaalakäyttö, sairaalakustannukset, Suomi 
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1. INTRODUCTION  
Hippocratic oath: 
primum, non nocere 
(first, do no harm)  
According to the WHO (1985) definition, diabetes mellitus (DM) is chronic, systemic disease, 
characterised by chronic elevation of blood glucose concentration (hyperglycaemia), which 
results from deficient production or action of insulin, a hormone controlling glucose, fat and 
amino acid metabolism.  
DM and allied categories of glucose intolerance have been classified as insulin-dependent 
diabetes mellitus (IDDM, type 1), non-insulin-dependent diabetes mellitus (NIDDM, type 2), 
malnutrition-related diabetes mellitus (MRDM), impaired glucose tolerance (IGT) and 
gestational diabetes mellitus (GDM), in which glucose intolerance is first detected during 
pregnancy (WHO 1985). In this study, T1DM is used as an abbreviation for type 1 diabetes (and 
similarly, T2DM for type 2 diabetes).  
T1DM is caused by immune-mediated destruction of islet insulin-secreting beta cells. This 
process is associated with both cellular and humoral immune changes in the peripheral blood that 
can be detected before the onset of clinical diabetes. Metabolic changes, altered glucose 
tolerance and reduced insulin secretion deteriorate and result in clinical diabetes (Pozzilli and Di 
Mario 2001). Beta cells of the islets of Langerhans in the pancreas produce insulin, and in 
T1DM, at the time of first acute clinical presentation, probably 85-90% of these cells have been 
destroyed (WHO 1985). Genetic susceptibility is necessary for the development of T1DM 
(Hyttinen et al 2003), and the global variance in incidence suggests that environmental factors 
are also important in the etiology, but little is known about these factors (Karvonen et al 2000). 
According to a Finnish study, for instance early exposure to cow’s milk formula-feeding and 
rapid growth in infancy are independent risk factors of childhood T1DM (Hyppönen et al 1999), 
but these results have not been unequivocally re-confirmed. 
T2DM is a metabolic disorder, mainly caused by resistance or deficiency of insulin (Kangas 
2002). T2DM is characterised by diagnosis in the age of >30 years and does not necessarily 
require treatment with insulin. It accounts for up to 95% of diagnosed diabetes and has 
modifiable risk factors, e.g. obesity and physical inactivity (Hodgson and Cohen 1999). One-
third of people with T2DM are unaware of their disease (American Diabetes Association 2003a). 
According to Jönsson (1998), only about 50% of T2DM has been diagnosed. 
12
  
 
 
Yet, another type of diabetes, LADA (latent or late-onset autoimmune diabetes of adulthood or 
type 1.5 diabetes), has also been proposed. It is a slowly progressive form of autoimmune 
diabetes of adults characterized by the presence of beta-cell specific antibodies and does not 
require insulin treatment during the early phase of the disease. Clinically, patients appear to be 
affected by T2DM, but may have the same disease process as T1DM patients (Pozzilli and Di 
Mario 2001). LADA represents 5-10% of all diabetic patients (Schernthaner et al 2001).  
Diabetes is a major cause of premature mortality, morbidity and reduced quality of life. It may 
result in long-term micro- and macrovascular complications, such as retinopathy, nephropathy, 
cardiac and cerebrovascular disease and peripheral vascular disease with neuropathy (Currie et al 
1996), which are manifested e.g. as impaired vision, hypertension, coronary artery disease, renal 
disorder, stroke, neurological disturbances, lower limb ulceration and gangrene. In USA., 
diabetes is the leading cause of blindness, end-stage renal disease (ESRD) and lower extremity 
amputations (Harris 1998). The probability of developing these complications is related to the 
duration of diabetes and the degree of metabolic control (Currie et al 1996). Diabetic 
ketoacidosis (DKA) and severe hypoglycaemia are acute complications, that may be life-
threatening (Rewers et al 2002). Diabetes is also associated with an increased risk of mental 
problems, e.g. depression (Karlson and Agardh 1997; Peyrot and Rubin 1997). The extent to 
which diabetes increases the risk of general medical conditions other than acute glycaemic and 
chronic complications of diabetes is unknown (Ray et al 1996).  
Mortality rates of male T1DM patients are 5-7 times higher and of female patients 9-12 times 
than those of the general population in the US. Life expectancy for persons with T1DM is 
reduced by about 15 years; 15% of patients will die by the age of 40 years (National Diabetes 
Data Group 1995). In Finland, the relative mortality of patients with T1DM 20-25 years after 
diagnosis was 8.9-fold for women and 4.7-fold for men compared with the general population  
based on the same cohort than the present study (Lounamaa 1993).  
Diabetes is thus a disease with major long-term implications, not only for the health and well-
being of affected individuals, but also for the costs to national health services (Leese 1992) and 
society at large. The long-term effects of diabetes are substantial in terms of limited health care 
resources consumed, and loss of production, life-years and quality of life. The management of 
diabetes aiming at preventing and treating acute and late complications requires the use of 
diverse health care resources (Gerard et al 1989). Diabetes generates direct costs to the health 
care system, individuals and society at large (e.g. hospitalisation, drugs), indirect costs due to 
13
  
 
 
loss of productivity (short-term illness, early retirement, death before retirement) and 
psychosocial costs (pain, loss of quality of life) (Leese 1995).  
The challenges imposed by diabetes on Western societies will probably be aggravated over the 
next few decades, as the number of people with diabetes is expected to rise dramatically. In 1997 
the number of affected individuals was 124 million worldwide, and this figure is predicted to 
increase to 221 million by 2010 (Amos et al 1997). By 2025, the number of adults (over 20 years 
of age) with diabetes is estimated to rise to 300 million (WHO 1997). In USA, the annual cost of 
diabetes in 2002 dollars may rise to 192 billion by 2020 (American Diabetes Association 2003a). 
The situation will become particularly challenging in Finland. The incidence of T1DM in Finland is 
the highest in the world (Karvonen et al 1993), increasing most in the youngest age groups 
(Karvonen et al 1999). This means that in the future the medical and financial burden will increase 
on Finnish society, on the health care sector and on persons with T1DM, as the number of patients 
with severe complications rises and complications emerge earlier. The need for and value of health 
economic information, especially longitudinal, will become increasingly emphasised. It is important 
for decision-makers to know about health care resources used and required for patients with T1DM 
when allocating funds and other resources within the health care sector and within society. The 
growing need to rationally allocate the limited health care resources poses emotional questions of 
science, politics, economics and ethics that patients and physicians must address (Vinicor 1998).  
T1DM is a serious nationwide disease in Finland, and it is crucial that the patient is willing to 
exercise self-management. If that fails, a need for institutional care is evident. T1DM starts at 
early age, and with good treatment the capacity to work will be maintained, but if the disease is 
untreated, the costs will be high. (Niskanen et al 2003).   
Inpatient hospital care is the major contributor to the health care costs of diabetes (Jönsson 1983; 
American Diabetes Association 1993b; Kangas et al 1996; American Diabetes Association 1998). 
Even a modest reduction in hospitalisations of people with diabetes could result in major savings of 
health care costs. If people at high risk for hospitalisation could be identified along with the risk factors 
amenable to manipulation, this burden could be reduced (Moss et al 1999). Hospitalisation data are 
therefore crucial in the effort to develop strategies for preventing admissions (Fishbein 1985).  
Although T1DM is considered one of the most important chronic diseases (Hart et al 1997), only 
a few studies have so far been conducted regarding hospital utilisation by T1DM patients with 
their numerous severe complications. Most of the studies are cross-sectional. The aim of this 
study was to assess the hospital resources used by a cohort of Finnish T1DM patients and 
associated costs, both cross-sectionally and longitudinally.  
14
  
 
 
2. REVIEW OF THE LITERATURE  
2.1. Epidemiology 
The range of global variation in the incidence of T1DM is large, and the incidence in Finland has 
been over 350-fold compared to that of, for example, China (Karvonen et al 2000, The Diamond 
project group 2006). 
The incidence of T1DM is increasing in Finland markedly (Tuomilehto et al 1999). In 1998, the 
incidence in Finland was 48.5 cases per 100,000 person-years, which was the highest annual 
incidence rate of childhood-onset T1DM in the world ever recorded (Podar et al 2001). T1DM 
has increased most in the youngest age groups, and the greatest increase (4.2% per year) 
occurred in children under 5 years (Karvonen et al 1999). The increase in incidence has been 
steady, during 1965-1992 at a rate of 2.8% per year (Tuomilehto et al 1995). Remarkable is, that 
after the beginning of the 1990s, the incidence of T1DM has grown even faster, going beyond 60 
per 100,000 person-years in 2005 (Harjutsalo 2007). 
A clear geographical variations among children have been shown in the incidence of T1DM in 
Finland. Living in rural areas increased the risk of T1DM (Rytkönen 2004). 
The global prevalence of diabetes ranges from almost 0% (New Guinea) to 50% (Indians of 
Arizona) (Disdier-Flores et al 2001). In Finland, at the end of 2005, the prevalence of diabetes 
has been estimated to be at least 4.5% of the population, about 240,000 patients, of which T1DM 
accounts for 45,000 patients (prevalence 0.9%) (Table 1). As about half of the T2DM persons 
are unaware of the disease (Peltonen et al 2006), the number of diabetic persons would surpass 
500,000 (Reunanen 2006). In USA the prevalence is 4.2% (American Diabetes Association 
2003a); in 1993, T1DM had affected around 700,000 persons (Libman et al 1993).  
Table 1. Number of persons with diabetes in Finland and prevalence (%) by age 
groups in 2005 (Reunanen 2006)  
 Age groups 
  0-29 30-64  65+ Total 
TYPE 1 10,000 21,000 14,000 45,000 
TYPE 2 1,500 83,000 109,000 193,500 
Type 2, diet-treated 500 29,000 38,000 67,500 
Type 2, drug-treated 1,000 54,000 71,000 126,000 
PREVALENCE (Total) 0.6 4.1 14.6 4.5 
TOTAL NUMBER OF PERSONS WITH DIABETES 11,500 104,000 123,000 238,500 
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2.2. Economics of diabetes 
As health care resources are scarce and limited, their efficient use is essential. Two basic 
approaches are available for addressing the economic aspects related to a disease: economic 
evaluations and cost of illness studies. 
Economic evaluations 
Economic evaluation considers resource costs and associated health outcomes (effectiveness) of 
certain interventions and compares them with alternative interventions to assess the relative 
efficiency of the interventions (McGuire 1996). Economic evaluation can be either partial or full. If 
there is no comparison with an alternative, the evaluation is partial and called description (of cost 
and/or outcome). An analysis is also partial if only costs (cost analysis) or outcome (efficacy or 
effectiveness evaluation) are compared with an alternative. In full economic evaluation, both costs 
and outcomes of alternatives are examined and compared. Full economic evaluation can be either 
cost-minimisation, cost-benefit, cost-effectiveness or cost-utility analysis (Drummond et al 1997).  
Cost-minimisation analysis may be used when the effectiveness of different interventions is the 
same. Cost-benefit analysis (CBA) values the decision options in monetary terms. CBA assigns 
monetary values to health effects by using two basic methods: human capital approach and 
willingness-to-pay (Petitti 2000). CBA is becoming less frequently used, since it is realised that 
health care aims at maximising health with the interventions rather than monetary benefits, and 
because of the controversy over the proper valuation methods of health effects in monetary terms.  
In cost-effectiveness analysis (CEA), the outcome is valued in non-monetary terms, e.g. years of 
lives saved or disability avoided. CEA addresses the issue of comparative cost per unit of 
outcome for the intervention when effectiveness of two or more interventions differs. An 
incremental cost-effectiveness ratio, defined as the difference in cost divided by the difference in 
effectiveness of two interventions, may need to be calculated to determine, which intervention is 
the more cost-effective (Petitti 2000). Indirect costs are often neglected in CEA studies (Ament 
and Evers 1993).  
Cost-utility analysis (CUA) uses quality-adjusted life-years (QALYs) gained as the effectiveness 
measure, which reflects societal or individual preferences for outcomes (Petitti 2000). CUA 
allow comparisons between interventions directed at different health conditions (Williams 2000). 
Quality of life can be measured by using e.g. a Finnish 15 D measure (Sintonen et al 1997) or 
various other measures (Nord 1999).  
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Another method developed to measure the burden of disease is the disability-adjusted life-years 
(DALYs) approach, which measure intangible costs associated with a certain disease, e.g. 
diabetes. It combines the number of healthy years lost as a result of early mortality with those 
lost due to disability (Jönsson 1998).  
Cost of illness studies 
Cost of illness (COI) studies depict the economic burden of an illness on society (Ament and 
Evers 1993). These are descriptive studies, that can be prevalence-, or incidence-based. These 
studies calculate the monetary value of resources used to prevent, detect and treat an illness 
(McGuire 1996). COI studies look at real resource costs rather than financial costs, so taxes and 
transfer payments should not be included (Tolpin and Bentkover 1983). COI studies consider the 
value of resources used for medical care (direct costs) and resources forgone due to reduction of 
productivity at paid work or unpaid housekeeping due to morbidity and mortality (indirect costs). 
Direct costs include expenditures for hospitalisation, outpatient care, nursing home care, services 
of primary physicians and specialists, dentists, drugs, rehabilitation, special devices needed (e.g. 
hearing aids, prostheses), research, training, construction, administrative functions, capital costs, 
costs of transportation and certain household expenditures (Hodgson 1983).  
Indirect costs are usually estimated by measuring the time lost from paid work or housekeeping 
and then valuing the time in different ways. Most frequently, the valuation is based on a human 
capital approach. In it, time lost from paid work is valued at wages or salaries, and time lost from 
housekeeping is valued by using shadow prices derived with market analogues.  
The human capital (HC) approach thus regards individuals as production factors whose output is 
valued as equal to each individual's market earnings (Songer et al 1998). Morbidity costs are 
calculated as the value of mean earnings the individual would have accrued without being 
affected by the disease. Mortality costs are calculated as the number of deaths due to a disease 
and the expected value of earnings by sex and age. The method considers life expectancy for age 
and sex groups, the changing pattern of earnings at successive ages, the varying labour force 
participation rates, the value for housekeeping services and the discount rate to calculate a stream 
of earnings to its present value (Rice 1994). The selection of discount rate may have a significant 
effect upon final costs so sensitivity analysis should be conducted using different discount rates. 
The methods of sensitivity analyses are described in more detail in the literature (Agro et al 
1997; Petitti 2000).  
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The other approach that has been used in COI calculations, willingness to pay (WTP), estimates 
the values individuals place on chances such as alteration in the probability of morbidity and/or 
mortality from a certain illness. WTP might be helpful in assessing the burden of psychosocial 
costs (Hodgson 1983), which are highly subjective, difficult to estimate, and usually omitted 
from COI studies (Pagano et al 1999). WTP has been used in relatively few COI studies: it 
generally gives considerably larger cost estimates than the HC approach and is more difficult and 
expensive to implement (Rice 1994; Songer et al 1998). According to Ament and Evers (1993), 
cost-benefit analysis with WTP techniques should be used more on a macro level to set 
priorities. One problem with the WTP method is that it is affected by a person's ability to pay 
(Sintonen et al 1997).  
The term cost used in COI analyses can be defined in several ways, depending on the purpose 
and perspective of analyses, yielding different results (Tolpin and Bentkover 1983).  
Possible perspectives include e.g. society, government, ministries, patient, employer, agency 
providing a programme, and third-party payer. Societal perspective is broadest and always 
relevant (Drummond et al 1997), but no single perspective is specifically recommended for COI 
studies on diabetes (Pagano et al 1999).  
There are two ways to conduct a COI study: 'top-down' or 'bottom-up' approaches (Table 2). The 
'top-down' approach is based on aggregate data on mortality, hospital admissions, general 
practitioner consultations, etc. The approach takes advantage of available national data, but may give 
a misleading picture if the incidence of a disease is changing or has changed. It relies on aggregate 
information, which is readily identifiable (Gray et al 1995). Entire health care expenditure is 
calculated, after which and the share attributable to diabetes is determined (Jönsson 1998).  
In the 'bottom-up' approach, data on disease incidence and prevalence are combined with 
information on the disease and treatment probabilities in order to estimate the annual incidence 
of a range of treatments and their costs (Gray et al 1995). 'Bottom-up' method permits a more 
comprehensive analysis of costs and allows more easily the relationship to the background 
characteristics of the population, such as sex and disease duration, and the costs of care, to be 
analysed (Jonsson et al 2000). Furthermore, international data on incidence can be utilised, and 
the method is more flexible, but complex to initiate (McGuire 1996). In the 'bottom-up' method, 
a subpopulation is first defined with a certain disease and all costs of illness are attached to it, 
then the costs of the subpopulation are extrapolated to the total population level. Since data are 
gathered from only a small population, cost extrapolation to a larger population may deviate 
notably from true costs (Jönsson 1998).  
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Table 2. Basic methods for calculating direct costs of a disease 
 
'Top-down' approach:     
*  Total expenditures for hospital care   x    Use of hospital services by specific diagnosis (dg) 
                                                                                  Total use of hospital services 
 
E.g. hospital costs for diabetes are multiple of the total expenditures for hospital care by the 
percentage of all hospital services by the diabetic population. 
 
'Bottom-up' approach: 
*  Average cost of hospital care by specific dg  x   Total use for hospital services by specific dg  
 
E.g. the costs of hospital care in diabetes are calculated by multiplying the average cost of a 
hospital stay per day by the total number of hospitalised days attributed to the diabetic 
population. 
 
Because of the problems with extrapolation, and the lack of risk of double counting, Jönsson and 
Henriksson prefer the 'top-down' method for assessing the economic impact of diabetes 
(Henriksson and Jönsson 1998; Jönsson 1998).  Pagano et al (1999), by contrast, recommend use 
of the 'bottom-up' method for costing of diabetes because of accuracy demands due to the high 
costs of the disease. That method also allows different cost items to be attributed to T1DM and 
T2DM separately (Henriksson and Jönsson 2000).  
In COI studies, the costs are assessed annually (prevalence-based) or during a lifetime 
(incidence-based). Prevalence-based costs can be determined by observing recent events, e.g. 
number of hospital admissions and average length of stay, and cost of a disease can be estimated 
by identifying the population and applying appropriate sampling and statistical techniques; it is 
not necessary to know how cost or the distribution of patients varies with time since the onset or 
stage of the disease (Hodgson 1994). Prevalence-based costs measure the direct and indirect 
economic burden incurred to society, usually during a year. The approach measures the value of 
resources used or lost irrespective of the time of disease onset (Rice 1994).  
COI studies based on incidence include cases of the disease developing for the first time in a 
certain year (Henriksson and Jönsson 1998). This method measures lifetime costs from onset 
until cure or death. Incidence-based costing requires knowledge of the natural history of the 
disease, the concomitant use of medical care and its cost each year from onset until cure or death 
and the probabilities of cure and survival at each stage (Hodgson 1994).  
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Incidence-based estimates of costs are considered by some researchers to be better suited for 
costing chronic diseases like diabetes (Hart et al 1997; Pagano et al 1999), while others favour 
the prevalence approach (Henriksson and Jönsson 1998). The incidence method is more 
appropriate if at a later stage one wishes to undertake an economic evaluation, such as CEA, to 
analyse different treatments (Rice 1994; Haddix et al 1996; Hart et al 1997); prevalence data are 
less appropriate for evaluating interventions, as it does not take into account the development of 
a disease and the influence of treatments (Ament and Evers 1993). Most COI studies have used 
the prevalence method, since the incidence method is more difficult to use (Hart et al 1997). The 
prevalence-based method is better if the results are used for cost control, as the method identifies 
the main components of expenditures and forgone resources and identifies possible targets for 
controlling expenses (Rice 1994).  
According to Tolpin and Benkover (1983), COI estimates may be used in (1) the evaluation of 
proposed research programmes; (2) the identification of cost-effective diagnostic and treatment 
modalities; (3) the formulation of public policy relating to health promotion, prevention, and 
safety regulation; and (4) the estimation of liability associated with the incidence of specific 
medical events. Costs of illness are also an important input to CBA (Hodgson 1983) and CEA 
analysis (Hodgson 1994).  
COI studies are used by policy-makers, governmental and non-governmental organizations, 
researchers and pharmaceutical companies. Especially governmental organizations use COI 
studies to aid in decision-making, in determining budgetary allocations, in prioritising research 
funding and in justifying funding for disease programmes (Songer et al 1998).  
It is questionable though whether all of these uses or suggested uses are appropriate if the 
purpose is to use resources efficiently, that is, cost-effectively. Resources should be allocated to 
the prevention and treatment of illnesses when efficient interventions exist for these purposes, 
not on the basis of the economic burden posed by the illnesses. When efficient interventions do 
not exist, allocating more resources adds to the burden.  
COI studies have received abundant criticism for a host of reasons. The human capital (HC) 
approach has several limitations: a merely financial valuation of labour discriminates against 
non-workers (e.g. children, the elderly); the value of life above economic productivity is ignored; 
in periods with high unemployment rates, wage rates do not give an accurate production loss 
estimate; wages may not be a good measure of productivity, as distortions of the labour market 
occur; and finally, HC does not reflect the way people value their own lives (Ament and Evers 
1993). Controversial issues among economists are whether the indirect costs resulting from 
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reduced productivity due to a disease should be counted and, if so how to measure them. If 
indirect cost data are used to set priorities, more resources could be directed to people of working 
age or certain occupations, causing ethical problems relating to equity. Short-term absence from 
work may be covered by others or made up by the sick worker, so the production losses to 
society would be overestimated. For long-term absences, a sick person's work could be covered 
by someone drawn from the ranks of unemployed (Drummond 1992). A method called 'friction 
cost' addresses this issue, including costs associated with the amount of time and costs needed to 
replace or substitute a sick worker (Koopmanschap and Ineveld 1992; Songer et al 1998). 
Another complaint about COI studies is that the human capital approach omits psychosocial 
(intangible) costs, e.g. pain and suffering (Drummond 1992; Rice 1994), which affect quality of 
life. COI estimates are generally focused on average costs, but marginal (incremental) costs are 
more relevant in priority-setting regarding the efficient use of resources (in addition to 
incremental health effects). Also lack of standardisation makes comparisons of different studies 
difficult (Songer et al 1998).  
One problem related to estimating the of costs of diabetes morbidity is that diabetes leads to 
severe complications that are considered as the primary disease, while diabetes is often 
considered as a secondary diagnosis, but costs are calculated based on primary diagnosis, and 
this leads to an underestimation of costs related to diabetes (Simell et al 1996). Analyses almost 
always measure the use and costs based on primary diagnosis reported in medical records, the 
condition mainly responsible for the use of health services. According to Hogdson and Cohen 
(1999), a complete assessment of the costs of a medical condition requires including additional 
expenditures arising from (1) chronic complications of the condition, (2) unrelated conditions for 
which the afflicted are at a higher risk of using health care and (3) co-morbid effects of the 
condition that raise the cost of care. Co-morbid costs accrue from longer hospital stays and 
additional costs for nursing home and home health care due to secondary diagnoses of diabetes 
and secondary chronic complications and unrelated diagnoses attributed to diabetes. For 
example, a diabetic patient with pneumonia may require longer hospital care than a non-diabetic 
patient (American Diabetes Association 1993a).  
A technique applying attributable risk (AR) attempts to overcome the underestimation of costs 
resulting from the use of only primary diagnosis data. This method represents the relative 
contribution of diabetes to the overall risk identified. It can be considered from the general or 
disease population perspectives (Songer et al 1998). The AR method can be used to calculate an 
etiological fraction (proportion of health care services for a particular medical condition 
attributable to diabetes) with the following formula (American Diabetes Association 2003a), 
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P x (Ri-1)  
Ei =  
P x (Ri-1) + 1 
where Ei is the fraction of health care use for medical condition "i" attributable to diabetes, P is 
the diabetes prevalence rate, and Ri is the relative risk of disease i among people with diabetes 
compared with people without diabetes.  
The AR procedures attempt to estimate costs attributed to secondary diagnoses more accurately, 
but may fail to account for the influence of confounding factors, overstating the role of diabetes 
in that attribution (Songer et al 1998). Calculating the costs of diabetes as a main diagnosis is the 
most straightforward and conservative approach, avoiding double counting (Henriksson and 
Jönsson 1998).  
Calculating excess costs in diabetic populations as compared with control groups appears to be the 
method preferred by Jonsson et al (2000). Due to the complex relationship between diabetes and 
various co-morbidities and deficient scientific knowledge of these associations, it may be difficult to 
define whether certain episodes of care are totally or partly due to diabetes (Jonsson et al 2000).  
According to Pagano et al (1999), investigation of the total cost is not important when the 
pathology of a disease, as with diabetes, is complicated and progressive. Identifying patient 
subgroups according to clinical and economic criteria (type of diabetes, age, disease duration, 
sex, type of complication) may produce a more precise and valuable analysis since patients at 
different severity stages of disease require different levels of resources.  
2.3. Hospital care of patients with diabetes 
In 2001, the total health care expenditure in Finland was 9.5 billion euros, per capita the amount 
was 1,820 €, and its share of Gross Domestic Product was 7%, one of the lowest in OECD 
countries (average 8%). In 2001, 76% of health care was financed from public funds, and the 
share of private financing was 24%. Insured persons accounted for 20%. The total expenditure 
consisted mainly of inpatient care (39%), outpatient care (28)%, dental care (6%), medicines 
(16%), medical devices (4%), investments (3.5%) and administration 2%. Public financing 
consisted of state (17%), local authorities (municipalities) (43%) and Social Insurance Institution 
('KELA’) (16%) (STAKES 2003).  
In 1997, 15.5% of Finnish people used inpatient care, and the average length of stay (LOS) was 
11.1 days. Women's share of all bed-days was 61%. LOS for diabetes was 13 days (13,728 
patients used 258,943 bed-days in 18,777 treatment periods, 1.4 periods per patient) (Pelanteri et 
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al 1998). In 2001, the average LOS in specialised inpatient care was 5.5 days by primary 
diagnosis for endocrine, nutritional and metabolic diseases. By speciality, LOS for internal 
medicine treatment was 6.2 days, paediatrics 3.8 days and eye diseases 2.3 days. The total 
average LOS for specialised inpatient care in Finland was 7 days (from 718,000 patients, 6.2 
million bed-days, 0.9 million discharges); the LOS was 5 days when psychiatric diseases ware 
excluded (STAKES 2002).  
Diabetes has a marked effect on inpatient hospital resource utilisation and costs. A Spanish study 
observed that diabetes accounted for 11% of total inpatient discharges, 15% of inpatient days and 
16% of costs (Carral et al 2002). In Taiwan, patients with diabetes accounted for 22% of total 
hospital days, the average LOS being 16.8 days (Lin et al 2001).  
In 1989, Finnish patients with diabetes comprised 7% of all patients receiving inpatient care; 
they used 12.6% of inpatient days. About 52,800 persons with diabetes received inpatient care; 
90% of them were entitled to reimbursement for antidiabetic drugs. These people used inpatient 
care 3.6 times more than the non-diabetic population, having 1.9 admissions per year per patient 
(Kangas 1995). Inpatient hospital use among diabetic and non-diabetic populations in Finland 
between 1987 and 1989 has been studied by Aro et al (1994), who found that diabetic patients 
stayed longer in hospital regardless of the diagnosis. Excess use varied strongly with sex, age 
and disease category, commonly being 3-5 days. Notably, diabetic children (aged 0-14 years) 
used about 10 times more inpatient days (5.1 days) than non-diabetic children (0.5 days), their 
risk for hospitalisation was 6.5 times higher and 41% of diabetic children were hospitalised 
primarily due to diabetes.  
Only few studies exist to compare hospitalisation rates of diabetic children with that in the 
general population. Moreover, large variation exists in hospitalisation rates and LOS between 
countries and time periods. Icks et al (2001) observed that diabetic children in Germany had 
about three times more hospital days than the control group (male 2.6 times; female 3.2 times), 
females having a higher hospitalisation incidence than males, especially during puberty. Mean 
LOS was about 7 days.  
Hirasing et al (1996) studied trends in hospital admissions among children (aged 0-19 years) 
with T1DM in the Netherlands and observed a dramatic decrease (>50%) in hospital days 
between 1980 and 1991. Although the incidence rose, LOS decreased by 2.6 (to 11.9 days) days 
during the same period. Since the diagnostic criteria remained the same, the authors explain the 
decrease with improved care, education and self-management. Early diagnosis makes 
ambulatory treatment more feasible, and home care could be practised more using team 
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management. According to Sutton et al (1998), a home stabilisation programme would reduce 
the average LOS at diagnosis to 3-5 days for children older than 5 years.  
In a study conducted in the Helsinki area in 1997, 27% of patients with T1DM had a short-term 
somatic hospital (duration less than a year). They used inpatient care 2.6 times more frequently 
than the control group, and their average length of stay (LOS) was 6.2 days. Per hospital user, 
there were 2.2 treatment periods (1.4 in control group) and 13.7 hospital days (11.7 in control 
group). By diagnosis, diseases unrelated to diabetes caused 48% of inpatient days, followed by 
diabetes without complications (12%), renal complications (9.5%), hypoglycaemia and 
ketoacidosis (6%) and other diabetic complications (5%). Among T2DM, 43% of inpatient days 
were due to diseases unrelated to diabetes, followed by long-term care (26%), macrovascular 
complications (25%), microvascular complications (3.5%) and diabetes without complications 
(3%) (Kangas 2001; Kangas 2002).  
Fishbein (1985) studied the precipitants for hospitalisations due to T1DM. Poor diabetes control 
(diet/medication) and infection accounted for 54% of single and 44% of multiple admissions 
(duration of diabetes on average 10 years). An outpatient diabetic education programme was 
found to be very successful in reducing hospital admissions due to those acute causes. 
 Health care systems in general vary among countries, but there are global recommendations for 
the care of diabetic patients. Outpatient health care of people with diabetes varies substantially 
among countries, although only a few studies are available (Kangas et al 1996). According to 
Currie et al (1996), patients with T1DM aged 10-30 years have been shown to have a 7-fold 
increased probability for age-specific patterns of outpatient attendance. In Finland, among 
insulin-treated patients with diabetes (diagnosed under the age of 30 years), 28% used health 
centres, 63% a hospital outpatient clinic and 7.5% private health care as their primary source of 
outpatient health care (Kangas 1995). In the Helsinki area in 1997, 81% of patients with T1DM 
had used specialised outpatient care (hospital outpatient, private), the share of private health care 
being 16%. Individuals in the control group used primary outpatient health care 3.5 times more 
than patients with T1DM (relative shares 75% vs. 21%), the corresponding share for persons 
with T2DM being 52%. There were on average 5.5 outpatient visits to a physician and 3 
consultations with a nurse per patient due to T1DM. The average age of T1DM patients in the 
Helsinki study was 35.7 years (SD 14.7) (Kangas 2002). 
Among non-diabetic populations in Finland, women have been observed to use health centres 1.5 
times more than men (Kokko 1988). Studies of hospital use among diabetic populations by sex 
are scarce, especially those related to T1DM.  
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2.4. Costs of diabetes 
It is complex to estimate the cost of diabetes in any country (Turtle 2000). Cost estimates vary 
considerably depending on the year, country and population in question. Almost all studies have 
used the prevalence method, giving cost estimates for a certain year, nationally or regionally. 
Studies typically calculate the costs of diabetes, failing to calculate separately the shares by the 
diabetes type and especially by sex. In some studies, control groups have been used avoid 
underestimation resulting from using only primary diagnosis (Selby et al 1997; Jonsson et al 
2000; Kangas 2002). Generally, comparison of studies is very difficult due to methodological 
differences and inclusion of different cost components.  
Accurate information on costs of diabetes is scarce. The costs of T1DM in a given country 
depend on the incidence of diabetes and the cost-effectiveness of its treatment. The three clinical 
stages of T1DM differ. The initial treatment period and the late treatment period cause cost 
peaks, but the follow-up period after the initial treatment produces clearly smaller costs. During 
the late treatment period, which is the most costly of the periods, costs begin to accumulate 
quickly due to the long-term complications. The lifetime financial costs of T1DM and the 
amount of human suffering are always substantial (Simell et al 1996). The costs of initial 
treatment are affected greatly by length of stay in hospital. In a Finnish study, most of the costs 
were incurred during the first month in a two-year follow-up (Simell et al 1993).  
Pagano et al (1999) conducted an analysis of 15 COI on diabetes. The authors observed a wide 
methodological variety, and the lack of technical details in many studies made it difficult to 
understand the method used. Three of the studies, those of Stern and Levy (1994); Gray et al 
(1995) and Hart et al (1997) were incidence-based. Only one study, that of Gray et al (1995) 
used sensitivity analysis to assess how changes in the main assumptions affect the baseline 
results. Most of the studies (11 of them) analysed diabetes as a whole, three of the studies 
focused on T1DM. The bottom-up approach was used by 12 studies. The main direct costs, 
inpatient, outpatient and drugs, were assessed separately in most of the studies. Eight studies 
estimated indirect costs, which in most studies turned out to be higher than direct costs. A major 
obstacle in estimating productivity loss due to mortality is that diabetes as a contributory cause 
of death is frequently not recorded on death certificates. The economic consequences of diabetes 
as a whole, with its complicated and progressive pathology involving several complications, are 
difficult to define and vary dramatically over time.  
Table 3 shows cost estimates of diabetes in different parts of the world.  
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In USA, Rubin et al (1995) estimated the total health care costs of diabetic patients to be 14.6% 
of the overall health care costs (105.2 billion dollars) in 1992. Inpatient hospital care accounted 
for 63% of the health care costs of diabetic patients. The per capita expenditure of inpatient care 
for diabetic patients was 4.8-fold that of non-diabetic patients; the corresponding ratio for all 
expenditures was 3.6. The approach adopted in that study was broader than usual since all health 
care costs were included, not just diabetes-related.  
A different approach, etiological fractions, was used by the ADA in calculating expenditures 
attributable to diabetes in USA for year 2002. They estimated the costs for diagnosed diabetes at 
132 billion dollars. Direct medical expenditures alone totalled 91.8 billion dollars, comprising 
23.2 billion dollars for diabetes care, 24.6 billion dollars for chronic complications attributable to 
diabetes and 44.1 billion dollars for excess prevalence of general medical conditions. Indirect 
costs totalled around 40 billion dollars (30%), the share being smaller than in other studies. Per 
capita medical expenditures totalled 13,243 dollars for people with diabetes compared with 
2,560 dollars for those without diabetes; when adjusted for age, sex and race, the cost ratio was 
2.4 times higher for persons with diabetes. Although people with diagnosed diabetes comprise 
'only' 4.2% of the American population, of the health care components analysed in the study 
almost 1 of every 5 dollars spent on health care in USA. is for a person with diabetes. According 
to the authors, the ADA study underestimates the true burden of diabetes, as the analysis 
accounts for only 58% of the cost components of the total health care expenditures in 2002 in 
USA (1.5 trillion dollars). Also, undiagnosed diabetes is omitted (American Diabetes 
Association 2003a). Compared with previous ADA studies in 1993 and 1998, it is worth noting 
that the direct costs in 2002 were at the same level as total costs earlier.  
Hodgson and Cohen (1999) used the attributable risk method in 1995 for the estimation of 
medical care expenditures of diabetes in USA. Total expenditures attributed to diabetes were 
about 48 billion dollars, including 18.8 billion dollars for first-listed diabetes, 18.7 billion dollars 
for chronic complications, 8.5 billion dollars for unrelated conditions and 1.9 billion dollars for 
co-morbidities. The range of total costs was 34.3 - 63.7 billion dollars. Expenditures were 
somewhat higher for females. The authors defined chronic complications of diabetes in the same 
way as defined by ADA (American Diabetes Association 1993a).  
In Sweden, the economic burden of diabetes was estimated at 5.7 billion SEK in 1994 
(Henriksson and Jönsson 1998), showing a 4.4-fold increase compared with an earlier 
calculation made in 1978 (Jönsson 1983). The studies investigated the cost of diabetes as a main 
diagnosis, which is a conservative and straightforward method and avoids double counting. The 
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cost structure remained very similar in both studies, demonstrating the share of indirect costs to 
be around 57%. As for direct costs, the studies concentrated on hospitalisation, outpatient care 
and drugs, as most COI studies do (Henriksson and Jönsson 1998).  
Another Swedish study investigated excess costs of medical care 1 and 8 years after diagnosis of 
diabetes in two cohorts of patients with diabetes at the age of 15-34 years and matched control 
groups. Ninety percent of the persons with diabetes were on insulin treatment. This is evidently 
the first follow-up study calculating the excess costs of care during the first decade after 
diagnosis of diabetes, before major long-term complications may have developed. The results 
indicated that one year after diagnosis the annual excess costs of care were at 1997 prices 4,743 
USD (men) and 4,976 USD (women). Hospital inpatient costs, accounted for over 50% of the 
excess costs. Eight years after diagnosis, the excess costs were 2,010 USD for men and 2,734 
USD for women. The higher costs for women were mainly due to hospital outpatient care, but 
also due to more intensive self-monitoring. The share of inpatient care was notably lower than in 
the 1-year cohort. Compared with the control group, the per capita costs were 5.6 times higher 
after 1 year of diagnosis; after 8 years, the figure was 3.8-fold. Inpatient LOS dropped 
dramatically; after 1 year, it was 7.1 days, and after 8 years 1.5 days (Jonsson et al 2000).  
In a Canadian stydy (Johnson et al 2006), health care use and costs in the decade after 
indentification of T1DM (156 patients) and T2DM (3,469 patients ) were analysed. The average 
10-year costs per person with T1DM (in 2001 Canadian dollars) was 33,684 $ and those due to 
T2DM 38,006 $.  Hospital use accounted for the largest proportion of total per capita costs 
yearly for both types of diabetes. In the incident year in 1992, the hospitalisation costs due to 
T1DM were 7 times higher than the ones in the year prior to diagnosis. Five types of resource 
categories were included in the (direct) costs (prescriptions, physicians, hospitalisations, day 
surgeries and dialysis). The authors argue, that as a chronic disease, even 10 years of follow-up 
might be considered a too short time period for the estimation of  costs of care for diabetes. To 
their knowledge, that study represented the largest cohort with the longest follow-up of health 
care use and costs published at that time (the study was accepted for publication in august 2006).  
In Finland, the only nationwide estimates thus far have been provided by Kangas (Kangas 1995; 
Kangas 2001; Kangas 2002). Kangas observed that including all direct costs of diabetes care is 
impossible. In the 1995 study by Kangas, the total direct health care costs of drug-treated 
diabetic patients in Finland were 1.5 billion FIM. Inpatient care constituted 81% of the sum. The 
newer study (Kangas 2001; Kangas 2002) used case-controlled, bottom-up and prevalence 
methods and estimated primarily the use and costs of health services of persons with T1DM and 
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T2DM in Helsinki, giving also a national estimate for total costs in 1997. The strengths of this 
study is that it used incremental costs, separated the types of diabetes and had an age- and sex-
matched control group. The costs and use of health services were not compared by sex. As to the 
methods used, this study was the first of its kind in Finland; Selby et al(1997) have used similar 
techniques earlier in Northern California.  
According to Kangas (2001; 2002), the national estimate for diabetes was 0.87 billion € (5.15 
billion FIM, 11% of the total Finnish national health budget in 1997). The figure includes both 
main types of diabetes. Incremental costs were estimated to be at least 0.47 billion € (2.8 billion 
FIM) in Finland. In Helsinki, persons with diabetes (2.6%) incurred 12.6% of the costs of the 
total health budget, so the costs of persons with diabetes were over 5-fold compared with their 
prevalence. Compared with the control group, short-term inpatient care (<365 days) of patients 
with T1DM was 3.7 times more expensive, total outpatient care 5,0 times more expensive and 
specialised outpatient care 8.4 times more expensive. Of the total costs of T1DM, the shares of 
short-term inpatient and outpatient care were both 30%, and that of drugs around 28%. 
Incremental costs formed 76% of total costs of T1DM and over 16% of total incremental costs 
(both types of diabetes combined). By disease duration of persons with T1DM, during the first 5 
years the costs were 2,893 € and SD was 417 € (17,200 FIM, SD 2,480 FIM) per person per 
year. The costs were lowest 10-15 years after diagnosis, 2,607 € with SD being 556 € (15,500 
FIM, SD 3,307 Fim), and highest 25-30 years after diagnosis, 4,710 € with SD being 1,332 € 
(28,000 FIM, SD 7,916 FIM). Total average costs of health care per person per year for T1DM 
were 3,717 €  (22,095 FIM); for T2DM, the costs were 1.5-fold, 5,634 € (33,493 FIM). 
Compared with control groups, these costs per person were over 4-fold for T1DM, and over 2-
fold for T2DM. 
One of the few incidence-based studies conducted to date is that by Hart et al (1997), which 
modelled the direct health care costs of the incidence of T1DM in Spain in 1994. The authors 
developed a discrete event model simulating the natural history of a cohort of newly diagnosed 
patients in a given year, and calculated the average costs that would accumulate over their 
lifetime (n=1791). The model used national and international epidemiological data and 
demographic information combined with local cost data. The average life expectancy of a patient 
with T1DM was 59.6 years, and the average lifetime costs were 12.7 million pesetas per 
individual. The authors limited their study only to complications, that they assumed to have the 
biggest economic impact (nephropathy, retinopathy and cardiovascular complications).  
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A study by Gray et al (1995) calculated the costs of T1DM in England and Wales in 1992. The 
direct health care and social care costs of T1DM were estimated to be 96 million pounds (1,021 
£ per person) in a population of 94,000 persons affected. The costs included insulin replacement 
therapy, hospital use, general practitioner and outpatient consultations, renal replacement therapy 
and payments for informal care. About half of the total costs were directly attributed to T1DM; 
the rest were associated with various complications of the disease. The single largest source of 
expenditure was renal replacement therapy. The cost estimates were most sensitive to incidence 
rates of T1DM, the amount of dialysis and the average duration of dialysis. A further 113 million 
pounds could have been lost yearly due to premature deaths resulting in lost productivity. The 
authors concluded that the direct and indirect costs of T1DM are significant.  
In Finland, the Diagnosis Related Group (DRG) unit cost in the year 2001 for a treatment period 
of T1DM (patients under 35 years of age) in specialised care was 1,925 euros and LOS was 4.5 
days; per bed-day, this figure is 428 euros (Hujanen 2003). The corresponding DRG cost for 
T2DM (patients over 35 years of age) was 1,584 euros and LOS was 6 days; per bed-day, 262 
euros (Hujanen 2003).  
2.5. Diabetes and use of drugs 
According to many studies, diabetic patients have high overall usage of medicines, independent 
of treatment needed for diabetes itself. In a Scottish study, patients with T1DM diabetes were 
over 2 times more likely to be dispensed a drug than non-diabetic people. The adjusted risk for 
male patients was 2.4 and for female patients 1.9. Nearly 8% of the UK drug budget (350 million 
pounds) is accounted for by diabetic patients (Evans et al 2000).  
Another large study conducted in Finland (N=116,224) investigated the co-morbidity, overall use 
and costs of drugs using age- and sex-matched control persons (Reunanen et al 2000). The use of 
almost all kinds of medication was markedly higher in persons with T1DM and T2DM than in 
controls. Costs of medications for both types of diabetes combined were 3.5 times higher than in 
controls; after excluding antidiabetic drugs, the costs were twice as high. In persons with T1DM, 
the total yearly cost was on average 1,272 dollars per patient, which was 12 times higher than in 
controls. Insulin treatment accounted for 62% of total drug costs. With T1DM, the costs of drugs 
other than antidiabetic agents were almost 5 times higher than in control persons. Of patients 
with T1DM, 15% had hypertension (odds ratio, OR 7.5). Coronary heart disease (OR 6.0), 
hypothyroidism (OR 7.3), vitamin D metabolic disorders (OR 50.4), glaucoma (OR 16.5), 
epilepsy (OR 2.2), transplant complications (OR 50.3), uremia requiring dialysis (OR 71.2), 
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rheumatoid arthritis (OR 1.7) and heart failure (OR 5.0) were also more common with T1DM 
patients than with controls. Cardiovascular medications were used by 21% of T1DM patients, 
but only 4% of control subjects (OR 5.6), ACE inhibitors were used 14 times more (OR 14.2), 
calcium-channel blockers, diuretics and nitrates were used almost 7 times more and lipid-
lowering agents were also used more often (OR 5.2), as was also the case with antidepressants 
(OR 1.6) and hypnotics and sedatives (OR 1.5).  
2.6. Complications of diabetes and costs  
A large amount of data is available about the incidence and prevalence of complications of 
diabetes, but in a few studies, costs related to diabetes, have been calculated, especially indirect 
and marginal costs. Moreover, researchers have failed to distinguish between T1DM and T2DM. 
The most important contributors to costs of diabetes are complications such as eye and limb 
disease, heart disease, neuropathy and nephropathy (Leese 1992). Diabetic complications form 
the principal clinical and economic burdens of diabetes, and evidence indicates that reduction in 
hyperglycaemia (measured by glycosylated haemoglobin, HbA1c) reduces diabetic 
complications, including microvascular and neurological disease, and will likely reduce the risk 
of macrovascular disease (Clark 1998). It is important to have accurate estimates of the incidence 
and costs of care for complications of diabetes, as such data allow policy-makers and health 
planners to estimate the savings that could be achieved by prevention and early intervention 
directed at the complications. Incidence and cost data are critical for conducting cost-effective 
analyses for drugs and interventions that are aimed at delaying or preventing diabetes-related 
complications. The high incidence and costs may support aggressive early intervention for 
persons with diabetes (Ramsey et al 1999).  
2.6.1. Acute complications of diabetes 
Diabetic ketoacidosis (DKA) and severe hypoglycaemia are acute complications of T1DM that 
are related to insufficient or excessive insulin treatment. Both are major life-threatening 
complications for patients with T1DM (Rewers et al 2002).  
Ketoacidosis 
Ketoacidosis is a challenge especially in adolescent girls, while severe hypoglycaemia affects 
disproportionally the youngest patients and boys of all ages (Rewers et al 2002). May et al 
(1993) studied 92 cases of ketoacidosis (age range 18-81) and noticed a female predominance in 
total and recurrent cases. LOS was 5.7 days in their study (SD 4.9). Javor et al (1997) 
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investigated DKA charges relative to medical charges of adult patients with T1DM, including 
inpatient, outpatient, emergency room visits and drug costs. The authors concluded that DKA 
episodes represent more than 1 dollar of every 4 dollars spent on direct medical care for adult 
patients with T1DM and 1 dollar of every 2 dollars in those persons having multiple episodes, 
and interventions targeted to these recurrent DKA episodes could be particularly cost-effective.  
Hypoglycaemia 
Of acute complications, hypoglycaemia is the most frequent, the most serious, and the most 
feared by patients and families, often requiring hospitalisation, which can be costly. In 1992 in 
France, there were 10,800 inpatient hospitalisations, 90% of these lasting several days and 1.9% 
resulting in patient death. Mean total medical cost of a hospital stay was 2,100 dollars and mean 
LOS was 6.6 days. In 1995, the annual cost for the society due to hypoglycaemia (inpatient care) 
was estimated at 16-22 million dollars (Allicar et al 2000).  
A Swedish study in 1998 investigated costs of severe hypoglycaemia of persons aged under 19 
years with T1DM (n=129). The average socio-economic burden for events of severe 
hypoglycaemia was 174 euros yearly per person. The authors conclude, that the results in the 
study suggest the potential for socio-economic savings and increased quality of life for patients 
and families from severe hypoglycaemia prevention programs (Nordfeldt and Jonsson 2001).  
2.6.2. Main chronic complications of diabetes 
Long-term complications of T1DM are caused by the inability to mimic the physiological insulin 
responses to meals, physical activity and other regulators of insulin release. Hyperglycaemia-
associated changes affect small and large blood vessels and lead to vasculopathy, which may 
result in retinopathy, nephropathy, neuropathy, ischaemic heart disease and obstruction of the 
arteries supplying the extremities. Thus, costs due to long-term complications  begin to 
accumulate quickly (Simell et al 1996). Also genetic factors probably play an important role for 
the development of diabetic complications. 
Acute coma is the leading cause of death for persons with T1DM in the early years of the 
disease, renal disease predominates in the middle years, and after 30 years two-thirds of deaths 
are due to cardiovascular disease (National Diabetes Data Group 1995).  
Currie et al (1996) calculated relative risks (RR) using primary diagnoses and primary procedure 
codes for in- and outpatient hospital use for patients with diabetes and separate complications in 
England between 1991 and 1994. Patients with diabetes have a 12-fold increased risk of 
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admission for coronary heart disease, 16-fold for neuropathy and peripheral vascular disease, 10-
fold for eye disease, 13-fold for renal disease and 12-fold for cerebrovascular disease compared 
with a non-diabetic population. Patients with diabetes occupied 9.4% of bed-days.  
Donnan et al (2000) compared hospital resource use of persons with T1DM (n=864) with a 
control group in Scotland and observed that the highest relative risks (RR) for hospitalisation 
were for endocrine (RR 283), ophthalmic (RR 47), renal (RR 6.5) and neurological (RR 3.9) 
complications; the high rate for endocrine complications was due to ketoacidosis and 
hypoglycaemia. On the other hand, patients with T1DM did not stay longer in hospital than non-
diabetic patients; a similar observation about LOS was made by Kangas (2002).  
In Finland, Kangas (2002) investigated costs related to complications of diabetes. For both types 
of diabetes, around one-third of patients had at least one complication, and these persons 
accounted for two thirds of the total treatment costs. Yearly cost per person with T1DM without 
any complication was 9,355 FIM, and with complication(s) the figure was 42,385 FIM. 
Incremental costs of persons with T1DM who had complications were 12 times higher than those 
of persons with T1DM without complications (n=779, 33% had at least one complication). For 
T2DM, the costs were 24 times higher. The shares of incremental costs of inpatient care of 
persons with T1DM by main complication groups were as follows: diabetes as main diagnosis 
(25%), macrovascular complications (15%), microvascular complications (30%; share of renal 
complications 19%) and diseases unrelated to diabetes (31%). When comparing these 
percentages with persons with T2DM, incremental costs for diseases unrelated to diabetes were 
dominant (53%), followed by macrovascular complications (34%); microvascular complications 
constituted only 5% of incremental costs.  
Ophthalmic complications  
Ophthalmic complications increase with age (Jacobs et al 1991), and diabetic retinopathy is 
strongly associated with duration of the disease (Pajunpää 1999). Diabetic patients also have a 
clearly higher risk for other eye diseases than non-diabetic persons, e.g. the relative risk for 
glaucoma is 10-fold and for cataract 9.6-fold for persons with diabetes aged under 65 years 
(Jacobs et al 1991). The relative risk for ophthalmic complications in persons under 45 years of 
age was estimated to be 39.8 compared with non-diabetics; for older age groups, it was 1.6-3.4 
(American Diabetes Association 1993a).  
Retinopathy affects virtually all persons with T1DM, and proliferative retinopathy is found in 
60% of patients by 20 years after diagnosis of diabetes (Harris 1998). Complications related to 
retinopathy are estimated to be symptomatic in 50% of the patients with T1DM with retinopathy 
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(Stern and Levy 1994). Retinopathy is characterised by changes in the small blood vessels of the 
retina. In the non-proliferative stages of the disease, the retina has micro-aneurysms, 
haemorrhages and exudates, but these might not result in visual loss. In the proliferative stage, 
retinopathy is characterised by the growth of abnormal blood vessels which can haemorrhage 
into the eye or produce retinal detachment, resulting in severe loss of vision. Vision loss can be 
prevented by a treatment called laser photocoagulation (Drummond et al 1992). Glycaemic 
control and lower levels of hyperglycaemia are related to reduced risk of progression of 
retinopathy (Klein and Klein 1998). Klein et al (1996) observed that in patients with T1DM and 
T2DM a 1% increase in HbA1c concentrations at baseline was associated with an almost 60% 
increase in the incidence of retinopathy and an almost 100% increase in the rate of progression to 
proliferative retinopathy.  
 The costs of visual problems due to diabetes are high (Pajunpää 1999), especially indirect costs 
as a patient may have to retire from work early and may be dependent on others for help (Leese 
1995; Simell et al 1996). In USA in 1990, the total yearly expenditure for blind diabetic patients 
under 65 years of age was 14,296 dollars per patient (Javitt et al 1994). From the perspective of a 
single-payer health system, blindness has been estimated to cost 2,000 dollars per person yearly 
in direct medical costs (Herman and Eastman 1998). In a Finnish study, the annual expenditures 
to society due to one visually impaired person were 15,675 euros, direct costs accounted for 72% 
of this figure. When the duration of visual impairment was estimated to be 8 years, the total costs 
for that period were 99,904 euros (discount rate 5%) or 117,575 euros (discount rate 0%). Costs 
of social sector were the biggest single item, 35% of total costs, followed by lost earnings of the 
patient and family (30%) and costs of social security (20%). Costs due to use of health services 
and rehabilitation were relatively small (10% and 5.5%), respectively. Interestingly, the average 
age of retirement due to diabetic retinopathy was as low as 36.8 years (Pajunpää 1999). The 
author included transfer payments (social security costs, e.g. pension) in the total costs, meaning 
that the costs per visually impaired person were 'overestimated' by 20% relative to had  they been 
omitted.  
Diabetic nephropathy 
Diabetic nephropathy (DN) usually develops 10-20 years after the onset of T1DM, producing a 
gradual loss of renal function. It is characterised by persistent proteinuria and rising blood 
pressure, leading to renal failure or death due to coronary disease (Mathiesen et al 1984). In a 
Finnish study, nephropathy in T1DM patients increased the risk of coronary heart disease and 
stroke by 10-fold. In T1DM with DN, cardiovascular complications occurred at 12-13 years after 
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diagnosis of diabetes, while in individuals without DN, the lag time was somewhat longer, 16-17 
years. The incidence of cardiovascular disease was clearly related to the duration of DM 
(Tuomilehto et al 1998). The earliest manifestation of nephropathy is albuminuria, which is a 
marker of greatly increased cardiovascular morbidity and mortality in T1DM and T2DM patients 
(American Diabetes Association 2003b).  
Progression to renal failure occurs within 3-20 years (median 10 years) after the onset of 
persistent proteinuria, although the process differs significantly among patients and is related to 
blood pressure, poor glycaemic control and smoking (Sawicki et al 1994). Mortality by the age 
of 45 can be 20-40 times higher in patients with T1DM with proteinuria than in those without 
proteinuria (Borch-Jonhsen et al 1985, Lounamaa 1993).  
Diabetes is the most common single cause of end-stage renal disease (ESRD) in USA and 
Europe. ESRD develops in 50% of T1DM patients with overt nephropathy within 10 years and 
in over 75% by 20 years. In 1997, the cost for treatment of diabetic patients with ESRD was 15.6 
billion dollars in USA (American Diabetes Association 2003b).  
People with diabetes have a 17-fold increased risk of ESRD compared with the general population. 
The risk of death from renal disease for T1DM patients is 23 times higher than with non-diabetic 
people (Leese 1992). Approximately 33-40% of T1DM patients develop DN (Andersen et al 1983; 
Chukwuma 1993). About 20-30% of patients with T1DM will have to be treated with dialysis or 
transplantation. DN is associated with a higher incidence of ophthalmic, nervous, peripheral 
vascular and cardiovascular lesions, and the prevalence of retinopathy is associated with 
progressive nephropathy as well. Advanced diabetic retinal disease is virtually always associated 
with overt diabetic retinopathy. Almost 77% of deaths from T1DM are associated with renal 
failure, the rest are due to cardiovascular disease. The best prognosis for survival in ESRD is with 
transplantation, haemodialysis or peritoneal dialysis (Narins and Narins 1988).  
In a longitudinal study conducted in Israel, nephropathy accounted for 32% of total direct 
treatment costs over 35 years (78,000 of 247,000 pounds in 1993 prices) The costs of everyday 
treatment (insulin, blood glucose self-tests, visits to doctor, laboratory tests) were 25%. 
Nephropathy comprised almost half of all direct costs of complications of T1DM. Over a period 
of 35 years of illness, complications accounted for 69% of total costs. The average direct cost of 
treatment was 7,100 pounds per patient per year (or 3,000 pounds discounted at a rate of 6%) 
(Stern and Levy 1994).  
In a study in Taiwan in 1997, the annual in- and outpatient costs for care of dialysis patients 
averaged 25,576 dollars per patient-year. This cost is approximately half of that in most Western 
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countries and Japan. Diabetic ESRD patients produced around 12% more costs of care per 
patient-year than non-diabetic ESRD patients (Yang et al 2001). In a Canadian study, around 
32% of the costs of dialysis were for peritoneal dialysis and 68% for haemodialysis (Johnson et 
al 2006). Median cost per life-year of hospitalisation for ESRD (extrapolated from data from 
Diabetes Control and Complications Trial) was 46,000 dollars, based on 1993 currency (The 
Diabetes Control and Complications Trial Research Group 1993; Turtle 2000).  
In Finland, the DRG unit cost in 2001 for a treatment period of dialysis in specialised care was 
2,643 euros. The corresponding cost for renal replacement was 24,600 €, with a LOS of 22 days. 
This cost was the 8th highest of all DRG procedures (total 495) (Hujanen 2003).  
Diabetic neuropathy 
Diabetic neuropathy usually occurs after several years of diabetes, and it primarily affects the 
sensory nerves of the lower limbs, with loss of sensation of pain and sometimes progressive 
destruction of soft tissues, bone and joints. Micro-organisms often enter the deep tissues of the 
foot and break down soft tissues, tendons and bones. When tissue destruction is extensive, 
amputation may be necessary. Physical or thermal trauma may precipitate gangrene in a foot. 
Bacterial colonisation of the necrotic tissue results in wide spread of infection, which may 
threaten the leg or even the survival of the patient, thus usually demanding urgent amputation. 
Three major factors contribute to the damage of the diabetic foot: chronic diabetic neuropathy, 
atherosclerotic obstruction of the arteries supplying the lower limb and bacterial infection. The 
combination of chronic foot ulceration, sepsis and gangrene is the main cause of prolonged 
hospitalisation for diabetic patients, accounting for more than half of the non-traumatic 
amputations performed in some developed countries (WHO 1985). Still, problems with 
definition, classification and diagnosis as well as uncertainties related to pathophysiology, 
natural history and prognosis have made it difficult to quantify the incidence, prevalence and 
costs of diabetic neuropathy (The Carter Center of Emory University 1985; Kangas 2002).  
According to Reiber (1992), foot problems are the most common complication of diabetes 
leading to hospitalisation. In a study by Jacobs et al (1991), diabetic patients under 45 years of 
age were 46 times more likely to be hospitalised due to neuropathy than the non-diabetic 
population. The ADA reported relative risk to be 27.4 for neurological complications compared 
with a control group (American Diabetes Association 1993a). Currie et al (1998) observed that 
the highest average LOS was for chronic ulcer of the skin: 25.3 days for diabetic patients vs. 
19.1 days for non-diabetic patients. The probability of lower-extremity amputation has been 
reported to be 27 times higher among diabetic persons compared with their non-diabetic peers 
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(Nabarro 1988). Of patients with diabetes, 5-15% require amputation of a lower extremity during 
their lifetime (Bild et al 1989). At least half of the patients with T1DM have developed 
symptoms of neuropathy by 25 years after diagnosis (American Diabetes Association 1993a; 
Stern and Levy 1994). The high economic burden of neuropathy has also been addressed in other 
studies (Ward 1995).  
The costs of foot ulcers were extraordinarily high in a study by Ramsey et al (1999). Costs of 
foot ulcers in patients with diabetes were much higher than equivalent costs in patients without 
diabetes. In Sweden, gangrene was reported to be the most expensive single complication of 
diabetes, accounting for as much as 25% of the costs of inpatient care (Jönsson 1983). Another 
extensive Swedish study by Tennvall et al (2000), calculated costs to the health care sector of 
deep foot infections in patients with diabetes. This study was unique since it calculated total 
treatment costs for in- and outpatient care from diagnosis until healing of a deep foot infection in 
a population of consecutively included diabetics over a 10-year period (n=220). Duration of 
diabetes was 19.6 years, and 77% of the patients had T2DM. Total cost of healing without 
amputation was 136,000 SEK per patient, cost of healing with minor amputation was 260,000 
SEK and cost with major amputation was 234,500 SEK; these costs are at 1997 price level. The 
cost of topical treatment was 51% of total costs. Wound healing duration and repeated surgery 
explained 95% of costs. The mean healing time for patients without amputation was 29 weeks; 
the corresponding times after minor and major amputation were 52 and 38 weeks. According to 
the study, costs of antibacterials (4% of total costs) should not be used as an argument in the 
choice between early amputation and conservative treatment. The authors also maintained that 
the high costs associated with the diabetic foot and variations of these costs are mostly explained 
by the heterogeneity of foot ulcers and their treatment and outcome. Variations in study design, 
definitions, settings and changes in treatment practice over time also explain differing costs 
between studies. Many of the health economic studies are conducted from different perspectives, 
which are often connected to differing patterns of health care financing across different countries 
(e.g. Europe vs. USA).  
The average lifetime cost per case of lower-extremity amputation has been calculated to be 48 
152 dollars (Eckman et al 1995). In the Netherlands in 1992, the mean costs associated with 
diabetes-related hospitalisations for amputation were 10,531 pounds (n=1,575) compared with 
8,151 pounds per hospitalisation (n=1,760) for the non-diabetic population. The mean LOS was 
correspondingly 41.8 and 31.8 for these populations. The authors estimated,  that approximately 
10% of diabetes-related health care costs were associated with lower-extremity amputations (van 
Houtum et al 1995). In Finland, the DRG unit cost in 2001 for a treatment period for amputation 
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of a limb due to endocrinologic, nutritional or metabolic cause was 6,036 euros and LOS was 10 
days (Hujanen 2003).  
Macrovascular diseases  
Coronary heart disease occurs more frequently and is more severe in diabetics than in non-
diabetics (Tuomilehto et al 2004). Atherosclerotic disease of the small arteries in diabetics is 
responsible for the high incidence of cerebral infarction, stroke, and diffuse cerebrovascular 
disease (WHO 1985, Tuomilehto et al 2004).  
In a study by Jacobs et al (1991), the risk for diabetic patients for hospitalisation due to 
atherosclerosis was 10-fold that of a control group. Moreover, the risk of cerebrovascular accident 
and heart disease was 6-10 times higher in diabetic patients. In a study by Currie et al (1997a), the 
relative risk (RR) of stroke in diabetic men versus non-diabetic men was 3.7, and in women 4.4. 
Approximately 15% of acute hospital care of cerebrovascular disease was related to diabetes in a UK 
population. According to the ADA, the RR for cardiovascular complications of diabetic patients aged 
under 45 years was 18.9 for heart diseases and 17.9 for arterial disorders; for venous disorders, the 
RR was 2.7 (American Diabetes Association 1993a). Macrovascular disease usually occurs 25 years 
or later after the initial outbreak of T1DM (Stern and Levy 1994). Over 20% of deaths from T1DM 
are associated with cardiovascular disease (Chukwuma 1993). During the early years of T1DM, renal 
disease is the leading cause of death (Diabetes Epidemiology Research International Mortality Study 
Group 1991b); after 30 years of the disease two-thirds of the deaths are due to cardiovascular 
diseases (Krolewski et al 1985; Borch-Johnsen et al 1987).  
Currie et al (1997b) discovered that patients with diabetes constituted 17% of coronary heart 
disease-related hospital admissions. Stern and Levy (1994) calculated that macrovascular disease 
accounts for 21% of total lifetime direct costs of a person with T1DM who has lived with the 
disease for 35 years (51,000 pounds in 1993 prices). In a study by Kangas (2002), macrovascular 
diseases accounted for 11% of total costs of T1DM in Helsinki; for comparison, in T2DM, the 
share was 27%.   
2.7. Interventions, prevention and treatment of diabetes 
Diabetes and its numerous complications also cause vast amounts of intangible costs (pain, 
suffering, decline in length and quality of life, which may be measured with e.g. QALYs lost). 
These psychosocial costs are alleviated and deferred by various treatments and prevention 
programmes. Chronic diseases such as diabetes incur lifetime costs, so money invested in 
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interventions and preventive care now may not bring benefits in terms of reduced complications 
for many years (e.g. 20-30 years), and this has little appeal to governments (Leese 1995). 
Effective local disease registers and screening for complications have been estimated to lead to 
annual savings of 1,200 million dollars, and the avoidance of 25,000 amputations and 10,000 
cases of blindness yearly in the European Community (Piwernetz 1990; Leese 1995).  
Three levels of prevention for diabetes have been presented (Alberti 1991; Tuomilehto et al 
1992, Leese 1995; Turtle 2000): 
• primary prevention: reducing the incidence of diabetes 
• secondary prevention: controlling metabolic abnormalities after diagnosis of diabetes 
(e.g. diet and exercise for elderly people with T1DM, education, tight glucose control, 
screening) 
• tertiary prevention: limiting the consequences of diabetic complications once they have 
emerged (e.g. laser treatment) 
 
Regarding T2DM, interventions (lifestyle change, weight reduction, exercise) have been 
effective in primary prevention (Tuomilehto and Lindström 2003), although they are difficult to 
implement due to limited acceptance (Turtle 2000). An example of a successful lifestyle 
intervention is a Finnish study, which managed to reduce the incidence of T2DM in persons at 
high risk by 58% (Tuomilehto et al 2001, Lindström 2006). Determining the cost-effectiveness 
of approaches for preventing T1DM is not possible yet, because it is unclear how T1DM could 
be prevented. 
Klonoff and Schwartz (2000) conducted an economic analysis of 17 widely practised 
interventions for diabetes. The interventions were classified as follows: 1) clearly cost-saving, 2) 
clearly cost-effective, 3) possibly cost-effective, 4) non-cost-effective or 5) unclear. The 
interventions included the following actions: 1) eye care, 2) pre-conception care, 3) nephropathy 
prevention in T1DM and T2DM, 4) improved glycaemic control, 5) self-management, 6) case 
management, 7) medical nutrition therapy, 8) self-monitoring of blood glucose, 9) foot care, 10) 
blood pressure control, 11) blood lipid control, 12) smoking cessation, 13) exercise, 14) weight 
loss, 15) HbA1c measurement, 16) influenza vaccination and 17) pneumococcus vaccination.  
For eye care, diabetic retinopathy screening and treatment programmes prevent blindness by 
detecting proliferative diabetic retinopathy (PDR) and macular edema (ME), and practising laser 
photocoagulation therapy. According to the authors, more economic studies have been reported 
40
  
 
 
on prevention of retinopathy than on any other intervention for diabetes. In the review by 
Klonoff and Schwartz (2000), there were 10 retinopathy screening studies, and the economic 
benefits were expressed as costs or savings per sight-year gained. In 9 of these studies, savings 
exceeded costs. Diabetic retinopathy screening and treatment programmes have been shown to 
be clearly cost-saving and worthwhile from both medical and economic perspective. 
Monte Carlo simulation was used to determine the cost-effectiveness of screening diabetic 
retinopathy in studies by Crijns et al (1999) and Javit and Aiello (1996). Crijns et al (1999) 
observed that for juvenile-onset patients ophthalmic care can reduce the prevalence of blindness 
by at least 52%, and savings in disability facilities and production losses surpass direct costs. In 
the study by Javitt and Aiello (1996), the incremental cost-effectiveness of screening and 
treatment of eye disease in patients with T1DM was 1,996 dollars per QALY gained. The 
authors concluded that these kinds of interventions are highly cost-effective health investments 
for society, as diabetic eye disease causes much blindness in working-aged individuals in USA. 
In Finland, Pajunpää (1999) calculated that the screening and treatment costs of finding one 
preventable case of visual impairment were 31,115 euros. The screening costs per diabetic 
person screened were 25 € with the photographic method and 11.5 euros with the 
ophthalmoscopic method. The author argues that retinal photographic screening is worthwhile, if 
at least 49 visual impairments can be prevented.  
Diabetic nephropathy screening and treatment programmes prevent end-stage renal disease 
(ESRD) by detecting microalbuminuria or clinical nephropathy and controlling blood pressure or 
using angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker 
therapy.These medications preserve renal function, independent of their antihypertensive effects, 
in diabetic patients who have microalbuminuria and proteinuria (Lewis et al 1993; Ravid et al 
1993; Klonoff and Schwartz 2000). According to the ADA, screening of persons with T1DM 
should begin after a disease duration of 5 years. Use of ACE inhibitors is recommended for all 
patients with microalbuminuria or advanced stages of neuropathy. Protein restriction and other 
treatments, e.g. phosphate-lowering therapies may also benefit selected patients (American 
Diabetes Association 2003b).  
The economic impact of the aforementioned interventions can be determined by comparing 
programme costs with savings associated with delaying or deferring dialysis or transplantation 
for ESRD (Klonoff and Schwartz 2000). Six nephropathy interventions were reviewed by Klonof 
and Schwartz (2000), and all of these interventions extended life or prevented ESRD. The 
authors concluded that nephropathy screening and treatment interventions provide additional 
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life-years and QALYs for persons with T1DM clearly cost-effectively; patients with T2DM also 
appear to obtain both economic and medical benefits.  
Borch-Johnsen et al (1993) analysed by using simulation the cost-benefit of screening for and 
antihypertensive treatment of early renal disease indicated by microalbuminuria in patients with 
T1DM. Screening and treatment interventions were likely to have life-saving effects and 
generate marked economic savings.  
ACE inhibitor therapy has been shown to be cost-effective in preventing diabetic nephropathy in 
various studies (Rodby et al 1996; Hendry et al 1997; Kiberd and Jindal 1998). Rodby et al 
(1996) observed that treatment with captopril resulted in direct cost savings of 32,550 dollars per 
patient with T1DM and nephropathy over a lifetime compared with placebo.  
A modern intervention approach is pancreas transplantation when the recipient no longer needs 
insulin injections,  but must receive chronic immunosuppressive therapy, which is often 
accompanied by severe side-effects. Approximately 85% of the pancreas transplant recipients 
have also received a kidney transplant (Stern and Levy 1994). Cost-effectiveness and cost-utility 
analyses relating to pancreas transplantation have been conducted by Douzdjian et al (1998; 
1999), who analysed the different treatments by using a decision tree with a 5-year time horizon. 
The outcome was that simultaneous pancreas-kidney transplant (SPK) is the optimal strategy for 
a patient with T1DM, with a 5-year cost of 102,422 dollars per QALY. The respective costs with 
the other strategies were  dialysis 317,746 dollars, kidney-alone transplant from a living donor 
123,923 dollars and from a cadaver 156,042 dollars. 
Interventions aimed at improved glycaemic control are clearly cost-effective, as such 
interventions in simulated populations of T1DM and have added life-years and QALYs (Klonoff 
and Schwartz 2000). The Diabetes Control and Complications Trial demonstrated that intensive 
treatment of persons with T1DM delays onset and slows progression of retinopathy, nephropathy 
and neuropathy by a range of 35% to over 76%. The study assumed that 70% of conventional 
therapy patients and 30% of intensive therapy patients would develop proliferative retinopathy 
by the age of 70. Intensive therapy should, however, be implemented with caution due to 
increased risk of hypoglycaemia (The Diabetes Control and Complications Trial Research Group 
1993). The DCCT Research Group (1996) conducted a health-economy analysis to examine the 
lifetime benefits and costs of intensive therapy, and whether it would be preferable to 
conventional therapy from the perspective of the health care system. On average, intensive 
therapy patients gained 7.7 additional years of sight, 5.8 years free from ESRD, and 5.6 years 
free from lower extremity amputation compared with conventional therapy patients. The gain 
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from any significant microvascular or neurologic complication was 15.3 life-years. Patients 
treated with conventional and intensive therapy lived on average 56.5 years and 61.6 years, 
respectively. Thus, intensive therapy yielded an increase of 5.1 years in survival. On average, 
intensive therapy costs were 33,746 dollars higher than the costs of conventional therapy (99,822 
vs. 66,076 dollars) per patient over a lifetime, or 28,661 dollars per year of life gained 
(discounted at 3% yearly). The incremental cost per QALY gained was 19,987 dollars (costs and 
benefits discounted at 3%). According to the authors, these ratios can be considered cost-
effective and they represent good monetary value for the investment. A sensitivity analysis 
revealed that a decrease in costs of slightly more than 50% would even make intensive therapy 
cost-saving option.  
According to the ADA, the yearly cost of intensive therapy was three times the cost of conventional 
therapy, a large portion of the costs relating to bigger use of outpatient services and resources used in 
self-care. Although more expensive, intensive therapy offers hope of cost-savings due to averted 
complications (American Diabetes Association 1995b). Potential long-term personal and economic 
savings of continuing a tight metabolic control are notable  (Simell et al 1996). 
Stern and Levy (1996) noted in Israel that the cost of intensified insulin treatment is three times 
higher than the cost of the standard treatment per year. For a 35-year period when intensified 
treatment was applied to all T1DM patients, the total costs exceeded the costs of standard care, 
although the costs for complications were smaller in intensified treatment. The authors suggest 
that the decision to adopt intensified therapy should be based on medical, ethical, political and 
economic principles, and the therapy should be applied to selected, motivated and prepared 
patient groups. Nephropathy is the most common and severest complication, and intensified 
therapy seemed to be most effective for these patients.  
In seven of nine self-management interventions, benefits exceeded costs. For every 1 dollar spent 
on training of patients, there was a net savings of 0.44 to 8.76 dollars. The authors classify 
diabetes self-management programmes as possibly cost-effective, because these programmes 
have deficiencies in their methodologies and they measured only short-term savings over 1 year 
(Klonoff and Schwartz 2000).  
For foot care, economic analyses are scarce. Klonoff and Schwartz (2000) assume, though, that 
interventions of foot care prove to be clearly cost-effective or even cost-saving. Ollendorf et al 
(1998) estimated that economic benefits of strategies to reduce amputation risk ranged from 2,900 to 
4,442 dollars over 3 years per person with a history of foot ulcer. Educational interventions produced 
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the highest benefits in that study. A foot intervention, which consists of podiatric care, education and 
specially fitted shoes can reduce the amputation rate by 50% (Bild et al 1989).  
As to other interventions applied, acetylsalicylic acid (i.e aspirin) therapy has been 
recommended for persons over 29 years of age, who have at least one risk factor for CVD and 
who have evidence of large-vessel disease. According to Rolka et al (2001), almost every adult 
in USA with diabetes has at least one risk factor for CVD, and may be considered a potential 
candidate for acetylsalicylic acid therapy. During 1988-1994 only 20% took acetylsalisylic acid.  
Treatment of dyslipidaemia (e.g. simvastatin therapy) has provided good value for money in 
diabetic patients with cardiovascular disease, demonstrating a good cost-effectiveness ratio and 
reducing hospitalisations. For diabetic patients in Sweden, the estimates of cost per life-year 
gained ranged from 1,600 € (based on clinical history) to 3,200 € (based on ADA criteria). In 
Finland, the corresponding range was from from 2,944 to 7,280 € (Jönsson et al 1999).  
Home-based management for newly diagnosed diabetic children has given good results, yielding 
better metabolic control and psychosocial outcomes than traditional hospital-based care 
(Dougherty et al 1999).  
In Finland, two T1DM predictive strategies were compared. A genetically targeted strategy 
together with auto-antibody follow-up of persons at high risk proved to be clearly cost-saving 
compared with a pure immunological strategy, i.e. repeated immunological screening of the 
entire population (Hahl et al 1998). Hahl et al (2003) have also analysed direct costs of T1DM 
prevention therapy with nasal insulin, by comparing two different diabetes prevention models 
using Monte Carlo simulation. The authors conclude that the costs of potential prevention of 
T1DM with nasal insulin are low when compared with estimates of the yearly direct health care 
costs of T1DM, and they study suggests (assuming that nasal insulin is effective in the 
prevention), that a 2 to 3-year delay in the T1DM onset may make prevention using the practice-
oriented model cost saving. 
Cost-effectiveness studies of interventions for diabetes are important to provide a basis for 
efforts to reduce the cost of diabetes as well as to ensure that people with diabetes are treated 
efficiently and with equity (Leese 1992). The key factors that affect the economic returns from 
medical research are the prevalence, incidence and burden of the disease in question, the costs 
and effectiveness of the medical intervention, the impact of the clinical trial on clinical practice 
and the likely time span of benefits from knowledge obtained during the trial (Drummond et al 
1992). Prevention has three major prerequisites: 1) identification of subjects at risk, 2) 
identification of the cause of the disease and/or its precipitators and 3) understanding of the 
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pathogenesis of the disease (Becker et al 2000). The disease should also be a burden to the 
individual and society, and a safe treatment should be available, that has soundly based potential 
to be effective (Schatz et al 2000).  
In 2007, there are still no clinically accepted prevention strategies for T1DM (Knip 2007), and it 
may take years, even decades to find one (Hyöty 1997, Reunanen 2004). Examples of successful 
prevention of certain other diseases, though, give reason to optimism (Knip 2007, Hyöty 1997).   
2.8. Proposals for cost of diabetes studies in the future 
According to Songer et al (1998), the cost of diabetes studies should concentrate more on 
narrower perspectives, like costs specific to T1DM, T2DM, gestational diabetes, subgroups (sex, 
age categories) or each specific complication of diabetes. More incidence-based studies are 
required. In addition, methods for measuring and valuing indirect costs should be refined, and 
better epidemiologic data are needed for calculations of attributable risks, e.g. contribution of 
diabetes to other diagnoses and contribution of co-morbidities to diabetic complications. 
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3. AIMS OF THE STUDY 
The overall aims were to describe the use of inpatient care of a cohort of childhood-onset 
diabetic patients (T1DM) during 1973-1997 and to estimate the costs of inpatient care. The 
specific aims were 
1. To describe: 
1.1. the use of inpatient care of a nationwide cohort of childhood-onset diabetic 
patients (T1DM),  
1.2. the yearly use of inpatient care by sex during 1973-1997, 
1.3. the cause of inpatient care (diabetes vs. other diseases), 
1.4. the effect of diabetes duration on hospital use, especially in the main complication 
groups, when diabetes had lasted on average 9.5 years and 16.5 years, respectively  
1.5. the use of inpatient care in the cohort in 1998 
 
2. To estimate the costs of inpatient care by sex due to T1DM and its main complications, 
and the total cost of inpatient care by calculating the costs of: 
2.1. inpatient care as a function of T1DM duration and compare costs at 9.5 years with 
those at 16.5 years after the diagnosis of T1DM 
2.2. inpatient care in the cohort in 1998 
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4. MATERIAL AND METHODS 
4.1. Inpatient care of T1DM patients during 1973-1997 
4.1.1. Population, study period and data sources  
The study population consisted of all Finnish T1DM patients diagnosed before the age of 18 
years between 1 January, 1965 and 31 December, 1979 and derived from the Finnish population-
based T1DM register.  
At the end of 1979, the dynamic cohort of this study consisted of 5,166 patients (2,327 females, 
2,839 males) and at the end of 1997 this figure was 4,701. The number of female and male 
patients in different years varied, as shown in Table 4. By the end of 1997, there were 465 
deaths (157 females, 308 males). Hospital use of the study population was followed from 1973 to 
1997; thus, the follow-up time was 25 years.  
 
Table 4. Yearly number of patients in the cohort by sex between 1973-1997 
        
Year Total number Females Males 
1973 2,980 1,364 1,616 
1974 3,343 1,518 1,825 
1975 3,692 1,679 2,013 
1976 4,024 1,830 2,194 
1977 4,373 1,994 2,379 
1978 4,746 2,152 2,594 
1979 5,120 2,315 2,805 
1980 5,114 2,311 2,803 
1981 5,108 2,309 2,799 
1982 5,099 2,305 2,794 
1983 5,091 2,304 2,787 
1984 5,073 2,300 2,773 
1985 5,062 2,298 2,764 
1986 5,047 2,293 2,754 
1987 5,027 2,286 2,741 
1988 5,005 2,279 2,726 
1989 4,971 2,269 2,702 
1990 4,949 2,260 2,689 
1991 4,916 2,248 2,668 
1992 4,885 2,239 2,646 
1993 4,854 2,230 2,624 
1994 4,824 2,221 2,603 
1995 4,787 2,206 2,581 
1996 4,743 2,188 2,555 
1997 4,701 2,170 2,531 
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The Finnish population-based T1DM register belongs to the material of the Diabetes 
Epidemiology Research International (DERI) Study, which has been used in evaluating mortality 
in T1DM (Diabetes Epidemiology Research International Mortality Study Group 1991a, 
Diabetes Epidemiology Research International Mortality Study Group 1991b, Asao et al 2003). 
The register was established by linking the Finnish Hospital Discharge Register (FHDR) with the 
Social Insurance Institution Central Drug Register (SIICDR) using the unique personal 
identification numbers recorded in both registers. T1DM patients aged 17 years or under at the 
diagnosis of diabetes were derived from the Central Drug Register, which was started in 1964 
and contains information on all patients receiving reimbursed medication for specified chronic 
disorder, including diabetes. These persons can be identified with personal identification codes 
containing information on date of birth, sex and control digits (Tuomilehto et al 1998). The 
Central Drug Registry only recorded the date of approval of the free-of-charge medication, so 
copies of the original certificates had been collected for the years 1965-1979 from the local 
offices of the Social Insurance Institution in 1987 to obtain the actual dates of diagnosis that had 
to be during 1965 to 1979 (Tuomilehto et al 1991). The use of hospital-days of patients in the 
Finnish T1DM register was based on the FHDR. Dates and causes of possible deaths of the 
subjects were obtained from the National Cause of Death Register administered by Statistics 
Finland. The register is based on official death certificates and covers completely the whole 
study period.  
Data on hospitalisations due to T1DM were obtained from the FHDR, which covers all inpatient 
discharges nationwide since 1968. The FHDR includes data on dates of admissions and 
discharges, four discharge diagnoses, the hospital identification numbers, and codes for hospital 
type where the patient was treated. After the first two years FHDR has been observed to be more 
complete (Mähönen et al 1997). The follow-up of hospitalisations for this study was started from 
1973 onwards to get more accurate and reliable data. Hospital use before the diagnosis of 
diabetes, use due to diagnosing diabetes (the first treatment period, a total of 2,165 discharges) 
and use due to pregnancies or complications of pregnancies were excluded (9,082 discharges, 
International Classification of Diseases - ICD codes 630-676) to achieve better comparability 
between patients' hospital use and treatment costs in different years.  
4.1.2. Variables used to describe inpatient care 
The following variables were calculated separately for the total population and both sexes: 
Bed-day (hospital-day): A day spent by person in a hospital ward. The days of arrival and 
departure are calculated as a single day.  
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Discharge (treatment period): Hospitalisation period lasting at least 15 hours. This period is 
included in the FHDR. 
Average length of stay (LOS): The number of hospital days divided by the number of treatment 
periods (discharges). 
Discharges per user: The number of discharges divided by the number of patients,who used 
hospital at least once during the year concerned. 
Proportion of T1DM patients using hospital annually: Number of hospital users during the year 
concerned divided by the number of patients in the T1DM register during the same year. 
Bed-days per user: The number of bed-days during the year concerned divided by the number of 
patients who used hospital at least once during the same year. 
Discharges and bed-days per 1,000 patients yearly: The number of discharges or the number of 
bed-days during the year concerned divided by the number of T1DM patients during the same 
year; this figure is then multiplied by 1,000. The size of the cohort varied between different 
years, and there were more men in the cohort. This variable was calculated to make hospital use 
comparable between the sexes and different years. 
4.2. Use of inpatient care by T1DM patients due to diabetes or other causes 
during 1973-1997  
The same population, study period, basic data and variables as presented in the subsection 4.1. of 
the study were used in subsection 5.2. in results. Hospital use due to diabetes (diabetes, 250x as 
main diagnosis) was separated from hospital use due to other causes (main diagnosis other than 
250x). Since also the main acute and the major late complications of diabetes carry the three-
digit code 250, the overall hospital use due to diabetes and its late complications can be 
conveniently distinguished from hospital use for other diseases. In Finland, the ICD codes on 
hospital discharges are assigned by the treating physician, and thus, they are considered fairly 
accurate. During the years 1973 through 1986, the ICD-8 version was used in Finland, and since 
1987, the ICD-9 classification was used. The codes in the ICD-8 version were converted to the 
corresponding codes in the ICD-9 version.  
The following codes of diabetes were applied (according to CD-9): 2500 (no complications), 
2501 (with ketoacidosis), 2502 (diabetic coma), 2503 (diabetic nephropathy), 2504 (diabetic 
retinopathy and other eye complications), 2505 (diabetic neuropathy), 2506 (diabetic 
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microangiopathy), 2507 (other specified complications) and 2508 (unspecified complications) 
(Lounamaa 1997). 
4.3. Inpatient care depending on duration of T1DM (duration 9.5 years vs. 16.5 
years). 
The same population as described in the subsection 4.1., was used in subsection 5.3. of the study. 
Two ‘cohorts’ were formed based on the duration of T1DM. The hospital use due to T1DM 
complications according to duration of the disease was examined here. Main diagnosis was used 
in calculations. Two 3-year periods of duration of diabetes, 9-11 and 16-18 years, were 
compared in 9 complication groups. Hospital use was calculated in 3-year periods and then 
divided by three, indicating the effect of duration of the disease on hospital use when T1DM has 
lasted on average 9.5 years compared with 16.5 years. Also, the share of hospital use due to each 
complication was compared to the amount of use due to all complications (all complication 
groups combined), hospital use due to other causes than diabetes and hospital use due to all 
hospitalisations (inpatient use due to any cause). T1DM-related hospital use due to complication 
groups and that due to diabetes without complications (ICD-8 code 25000 and ICD-9 code 
2500B) were presented separately.  
ICD-8 codes were converted to correspond ICD-9 codes, because the coding changed in the 
beginning of 1987.  
ICD-10 was officially adopted in 1.1.1996 in Finland (first edition was published in 1995 and the 
second in 1998). The ICD-10 codes for diabetes in Hospital Discharge Register changed 
markedly compared to the earlier versions (ICD-8 and ICD-9) and if this study would have used 
ICD-10 codes, another translation of the codes would have been needed, which would have 
complicated the study much. In National Public Health institute the Hospital Discharge Register 
data was still available in ICD-9 format in 1998. That made it convenient to make the follow-up 
period between 1973-1998. 
The complication groups and complications were based on the criteria of the American Diabetes 
Association (1998). Cerebrovascular complications in this study were extracted from 
neurological disorders to present them as an own group. In addition, diabetic coma was included 
in the grouping as a separate group. Hypoglycaemia was calculated separately using the ICD-9 
code to assess the approximate amount of hospital use caused by it, and it was assigned to the 
main group “other use” (there was no specific ICD-8 code for hypoglycaemia). The detailed list 
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of complication groups, including corresponding diseases (ICD-8 and ICD-9), is shown in 
Appendix 3. 
The nine complication groups were as follows: 
• Cerebrovascular disease 
• Cardiac disease 
• Peripheral vascular disease 
• Neurological complications 
• Renal complications 
• Endocrine complications 
• Ophthalmic complications 
• Other complications 
• Coma 
The average number of patients was 5,120 in the 9.5-year cohort and 5,010 in the 16.5-year 
cohort. The exact dates of death were used when calculating the number of people alive (N1) at 
the beginning and at the end (N2) of the two periods, and then summed and divided by 2 
(N1+N2 / 2 ) to obtain the average number of people alive during the two study periods. These 
figures were needed to calculate some of the variables describing the hospital use (bed-days and 
discharges per 1,000 patients). 
The following principles were applied when calculating treatment periods and bed-days:  
- If there were two days or less between two treatment periods, they were defined as two 
different treatment periods if the main diagnoses of the periods were different. If the main 
diagnoses of the periods were the same, the periods were defined as one treatment period. 
- The days of admission to hospital and discharge from hospital were treated as a single bed-
day (e.g. 15.7.1996 – 17.7.1996 = two bed-days). 
- Overlapping treatment periods of the same patients were evidently some kind of errors in 
FHDR (a person cannot be in two places at the same time, e.g. in different hospitals), so the 
overlapping part was omitted to avoid overestimation of bed-days.  
Variables used to describe inpatient care in this subsection: 
Bed-day (hospital-day): A day spent by a person in a hospital ward. The days of arrival and 
departure are calculated as a single day.  
51
  
 
 
Discharge (treatment period): Hospitalisation period lasting at least 15 hours. These and longer 
periods are included in the FHDR. Short consecutive hospitalisation periods were treated as one 
period, if the main diagnoses were the same and the time between the periods was two days or 
less. Otherwise, the treatment periods were considered separate. 
Discharges and bed-days per 1,000 patients yearly: The number of discharges or the number of 
bed-days divided by the average number of diabetic patients in the study period (e.g. 9-11) and 
multiplied by 1,000. The average number of patients was calculated by adding the number of 
patients alive at the beginning of a study period to the number of patients alive at the end of a 
period and then dividing by two.  
Average length of stay (LOS): The number of hospital days divided by the number of treatment 
periods (discharges) gives a yearly average length of stay. LOS was calculated (for total 
population) by using real hospital days during a treatment period, not by using duration criteria 
as in the case with bed-days and discharges. LOS for total population was calculated based on 
the amount of real treatment periods to get the actual average time in hospital for each 
complication group (e.g. a treatment period may have started before the observation period of 9-
11 years or ended after it; in that case, only the bed-days contained within the observation period 
were taken into account). For men and women, LOS was calculated straightforwardly by 
dividing bed-days by discharges (‘crude LOS’), as the difference between real treatment periods 
and crude LOS turned out to be negligible.  
Discharges per user: The number of discharges divided by the number of patients who used 
hospital at least once during the diabetes duration period concerned. 
Bed-days per user: The number of bed-days divided by the number of patients who used hospital 
at least once during the diabetes duration period concerned. 
The variables were calculated separately for the total population and for both sexes. 
4.4. Costs of inpatient care depending on duration of T1DM (duration 9.5 
years vs. 16.5 years). 
In subsection 5.4., the treatment costs of inpatient care were calculated when T1DM had lasted 
on average 9.5 or 16.5 years. The same population and the 9 complication groups described in 
the subsections 4.1. and 4.3. were used. Costs of treatment due to diabetes without complications 
(ICD codes 25000 and 2500B), which belonged in the subsection 5.3. to a group ('Other use'), 
are presented separately in figures and tables. Costs of treatment due to T1DM-related hospital 
52
  
 
 
use (25000/2500B + complication groups combined) are also presented. Hospitalisations of 
patients under 16 years of age were calculated separately (as typically in Finland, they are treated 
in children's wards, which have different cost per bed-day prices than other inpatient wards).  
The unit costs for bed-days for different complication groups were obtained from a publication 
by National Research and Development Centre for Welfare and Health, STAKES (Heikkinen et 
al 2001). These costs are average unit production costs of the health sector in Finland (at national 
level), including out-of-pocket payments by patients. These costs have been recommended for 
use in health economic analyses in Finland when resources used in health care need to be valued. 
These costs form a solid and general basis for different comparison purposes.  
The following unit costs per bed-day by diagnosis were used for different groups (these costs 
were at 1999 price levels): 
• Cerebrovascular disease 348 € 
• Cardiac disease 348 € 
• Peripheral vascular disease 348 € 
• Neurological complications 328 € 
• Renal complications 348 € 
• Endocrine complications 348 € 
• Ophthalmic complications 632 € 
• Other complications 348 € 
• Coma 348 € 
• Hypoglycaemia 348 € 
• 25000/2500B (diabetes without complications) 348 € 
• Other diagnoses than T1DM-related 429 € 
• Paediatrics (T1DM in children’s ward)  606 € 
The treatment costs per bed-day on the internal medicine ward was 348 €, and this price was 
used in most of the groups. In costing hospital use other than T1DM-related, the average cost of 
all hospital types in Finland (429 €) was used. In other groups, the cost of the equivalent special 
ward was used.  
Definition of certain variables used to describe inpatient costs 
Cost per patient: Average costs per patient in the cohort. The number of patients depended on 
the duration of T1DM and on the number of female and male patients. 
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The costs by duration of T1DM were first calculated in the two 3-year periods (to decrease the 
effect of yearly fluctuations) by multiplying the number of bed-days by the hospital cost per bed-
day in question. These costs were then divided by 3 (to show costs per year), and then by the 
average number of patients (alive in 3 years).  
Cost per hospital user: Costs in the 3-year period concerned divided by the number of patients 
who used hospital at least once during this diabetes duration period. 
Costs per treatment period: Costs and number of discharges were calculated per 1000 persons 
per year, and then divided by each other. 
The variables were calculated separately for the total population and for both sexes. 
4.5. Inpatient care and costs in 1998 
In subsections 5.5. and 5.6. the same population and complication groups were used as described 
in the subsections 4.1. and 4.3. Use of inpatient hospital care and the corresponding costs were 
calculated cross-sectionally in 1998. ICD-9 classification was used. In subsection 5.6., the costs per 
bed-day were valued at 1999 prices, and the bed-day prices for different complication groups were 
considered to be the same as those in subsection 4.4. There were no patients under 16 years of age.  
54
  
 
 
5. RESULTS 
5.1. Inpatient care of a cohort of T1DM patients during 1973-1997  
The mean age of the patients in the cohort at the end of 1973 was 14.7 years (min 2.3; max 26.7), 
and the mean duration of diabetes 4.4 years (min 0.04; max 9.0). At the end of 1979, the mean 
age was 17.6 years (min 1.1; max 32.7), and the mean duration of diabetes 7.3 years (min 0.04; 
max 15.1). At the end of 1997, the mean age was 35.6 years (min 19.2; max 50.7), and the mean 
duration of diabetes 25.4 years (min 18.1; max 33.0).  
5.1.1. Rate of hospitalisation 
The proportion of patients using hospital yearly remained between 26% and 30% during the first 
half of the follow-up until 1987 (Figure 1). During the next three years the hospitalisation rate 
dropped to 21.6%, and remained at this lower level, being 19.8% in 1997. Thus, the proportion 
of users was lower during the last seven years than during the first 14 years.  
Women used hospital care relatively more than men, the difference being biggest during 1977 to 
1987. The proportions of both female and male hospital users decreased since the late 1980s: that of 
females from 33.7% (1985) to 20.8% (1997) and that of males from 26.5% (1980) to 18.9% (1997).  
5.1.2. Total inpatient care 
During the follow-up period the total number of hospital bed-days used was 370,688 (Table 5). 
The yearly number of bed-days increased until 1979, after which it fell rather linearly by 50% 
from 20,190 (in 1979) to 10,164 (in 1997).  
The total number of hospital discharges during the follow-up period was 50,287. The annual 
number of discharges increased during the first six calendar years and remained relatively steady 
after that, ranging from 1,900 to 2,400 per year.  
Figure 2 shows that women had more bed-days and discharges than men, except during the last 
six years. The number of women’s bed-days dropped during the last half of the follow-up by as 
much as 57% from the peak rate in 1980 to the lowest figure in 1995. The decrease during the 
entire study period was 47%. The number of men’s bed-days declined less steeply than that of 
women; the decrease was 46% from the highest rate in 1979 to the lowest figure in 1997, and 
39% during the entire study period. 
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Table 5. Number of total bed-days and discharges of T1DM patients diagnosed in Finland 
during 1965 to 1979 by the year of admission and sex between 1973-1997 
              
 Bed-days Bed-days Bed-days Discharges Discharges Discharges 
Year total females males total females males 
1973 11,370 5,916 5,454 1,203 607 596 
1974 11,661 5,752 5,909 1,327 650 677 
1975 12,144 5,821 6,323 1,449 689 760 
1976 14,900 6,771 8,139 1,495 694 801 
1977 17,509 9,446 8,063 1,834 983 851 
1978 18,655 9,183 9,472 1,993 1,027 966 
1979 20,190 9,549 10,641 2,171 1,115 1,056 
1980 20,121 10,986 9,135 2,331 1,283 1,048 
1981 18,186 9,475 8,711 2,161 1,188 973 
1982 19,387 10,250 9,137 2,377 1,262 1,115 
1983 17,769 9,750 8,020 2,314 1,275 1,039 
1984 16,459 9,167 7,292 2,300 1,286 1,014 
1985 17,010 9,355 7,655 2,426 1,392 1,034 
1986 15,698 7,984 7,714 2,334 1,292 1,042 
1987 15,742 8,048 7,694 2,425 1,248 1,177 
1988 14,801 7,559 7,242 2,198 1,079 1,119 
1989 13,754 6,727 7,027 2,015 1,001 1,014 
1990 13,348 6,653 6,695 2,070 981 1,089 
1991 12,899 6,341 6,558 1,999 1,006 993 
1992 11,964 5,493 6,471 1,966 968 998 
1993 11,769 5,684 6,085 2,056 1,051 1,005 
1994 12,721 5,163 7,558 2,006 947 1,059 
1995 11,583 4,522 7,061 1,941 921 1,020 
1996 10,884 4,822 6,062 2,009 979 1,030 
1997 10,164 4,951 5,213 1,887 887 1,000 
       
Total: 370,688 185,368 185,331 50,287 25,811 24,476 
              
       
 
The number of discharges per 1,000 female patients increased between 1980 and 1987, but 
decreased after this to the level that had prevailed at the beginning of the follow-up period. The 
peak year was 1985. The number of discharges per 1,000 male patients remained rather constant 
during the 25 years. Overall, female patients used more inpatient care than male patients; they 
had 25.6% more discharges and 19.1% more bed-days than men during the entire follow-up. 
The total average length of stay (LOS) decreased steadily during the follow-up from 9.5 days 
(1973) to 5.4 days (1997) (Figure 3). The drop was 44%. Male patients stayed in hospital on 
average for 7.6 days and female patients slightly less (7.2 days) during the follow-up. The 
number of yearly hospital discharges per user increased from 1.5 to 2.0, while the number of 
yearly bed-days per user dropped from 14.2 to 10.8 days during the 25-year study period. 
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5.2. Use of inpatient care by T1DM patients due to diabetes or other causes 
during 1973-1997 
5.2.1 Rate of use of inpatient care 
During the first half of the follow-up period, from 1973 to 1988, the majority of inpatient care 
used by the patients was due to T1DM (Figure 4). During the last five years, from 1992 to 1997, 
the proportions of patients using hospital due to causes other than T1DM were higher than the 
proportions of persons using hospital due to T1DM. Between 1973 and 1988, approximately 
20% of patients used hospital at least once a year with T1DM as the main diagnosis. After this, 
there was a steady fall in hospital use to 9% in 1997.  
Female patients used hospital more frequently than men, especially between 1977 and 1987, 
when the difference was 4-7 percentage points. After this the sex difference in hospital use 
levelled off. From the peak year of 1977, the percentage of female patients hospitalised yearly 
due to diabetes dropped from 28% to 8% in 1997. The proportion of male patients using hospital 
yearly was around 20% during 1973-1988 after which it declined steadily to 10% in 1997.  
The proportion of hospitalisations with a main diagnosis other than T1DM increased steadily from 
6% in 1973 to 14% in 1997. This proportion among female patients was somewhat higher than 
among male patients during the entire 25-year period. Compared with hospitalisations due to T1DM, 
the turning point for hospitalisations due to other diseases was the year 1992 (when the duration of 
diabetes ranged from 13 to 27 years and the attained age from 13 to 44 years). Since then, the 
percentage of hospital users due to other causes overtook that due to T1DM, and thereafter, a steadily 
increasing majority of hospitalisations was attributed to other diseases than T1DM. 
5.2.2. Use of inpatient care due to diabetes as the main diagnosis 
There were a total of 247,668 bed-days and 33,189 hospital discharges during the follow-up 
period with diabetes (ICD 250) as the main diagnosis. These bed-days decreased by 67% from 
the peak year of 1980 (14,984 bed-days) to 4,952 bed-days in 1995. Since 1990, the yearly 
number of bed-days remained unchanged. The number of yearly discharges due to T1DM first 
increased, being highest (1,750 discharges) in 1985, 108% higher than in 1997 (843 discharges). 
The yearly discharge rate remained more or less unchanged between 1979 and 1987, and 
dropped relatively steeply between 1988 and 1992. 
60
  
 
0 
%
5 
%
10
 %
15
 %
20
 %
25
 %
30
 %
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
m
a
in
 
dg
  2
50
; b
ot
h 
se
xe
s
m
a
in
 
dg
 
 
25
0;
 w
o
m
e
n
m
a
in
 
dg
 
 
25
0;
 m
e
n
m
a
in
 
dg
  o
th
er
 th
an
 2
50
; b
ot
h 
se
xe
s
m
a
in
 
dg
 
 
o
th
er
 th
an
 2
50
; w
o
m
e
n
m
a
in
 
dg
 
 
o
th
er
 th
an
 2
50
; m
en
 
   
   
Fi
gu
re
 4
. 
Pr
op
or
tio
n 
(%
) o
f T
1D
M
 p
at
ie
nt
s u
si
ng
 h
os
pi
ta
l b
y 
m
ai
n 
di
ag
no
si
s (
dg
), 
(d
g 
25
0=
di
ab
et
es
) d
ur
in
g 
19
73
-1
97
7
 
61
  
 
Figure 5 shows the number of yearly discharges and bed-days by sex per 1,000 patients during 
the follow-up period. Female patients had consumed more bed-days and had more discharges 
than male patients until 1987. After this, the sex differences levelled off. During the entire 
follow-up period females had consumed on average 21% more bed-days and experienced 26% 
more discharges than males. In female patients, hospital admissions due to T1DM were 
relatively frequent during the first 10 years of the follow-up period, decreasing then steadily until 
the mid-1990s and levelling off thereafter. In females, the drop in the number of hospital bed-
days from 3,669 in 1980 to 872 in 1995 was more dramatic (76%) than that in males (49%).  
The yearly number of bed-days was high during the first five years of the study, decreasing 
thereafter and levelling off in the early 1990s. The decrease in bed-days related to T1DM was 
less in male than in female patients; in males, the number of bed-days decreased by 62% from 
the peak year in 1978 (3,013 bed-days) to the lowest year in 1993 (1,149 bed-days). During the 
25 years, the yearly number of bed-days among males decreased by 57%, while in females the 
drop was 73%.  
In female patients, the number of yearly hospital discharges increased steadily until the peak year 
of 1985. The steepest decline in discharges was observed during 1988-1990. From 1985 to 1997, 
the drop in rate of female patients’ yearly discharges was 63%. In the entire 25-year period, the 
number of discharges for females fell from 359 to 166 (54%) per 1,000 patients per year. The 
discharge rate for males remained steadier than in females during the follow-up. During the 25-
year period, yearly discharges in males dropped from 296 to 190 (36%) per 1,000 patients.  
The LOS due to T1DM remained steady during 1973-1978, then slowly decreasing until the early 
1990s (Figure 6). After this the change in LOS levelled off among diabetic men. The drop was 
4.4 days from 1978 (9.8 days) to 1995 (5.4 days). The essential decrease took place between 
1973 and 1984 (3 days). In 1997, the total LOS was 6.0 days. During the entire 25-year period, 
the LOS was 7.4 days; for male patients, it was slightly longer than for females (7.6 days and 7.2 
days, respectively). The longest average LOS in males was in 1978 (10.4 days) and in females in 
1973 (9.8 days).  
The number of bed-days per user due to T1DM first decreased from 13.9 days in 1973 to 9.5 
days in 1987, after which it gradually increased up to 12.0 days in 1997. The average number 
during the entire period was 11.4 days per year. Although the average numbers of yearly bed-
days per user during 1973-1997 were similar for both sexes (11.4 days), the number was higher 
for female than for male patients during 1980-1985, while male patients had more yearly bed-
days per hospital user during the latest follow-up years. The overall trend in bed-days per user 
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was relatively stable until the beginning of the 1980s, after which there was a fall until 1987, 
particularly for females, followed by an increasing trend, particularly for males. 
The number of discharges per patient due to T1DM was on average 1.6 discharges per year 
during the 25-year study period. There was a steady increasing trend in discharges per patient for 
both sexes, from 1.3 to 2.0 discharges per year. Patients thus seemed to be hospitalised due to 
T1DM more often as they grew older and as the duration of diabetes became longer, but they 
stayed in hospital for shorter periods at one time. 
5.2.3. Use of inpatient care due to other causes (main diagnosis other than 250) 
The use of inpatient care with a main diagnosis other than diabetes showed somewhat different 
patterns and trends than use when T1DM was the primary diagnosis. There were 123,642 bed-
days and 16,750 discharges due to other causes during the entire 25-year follow-up period; this 
was approximately half of those with T1DM as the main diagnostic code. The total yearly 
number of discharges due to other causes showed a steady increasing trend from 509 in 1979 
(when the entire cohort was complete in terms of number of patients) to 1,050 in 1997, an 
increase of 106%.  
Figure 7 shows the number of yearly discharges and bed-days by sex per 1,000 patients due to 
other causes than diabetes. During the entire study period, female patients had 25% more 
discharges and 15% more bed-days than male patients. The yearly number of discharges per 
1,000 male patients increased by 186% and among females by 183% during the 25 years. During 
1973-1997, the yearly number of bed-days per 1,000 male patients increased by 24%, mainly 
during the first four years. In the late 1980s through 1995, another steep increase took place. The 
number of bed-days per 1,000 male patients escalated by 207% from 502 in 1974 to 1,541 in 
1995 and declined then by 40% in the next two years. The number of bed-days per 1,000 female 
patients increased by 52% in 25 years, from 870 to 1,325 per 1,000 patients per year. In female 
patients, the number of bed-days increased by 162% between 1975 and 1990, declining 
thereafter such that the number in 1997 was the same as in 1985 (about 1,300). During 1982-
1991, female patients had used one-third more bed-days than males.  
The average LOS with the main diagnostic code other than 250 dropped steadily, from 12.6 days 
in 1976 to 5.0 in 1997 (60%) (Figure 8). During the entire follow-up period, the average LOS 
was 7.9 days; 8.2 days among males and 7.6 days among females. During 1978-1982 and 1992-
1996, the LOS of male patients was 1-3 days longer than that of females. The LOS dropped from 
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12.7 days in 1976 to 4.4 days in 1997 for male patients, and the corresponding drop for women 
was from 12.5 to 5.5 days.  
The yearly number of bed-days per user also decreased steadily, from 16.0 in 1976 to 7.7 in 
1997. The overall trend indicated a 50% decline in female and a 54% decline in male patients 
from the mid-1970s to 1997. During 1990-1995, the number of bed-days increased markedly, 
falling again thereafter. 
The number of discharges per user increased from 1.2 to 1.6 during the 25-year study period, 
similarly for both sexes. Overall, the number of discharges per user was 1.4 per year, for both sexes. 
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5.3. Inpatient care of T1DM patients by duration of diabetes (9.5 years vs. 16.5 
years) and sex 
The mean age at diagnosis in the cohort was 10.3 years (SD 4.4; min 0.7 and max 17.9). When 
the average duration of diabetes was 9.5 or 16.5 years, the mean ages of patients were 20 years 
(min 10; max 27.5) and 27 years (min 17; max 34.5), respectively. The mean age at diagnosis for 
men was 0.7 years older than that for women in both cohorts with different durations of T1DM. 
5.3.1 Hospital users  
Table 6 shows the numbers of hospital users during the 3-year periods by sex, complication 
group and duration of diabetes (9.5 or 16.5 years on average). Hospital users due to T1DM 
without complications (ICD codes 2500B/25000) are also shown. 
The total number of hospital users and the number of users due to other causes than 
complications declined, but the number of users due to complications almost doubled when the 
duration of diabetes increased. The number of users due to peripheral vascular complications 
increased almost 5-fold, that due to renal complications 3.5-fold and that due to ophthalmic 
complications 2.8-fold. The figure for neurological complications doubled. Although there were 
about 20% more men than women in both cohorts defined by the duration of diabetes, more 
women than men used hospital, and the sex difference was especially marked in use due to renal 
and ophthalmic complications. 
5.3.2. Discharges 
Total population 
In Figures 9 and 10, the yearly shares of the discharges of each complication group from the 
total amount of discharges of all complications are depicted in the two cohorts with a different 
duration of T1DM. In the first cohort, with a T1MD duration of 9.5 years, other, ophthalmic and 
renal complications and coma were the most common complication groups and their shares of 
the total number of all discharges due to any cause were 5.2%, 3.8%, 1.9% and 1.7%, 
respectively. The nine complication groups presented in Figure 9 formed 14.1% of the total 
number of all discharges during the follow-up period in the first cohort. 
In the second cohort, with a T1DM duration of 16.5 years (Figure 10), ophthalmic, other, renal 
and peripheral vascular diseases formed the biggest shares of the numbers of discharges due to 
all complications. The growth of the share of discharges due to renal and ophthalmic 
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complications and the decrease of discharges due to other complications and coma are striking. 
Here, the nine complication groups formed 41.3% of the total number of all discharges, 
indicating a remarkable increase compared with the share in the first cohort. The shares of the 
discharges due to ophthalmic, other, renal and peripheral vascular diseases of the total number of 
all discharges rose to 13.8%, 11.4%, 10.1% and 2.7%, respectively. 
Figure 11 shows the numbers of discharges per 1,000 patients per year by duration of diabetes. 
Ophthalmic diseases became the biggest complication group when the duration of diabetes 
increased. Peripheral vascular (+479%), renal (+457%), cardiovascular (+327%), ophthalmic 
(+281%), other (+129%) and neurological complications (+117%) showed the greatest increases 
in the yearly numbers of discharges per 1,000 patients when the duration of diabetes increased. 
Interestingly, the number of discharges due to diabetic coma showed a decline (-37%). Measured 
by discharges per 1,000 patients per year, the total number of discharges for these nine 
complication groups altogether had a 3-fold increase (+208%, from 57 to 175 discharges per 
1,000 patients per year). In comparison, inpatient hospital use due to causes other than these 
complications decreased by over 28% (346 to 249 per 1,000 patients per year), and the total 
number of discharges due to any causes increased by 5% (403 to 423 per 1,000 patients per 
year), when the duration of diabetes increased.  
Figure 12 shows the relative shares of the discharges per 1,000 patients per year of each 
complication group compared with 'itself' (shares of each complication group of the total 
discharges of that complication group in the two periods). As the duration of T1DM increased, 
the biggest relative increases were due to renal, peripheral vascular, cardiovascular and 
ophthalmic complications. The number of patients due to endocrine complications was 
negligible.  
Figure 13 shows the mean numbers of yearly discharges per user in each complication group 
and for other use and total use in the two duration cohorts. Renal, cardiovascular and other 
complications showed the biggest rise (each +0.8 discharges per user) when the duration of 
T1DM increased. The mean figure for all nine complication groups changed from 1.5 to 2.5 
discharges per hospital user. For total hospitalisations, the change was from 2.3 to 2.7 discharges 
per hospital user. 
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Discharges by sex 
In Figure 14, the shares of the yearly discharges of each complication group from the discharges 
of all complications are shown by sex in the two cohorts with a different duration of diabetes.  
Among women, other complications, ophthalmic and renal complications and coma were the 
most common complication groups when the T1DM duration was 9.5 years. When the duration 
of diabetes increased, the share of the discharges due to coma showed the biggest drop in 
percentage units (-10.8%), while ophthalmic (+2.7%), renal (+13.9%) and other (-9.4%) 
complications remained the biggest groups. The growth of the shares of the discharges from total 
hospitalisations for any cause was biggest for renal (2.0% to 11.5%) and ophthalmic (4.3% to 
13.7%) complications when the duration of diabetes increased. 
Among men, other complications, ophthalmic and renal complications and coma were also the 
most common complication groups when the T1DM duration was 9.5 years. When the duration 
was 16.5 years, ophthalmic (+10.6%), other (-9.8%), renal (+7.5%) and peripheral vascular 
(+3.5%) complications were the biggest complication groups. Discharges due to coma dropped (-
8.6%). The growth of the shares of the discharges from total hospitalisations for any cause for 
men was biggest for ophthalmic (3.2% to 13.8%) and renal (1.8% to 8.5%) complications when 
the duration of diabetes increased. 
The biggest differences between sexes (Appendix 2, Figure 1) were the higher share of 
discharges due to ophthalmic complications among women in the 9.5-year cohort and the bigger 
share of discharges due to renal complications among women in the 16.5-year cohort. The 
biggest changes in the shares of discharges due to complications were the increases in the shares 
of women’s renal complications and men’s ophthalmic complications. In both cohorts, men’s 
share of discharges due to other complications was somewhat higher than women's. 
Figure 1 in Appendix 2 shows the mean numbers of discharges per 1,000 patients per year by 
sex and duration of diabetes. Discharges of all complications increased clearly except, those due 
to coma, endocrine complications and cerebrovascular complications in men.  
The most obvious difference between sexes was that women had clearly more discharges per 
1,000 persons per year than men; in the 9.5-year cohort 45% more and in the 16.5-year cohort 
40% more than men for all hospitalisations, and correspondingly, the shares were 39% and 36% 
more for complications. The biggest differences between sexes were that women had almost 
twice more yearly discharges due to ophthalmic complications than men in the first cohort and 
39% more in the second one, and 53% more due to renal complications in the 9.5-year cohort 
and 89% more in the 16.5-year cohort.
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The proportional changes in discharges between the cohorts are presented in Appendix 2, 
Figure 2, which shows marked increases in yearly discharges due to renal (+505%), peripheral 
vascular (+473%), neurological (+234%) and ophthalmic (+231%) complications among 
women. Yearly discharges due to cardiovascular complications had the biggest increase 
(+712%), but the number of users was small.  
The mean number of yearly discharges per 1,000 female patients for the nine complication 
groups altogether had a 3-fold increase (+204%, from 67 to 205 discharges per 1,000 women per 
year). In comparison, the mean number of yearly discharges per 1,000 female patients due to 
causes other than these complications decreased by over 29% (419 to 296 per 1,000 women per 
year), and the mean number of yearly discharges due to any cause increased by 3% (486 to 501 
per 1,000 women per year) when the duration of diabetes increased.  
Proportional changes in yearly numbers of discharges per 1,000 men between the two duration 
cohorts are also shown in Appendix 2, Figure 2. Considerable increases can be seen in yearly 
discharges due to peripheral vascular (+484%), renal (+394%), ophthalmic (+358%) and 
cardiovascular (+242%) complications. The mean number of discharges for all complication 
groups increased over 3-fold (+210%, from 48 to 150 discharges per 1,000 men per year). Yearly 
discharges due to causes other than complications decreased by over 27% (287 to 209 per 1,000 
men per year), and the mean number of discharges due to any cause increased by 7% (336 to 359 
per 1,000 men per year) when the duration of diabetes increased.  
Figure 3 in Appendix 2 shows the mean numbers of yearly discharges per hospital user by sex 
during the 3-year follow-up periods in the two duration cohorts. Among women, the biggest 
increases occured in the hospital use due to cardiovascular (+1.0 discharge per user), renal 
(+0.9), all (+0.9) and other (+0.7) complications. Among men, the use due to other (+1.0 
discharge per user), all (+1.0), renal and cardiovascular (+0.7 each) complications showed the 
biggest rises. The number of discharges per user was highest for renal (2.3 for both sexes), other 
and cardiovascular complications when the duration of diabetes increased.  
5.3.3. Bed-days 
Total population 
The shares of yearly bed-days of each complication group (of bed-days of all complications) are 
described in the two duration cohorts in Figures 15 and 16. In the 9.5-year cohort, the shares of 
bed-days of other complications, ophthalmic complications, renal complications and coma were 
the highest, and their shares of the total amount of bed-days (any hospital use during the 3-year 
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period) were 6.0%, 3.6%, 2.2% and 1.5%, respectively. The nine complication groups formed 
14.7% of the total amount of bed-days due to any cause during this period. 
In the 16.5-year cohort (Figure 16), other, renal, ophthalmic and peripheral vascular diseases 
constituted the biggest shares of the amount of bed-days of all complications. Peripheral 
vascular, cardiovascular and especially renal complications showed the biggest increases in 
shares, while the shares of other complications and coma dropped clearly. The shares of other, 
renal, ophthalmic and peripheral vascular complications of the total amount of bed-days were 
15%, 12.1%, 11.3% and 3%, respectively. The share of the first four complication groups 
combined (cerebro-, cardio-, peripheral vascular-, and neurologic complications) increased from 
1.3% to 5.5%, as calculated from the total amount of bed-days. 
Calculated as a total yearly number of bed-days used due to complications during the first and 
second follow-up periods of three years, the hospital use due to complications increased (6,742 
to 18,158), while the number of bed-days used due to any cause decreased (45,986 to 40,669). 
The share of the bed-days of the nine complication groups of the total amount of bed-days rose 
from 14.7% to 44.6%, while the share of bed-days used due to treatment of other diseases than 
complications dropped considerably (from 85.3% to 55.4%).  
The mean numbers of yearly bed-days per 1,000 patients per year by the complication group and 
the duration of diabetes are presented in Figure 17. According to this measure, other 
complications remained the biggest complication group when the duration of diabetes increased, 
while renal diseases replaced ophthalmic diseases as the second biggest group.  
Measured by yearly bed-days per 1,000 patients, the hospital use due to cardiovascular 
(+1,406%), peripheral vascular (+474%), renal (+387%), ophthalmic (+185%), cerebrovascular 
(+131%), other (+126%) and neurological (+52%) complications increased when the duration of 
diabetes increased. Endocrine complications were practically non-existent (only 1 patient, 3 bed-
days/3 years). Yearly bed-days due to diabetic coma decreased by 54%. Bed-days due to renal 
complications had the biggest absolute change (+261 bed-days per 1,000 patients per year).  
In the amount of bed-days per 1,000 patients per year, there was a 2.8-fold increase (175%) for the 
nine complication groups (439 to 1,208 per 1,000 patients per year) when the duration of diabetes 
increased, but a drop (41%) for other diseases than complications of diabetes and even a decline 
(10%) in the total yearly number of bed-days (from 2,994 to 2,706 per 1,000 patients per year).  
Figure 18 shows the relative shares of the yearly bed-days per 1,000 patients of each 
complication group compared with 'itself' (shares of each complication group of the total bed-
days of that complication group in the two periods). The biggest relative increases were due to 
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cardiovascular, peripheral vascular, renal and ophthalmic complications as duration of T1DM 
increased. 
Figure 19 shows mean yearly bed-days per hospital user during the two periods of three years. 
Notable is that those using hospital bed-days due to cardiovascular complications (increase from 
3.0 to 17.3), other complications (11.8 to 18.5) and renal complications (12.9 to 17.6) used more 
bed-days per year when the duration of diabetes increased. Bed-days per user due to neurological 
diseases and coma and other diseases than complications decreased. The mean bed-days per user 
for all complications combined increased from 11.8 to 17.3 days.
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Bed-days by sex 
Figure 4 in Appendix 2 depicts the shares of yearly bed-days of each complication group (from 
the total amount of bed-days due to complications) by sex in the two duration cohorts. Among 
women, other and ophthalmic complications caused the highest number of bed-days in the 9.5-
year cohort, followed by renal complications and coma. When the duration of diabetes increased, 
the share of bed-days due to coma showed the biggest drop in percentage units (-9.5%), while 
other (-5.4%), renal (+12.6%) and ophthalmic (-2.7%) complications became clearly the biggest 
groups, followed by peripheral vascular complications (+1.7%).  
The growth of shares in bed-days of the total amount of bed-days for any cause was biggest for 
renal (2.4% to 13.1%), other (5.3% to 14.1%) and ophthalmic (4.2% to 11.9%) complications 
when the duration of diabetes increased. The combined share of bed-days for the nine 
complication groups of total hospitalisations increased considerably (14.3% to 44.4%) with the 
increase of the duration of diabetes. 
Among men, measured by bed-days, other complications clearly formed the most common 
complication group in the 9.5-year cohort, followed by ophthalmic and renal complications and 
coma. In the 16.5-year cohort, other complications remained still the biggest group (change -
9.3%), followed by renal (change +10.9%), ophthalmic (change +4.3%) and peripheral vascular 
complications (change +5.5%). Bed-days due to coma dropped (–7.9%). 
The growth of shares in bed-days of the total amount of bed-days for any cause among men was 
biggest for other complications (6.8% to 16%), renal (2.1% to 11.1%) and ophthalmic (2.9% to 
10.7%) complications when the duration of diabetes increased. The change in the shares of bed-
days of all complication groups combined was notable (15.1% to 44.9%). 
The biggest differences between sexes were the bigger share of bed-days due to ophthalmic 
complications among women (difference 9.7 percentage units) and that due to other 
complications among men (difference 8 percentage units) in the 9.5-year cohort, that due to renal 
complications among women (difference 4.7 percentage units) and that due to peripheral 
complications among men (difference 4.6 percentage units) in the 16.5-year cohort. The biggest 
changes in the shares of bed-days of complications were the increases in the shares of women’s 
and men’s renal complications. 
Figure 5 in Appendix 2 shows the mean number of bed-days per 1,000 patients per year by sex 
and duration of diabetes. Among women bed-days of all complications, except those due to coma, 
increased clearly. The proportional changes between the duration cohorts are shown in Figure 2 
of Appendix 2. Considerable increases occurred in yearly bed-days per 1,000 females due to 
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renal (+379%), peripheral vascular (+340%), neurological (+222%) and ophthalmic (+151%) 
complications. Bed-days due to cardiovascular and cerebrovascular complications had big 
increases, but here the numbers of female users were small. Yearly numbers of bed-days for 
coma dropped markedly (-64%). 
The total number of yearly bed-days per 1,000 female patients for these nine complication 
groups altogether had a 2.7-fold increase (+173%, 506 to 1,383 bed-days per 1,000 women per 
year). In comparison, the yearly bed-days per 1,000 female patients due to causes other than 
complications decreased by over 43% (3,038 to 1,731 per 1,000 women per year) and the total 
number of yearly bed-days due to any causes decreased by 12% (3,543 to 3,114 per 1,000 
women per year) when the duration of diabetes increased.  
Proportional changes in yearly numbers of bed-days per 1,000 men between the duration cohorts 
are also shown in Figure 2 in Appendix 2. Considerable increases can be seen in yearly bed-
days due to peripheral vascular (+589%), renal (+397%), ophthalmic (+239%) and 
cardiovascular (+689%, n=7 to 15 patients) complications. The yearly number of bed-days due 
to coma dropped (-43%). The total yearly number of bed-days used per 1,000 men due to all 
complication groups increased 2.8-fold (+177%, from 384 to 1,063 bed-days per 1,000 men per 
year). Yearly bed-days due to causes other than complications decreased by over 40% (2,158 to 
1,303 per 1,000 men per year) and the yearly total number of bed-days due to any causes 
decreased by 7% (2,542 to 2,366 per 1,000 men per year) when the duration of diabetes 
increased.  
A distinct difference between sexes was that women clearly used more bed-days per 1,000 
patients per year than men; in the 9.5-year cohort 39% more and in the 16.5-year cohort 32% 
more than men for all hospitalisations, and correspondingly, 32% and 30% more for 
complications.  
The biggest differences between sexes were that women had almost 100% more yearly bed-days 
(per 1,000 patients) due to ophthalmic complications than men in the 9.5-year cohort and 47% 
more in the 16.5-year cohort, and 60% more yearly bed-days due to renal complications in the 
9.5-year cohort and 55% more in the 16.5-year cohort. Men had 52% more yearly bed-days due 
to peripheral complications when diabetes lasted longer. The number of women's bed-days due 
to coma dropped more than men's. 
Figure 6 in Appendix 2 shows the mean numbers of yearly bed-days per hospital user by sex 
during the 3-year follow-up periods in the duration cohorts. Among women, the biggest increases 
occurred in the amount of bed-days due to other (+6.4 bed-days per user), all (+5.1) and renal 
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(+3.6) complications. The mean numbers of bed-days per user of cardiovascular (+24.8) and 
cerebrovascular (+6.4) complications had notable increases, but the numbers of hospital users 
due to these complications were smaller than those due to other complication groups. Bed-days 
due to other causes than complications dropped (16.9 to 12.2 bed-days per user).  
Among men, the mean number of cardiovascular bed-days per hospital user (+9.2), other (+7.1), 
renal (+6.6), all (+5.8) and peripheral vascular (+5.2) complications showed marked increases. 
When the duration of diabetes was longer, men clearly had more bed-days per user due to 
peripheral vascular (15.1 vs. 7.3) and renal (20.1 vs. 16.1) complications than women. 
5.3.4. Length of stay 
Total population 
Figure 20 depicts the average LOS in inpatient care according to the duration of diabetes. 
Generally, LOS was longest for the treatment of cerebrovascular complications, and here it also 
increased with the longer duration of diabetes. The biggest increase in LOS was for the treatment 
of cardiovascular complications (2.5 to 8.7 days). LOS for the treatment of neurological and 
opthalmic complications and coma had a drop of about 2 days. All complication groups 
combined had a drop in LOS from 7.9 to 7 days, and LOS for total inpatient care (for any cause) 
dropped from 7.6 to 6.9 days. 
 
Length of stay by sex 
Figure 7 in Appendix 2 shows LOS by sex and duration of diabetes. Generally, among both 
sexes, LOS for many complications seemed to decrease as diabetes lasted longer, and men 
seemed to have stayed slightly longer in hospital during their treatment periods than women. 
LOS due to ophthalmic complications and coma had a clear drop among both sexes, as did LOS 
due to renal complications among women, when the duration of diabetes increased. LOS due to 
peripheral vascular complications clearly dropped among women, but increased among men, 
when diabetes lasted longer. However, LOS due to cardiovascular complications increased in 
both sexes when the duration of T1DM increased. LOS due to cerebrovascular complications 
increased in women, but decreased in men. However, the number of patients in these groups was 
small, which affect the reliability of these results. LOS due to other causes than complications 
dropped more than LOS due to complications. 
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Table 7 shows the mean LOS calculated by two different methods. In calculating ‘LOS by time’, 
bed-days in the treatment period, that started before or continued after the observation period 
were omitted. ‘LOS by discharge’ takes into account all bed-days within a particular treatment 
period. As shown, ‘LOS by discharge’ may yield a somewhat longer LOS than ‘LOS by time’. 
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5.3.5. Most common diagnoses 
Table 1 in Appendix 1 shows the individual diagnoses (ICD-8/ICD-9), that caused the most 
bed-days during the two 3-year observation periods. Regarding total inpatient care, diabetes 
without complications (25000/2500B) was a dominating diagnosis when diabetes had lasted 9-11 
years, representing 61% of all bed-days and 71% of bed-days due to other causes than 
complications. The number of bed-days due to the treatment of diabetes without complications 
was 4.2-fold that due to the treatment of complications when diabetes had lasted 9-11 years. Its 
share dropped by 72%, when the duration of diabetes increased, representing 19% of all bed-
days and 34% of bed-days due to other causes than complications. It is notable that the number 
of bed-days due to treating complications was now 2.4-fold that due to treating other diseases 
than complications.  
The number of bed-days for treating diabetic nephropathy (25004/2503B) showed a 7-fold rise 
when the duration of diabetes increased. 
The numbers of bed-days for treating all other defined complications (25008/2507B), ophthalmic 
complications and retinopathy (25002-3/2504B/3620B) increased over 3-fold, while the number 
of bed-days for treating non-defined complications (25009/2508B) decreased 63% when the 
duration of diabetes increased.  
The treatment of mental diseases and disorders (e.g. various personality disorders. schizophrenia. 
depression) seemed to cause a lot of bed-days and long treatment periods, although most of the 
inpatient periods were caused by only few patients. The longest treatment periods were for 
treating schizophrenia (71 days in the younger cohort and 330 days in the older one). Bed-days 
due to certain other mental disorders also increased as diabetes lasted longer.  
Measured by bed-days and discharges, ketoacidosis (2501B), diabetic microangiopathy (2506B), 
diabetic neuropathy (25005/2505B) and coma (25007/2502B) were among the most common 
diagnoses in the cohort with a longer duration of diabetes.  
The changes in the numbers of bed-days during the two 3-year periods relating to certain 
diagnoses in opthalmic complications turned out to be interesting. The number of bed-days due 
to treatment of glaucoma (375.xx/365.x) was 8-fold and that due to treatment of diabetic 
retinopathy (25002/3620B) 2.7-fold in the older cohort compared with the younger one. The 
number of bed-days due to treating cataracts (25001/3664A/374.xx/366.x) increased by 36% as 
diabetes lasted longer. 
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5.3.6. T1DM-related hospital use 
T1DM-related hospital use (ICD-8 code 25000 and ICD-9 code 2500B, and complications) is 
presented below in this subsection separately, as is total hospital use.  
Table 8 shows the numbers of total and T1DM-related bed-days by sex in the two 3-year 
observation periods in the cohort. As shown, the number of bed-days used for treatment of 
T1DM without complications had a considerable drop, while that for treatment of complications 
increased notably.  
 
Table 8. Numbers of total and T1DM-related bed-days by sex in two observation periods 
of three years.  
              
       
 Number of bed-days 
 T1DM 9-11 years T1DM 16-18 years   
  Females Males Total Females Males Total 
ICD codes 
25000/2500B 15,499 12,545 28,044 4,156 3,555 7,711 
Complications 3,507 3,235 6,742 9,443 8,715 18,158 
 = T1DM use 19,006 15,780 34,786 13,599 12,270 25,869 
Total use 24,571 21,415 45,986 21,265 19,404 40,669 
              
 
  
 
Table 9 shows the yearly number of bed-days by sex and duration of T1DM among patients 
without complications (ICD codes 25000/2500B) and those with complications per 1,000 
patients per year. The table clearly shows women’s dominance in the use of bed-days, especially 
bed-days due to T1DM without complications (50.1% more bed-days than men when T1DM had 
lasted 9.5 years and 40.4% more after a duration of 16.5 years). Women had 30%-50% more 
bed-days than men in all of the categories shown in the table. The sex difference in T1DM-
related hospital use levelled off somewhat as diabetes lasted 16.5 years (46.3% to 33.1%).  
Table 9 shows that there were notable changes in 7 years (duration of T1DM 9.5 years vs. 
16.5years) in the use of bed-days. The yearly number of bed-days of T1DM without 
complications dropped by 72% in 7 years (the amount was 3.5 times bigger in the 9.5-year 
cohort), while bed-days due to complications of T1DM ‘acted’ in the opposite way, their number 
increased 2.8-fold in 7 years. The number of bed-days of T1DM-related hospital use dropped by 
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24% (females -27%. males -20%) in 7 years; its share was almost one-third bigger in the 9.5-
year cohort. The number of total bed-days for any cause per 1,000 patients per year decreased by 
9.6% (females –12%. males –7%) in 7 years. 
 
Table 9. Numbers of total and T1DM-related yearly bed-days by sex per 1000 patients by 
duration of T1DM 
          
     
 Number of bed-days per 1,000/year   
 T1DM 9.5 years  
 Females Males Total Difference (%) between sexes 
ICD codes 25000/2500B 2,235 1,489 1,826 50.1 
Complications 506 384 439 31.7 
 = T1DM use 2,741 1,873 2,265 46.3 
Total use 3,543 2,542 2,994 39.4 
     
 T1DM 16.5 years  
 Females Males Total Difference (%) between sexes 
ICD codes 25000/2500B 609 433 513 40.4 
Complications 1,383 1,063 1,208 30.2 
 = T1DM use 1,992 1,496 1,721 33.1 
Total use 3,114 2,366 2,706 31.6 
          
     
 
There were considerable changes in the structure of hospital use with longer disease duration. 
When diabetes had lasted on average 9.5 years, 61% of the total yearly bed-days per 1,000 
patients was due to T1DM without complications, compared with 19% when diabetes had lasted 
16.5 years. The corresponding shares due to complications were 14.7% and 44.6%; and 75.6% 
and 63.6% for T1DM-related hospital use when the disease lasted longer. Between sexes, the 
differences in the structures were rather small; when T1DM had lasted 9.5 years, women seemed 
to use slightly more bed-days for the treatment of T1DM without complications than male 
patients. The difference levelled off with longer disease duration.  
Around 20% of T1DM-related bed-days was due to complications when diabetes had lasted on 
average 9.5 years, but the share rose to over 70% when diabetes had lasted 16.5 years. 
Table 10 shows the numbers of discharges due to T1DM without complications, due to T1DM 
with complications, due to total T1DM-related hospital use and due to total hospital use (for any 
cause) per 1,000 patients per year by sex and duration of diabetes, and the differences between 
the sexes. Women's dominance was even clearer in the yearly numbers of discharges than in 
96
  
 
 
those of bed-days, especially in the numbers of discharges when the duration of diabetes was 9.5 
years; women used hospital over 55% more frequently than men due to T1DM without 
complications, and their T1DM-related hospital use was almost 52% more frequent.  
 
Table 10. Numbers of total and T1DM-related yearly discharges by sex per 1000 patients 
by duration of T1DM 
          
     
 
Number of discharges per 
1,000/year   
 T1DM 9.5 years  
 Females Males Total Difference (%) between sexes 
ICD codes 
25000/2500B 312 201 251 55.2 
Complications 67 48 57 39.6 
 = T1DM use 379 250 308 51.6 
Total use 486 335 403 45.1 
     
 T1DM 16.5 years  
 Females Males Total Difference (%) between sexes 
ICD codes 
25000/2500B 123 85 102 44.7 
Complications 205 150 175 36.7 
 = T1DM use 328 235 227 39.6 
Total use 501 359 423 39.6 
          
     
 
 
There were notable changes in 7 years (duration of diabetes 9.5 years vs. 16.5 years) in the 
frequency of discharges. The yearly number of discharges per 1,000 patients due to T1DM 
without complications dropped by 59% in 7 years (their amount being 2.5 times bigger in the 
younger cohort), while the number of discharges per 1,000 patients due to complications of 
T1DM increased 3-fold in 7 years. The number of discharges per 1,000 patients in T1DM-related 
hospital use dropped by 10% (females -14%, males -6%) in 7 years. However, the yearly number 
of all discharges per 1,000 patients for any cause increased little in 7 years. 
Table 11 presents the LOS due to T1DM without complications. T1DM with complications, 
total T1DM-related hospital use and total hospital use (due to any cause) per year by sex and 
duration of diabetes. LOS decreased clearly with diabetes duration, especially in the treatment of 
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T1DM without complications (-2.3 days). In their treatment periods, male patients stayed a bit 
longer in hospital than female ones.  
 
Table 11. Total and T1DM-related yearly mean LOS in hospital by sex by duration of 
T1DM 
              
       
 Mean length of stay in hospital 
 T1DM 9.5 years T1DM 16.5 years   
  Females Males Total Females Males Total 
ICD codes 
25000/2500B 7.2 7.4 7.3 4.9 5.1 5.0 
Complications 7.5 7.9 7.7 6.8 7.1 6.9 
 = T1DM use 7.2 7.5 7.4 6.1 6.4 6.2 
Total use 7.3 7.6 7.4 6.2 6.6 6.4 
              
       
 
5.4. Yearly costs of inpatient care of T1DM by duration of diabetes  
(9.5 years vs. 16.5 years) and sex 
5.4.1. Structure of costs of inpatient care  
Total population 
Table 2 in Appendix 1 presents the distribution of hospital costs by complications and total 
hospital use. Figures 21 and 22 show graphically how the distribution of total hospital cost due 
to complications, diabetes without complications (ICD codes 2500B/25000) and the rest of other 
use changed rather radically as the duration of T1DM increased. ‘Other use’ consists of use due 
to diabetes without complications, hypoglycaemia and the rest of other use. ‘T1DM use’ consists 
of use due to all complication groups combined (total complications) and due to diabetes without 
complications (ICD codes 2500B/25000).  
The tables and figures mentioned above show that of the total costs of hospital use when T1DM 
duration was 9.5 years the costs due to complications formed around 14%, the costs due to 
diabetes without complications almost 61% and the costs of the rest of other use 25%. The costs 
of T1DM-related use formed three quarters of the total costs. Compared with the costs due to all 
complications, the total costs were 7-fold, the costs due to other reasons 6-fold and the costs due 
to diabetes without complications 4.3-fold when T1DM had lasted 9.5 years. Of all 
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complications, the costs due to other complications, and ophthalmic and renal complications 
were the highest; their combined share of total costs was around 12%, and over 84% of the costs 
of all complications.  
When T1DM had lasted 16.5 years, the share of all complications of the total costs rose to over 
45%, that due to diabetes without complications dropped to around 16% and that due to the rest 
of other use increased to almost 39%. Compared with the costs due to all complications, the total 
costs were 2.2-fold, the costs due to other reasons 1.2-fold and the costs due to diabetes without 
complications around one-third when T1DM had lasted 16.5 years. The most expensive 
complication groups were ophthalmic, other complications and renal complications; and their 
combined share was over 40% of total costs, and over 88% of the costs of all complications.  
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Cost structure by sex 
Table 12 shows the distribution of hospital costs by sex and duration of T1DM. Women seemed 
to have a higher proportion of complication treatment costs due to ophthalmic complications, 
while those due to other complications were relatively higher in men, when T1DM had lasted 9.5 
years. The latter difference somewhat levelled of, as the increased duration of T1DM .  
5.4.2. Costs of inpatient care per patient 
Total population 
Yearly average costs per patient by duration of T1DM are presented in Table 3 in Appendix 1 
and in Figure 23. When the duration of T1DM was 9.5 years, the total hospital costs per patient 
were around 1,399 €, those of T1DM-related costs were 1,050 € and those of all complications 
were over 198 €. Of all complications, treatment costs of other and ophthalmic complications 
were clearly the most prominent.  
When the duration of T1DM was 16.5 years, total yearly hospital costs per patient decreased by 
20.7% (to 1,109 €), while those of all complications 2.5-folded (507 €). T1DM-related treatment 
costs and other hospital costs dropped notably due to a remarkable decrease (-79.5%) in costs for 
treating diabetes without complications (2500B). Costs of all complication groups, except those 
of coma, increased markedly. Costs due to peripheral vascular complications 5.7-folded, those of 
renal complications 4.6-folded and those of ophthalmic complications 2.8-folded as the duration 
of T1DM increased by an average of 7 years. Costs of treating a patient with cerebrovascular or 
cardiovascular complications showed big changes in percentages when T1DM had lasted 9.5 
years on average, but the numbers of hospital users were small (n=5 and 9).  
101
  
 
T
ab
le
 1
2.
 S
ha
re
s (
%
) o
f t
he
 a
nn
ua
l c
os
ts
 o
f c
om
pl
ic
at
io
n 
gr
ou
ps
 o
f t
ot
al
 in
pa
tie
nt
 c
os
ts
 a
nd
 sh
ar
es
(%
) o
f t
he
 a
nn
ua
l  
   
   
   
   
   
  c
os
ts
 o
f c
om
pl
ic
at
io
n 
gr
ou
ps
 o
f t
he
 c
os
ts
 o
f a
ll 
co
m
pl
ic
at
io
ns
 b
y 
th
e 
du
ra
tio
n 
of
 T
1D
M
 a
nd
 se
x.
 
 
 
 
Sh
ar
es
 (%
) o
f t
ot
al
 c
os
ts
 
 
Sh
ar
es
 (%
) o
f c
om
pl
ic
at
io
n 
co
st
s 
 
 T
1D
M
 9
.5
 
yr
s. 
 
 T
1D
M
 9
.5
 
yr
s. 
 
 T
1D
M
 1
6.
5 
yr
s. 
 
 T
1D
M
 1
6.
5 
yr
s. 
 
 
 T
1D
M
 9
.5
 
yr
s. 
 
 T
1D
M
 9
.5
 
yr
s. 
 
 T
1D
M
 1
6.
5 
yr
s. 
 
 T
1D
M
 1
6.
5 
yr
s. 
 
  
Fe
m
al
es
 
M
al
es
 
Fe
m
al
es
 
M
al
es
 
  
Fe
m
al
es
 
M
al
es
 
Fe
m
al
es
 
M
al
es
 
C
ER
V
A
SC
 
0.
1 
0.
1 
0.
5 
0.
1 
 
0.
8 
0.
8 
1.
1 
0.
2 
C
A
R
V
A
SC
 
0.
0 
0.
1 
0.
8 
0.
8 
 
0.
0 
0.
6 
1.
8 
1.
8 
PE
R
V
A
SC
 
0.
3 
0.
4 
1.
7 
3.
5 
 
2.
1 
3.
0 
3.
8 
7.
7 
N
EU
R
O
L 
0.
2 
0.
7 
0.
9 
0.
8 
 
1.
5 
5.
0 
2.
0 
1.
7 
R
EN
A
L 
1.
9 
1.
6 
11
.1
 
9.
5 
 
13
.2
 
11
.3
 
24
.2
 
20
.7
 
EN
D
O
C
R
IN
 
0.
0 
0.
0 
0.
0 
0.
0 
 
0.
0 
0.
0 
0.
0 
0.
0 
O
PH
TH
A
LM
IC
 
5.
7 
3.
9 
18
.3
 
16
.5
 
 
39
.4
 
28
.1
 
39
.9
 
36
.1
 
O
TH
ER
 c
om
pl
ic
at
. 
4.
8 
6.
0 
11
.9
 
13
.7
 
 
33
.1
 
43
.0
 
26
.0
 
30
.0
 
C
O
M
A
 
1.
4 
1.
1 
0.
5 
0.
8 
 
9.
8 
8.
2 
1.
2 
1.
7 
C
om
pl
ic
at
io
ns
 
to
ta
l 
14
.4
 
14
.0
 
45
.8
 
45
.7
 
 
10
0.
0 
10
0.
0 
10
0.
0 
10
0.
0 
H
yp
og
ly
ca
em
ia
 
0.
0 
0.
0 
0.
4 
0.
2 
 
0.
0 
0.
0 
1.
0 
0.
5 
25
00
B
/2
50
00
 
62
.5
 
58
.9
 
16
.2
 
15
.2
 
 
43
4.
0 
42
2.
5 
35
.5
 
33
.2
 
R
es
t o
f o
th
er
 u
se
 
23
.0
 
27
.1
 
38
.0
 
39
.2
 
 
15
9.
9 
19
4.
3 
83
.1
 
85
.8
 
O
TH
ER
 u
se
 
85
.6
 
86
.0
 
54
.2
 
54
.3
 
 
59
3.
9 
61
6.
8 
11
8.
6 
11
9.
0 
T1
D
M
 u
se
 
77
.0
 
72
.9
 
62
.0
 
60
.8
 
 
53
4.
0 
52
2.
5 
13
5.
5 
13
3.
2 
TO
TA
L 
us
e 
10
0.
0 
10
0.
0 
10
0.
0 
10
0.
0 
 
69
3.
9 
71
6.
8 
21
8.
6 
21
9.
0 
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
ce
rv
as
c 
= 
ce
re
br
ov
as
cu
la
r d
is
ea
se
; c
ar
va
sc
 =
 c
ar
di
ac
 d
is
ea
se
; p
er
va
sc
 =
 p
er
ip
he
ra
l v
as
cu
la
r d
is
ea
se
; 
ne
ur
ol
 =
 n
eu
ro
lo
gi
ca
l c
om
pl
ic
at
io
ns
; r
en
al
 =
 re
na
l c
om
pl
ic
at
io
ns
; e
nd
oc
rin
 =
 e
nd
oc
rin
e 
co
m
pl
ic
at
io
ns
;  
op
ht
ha
lm
ic
 =
 o
ph
th
al
m
ic
 c
om
pl
ic
at
io
ns
; 2
50
0B
/2
50
00
 =
 T
1D
M
 w
ith
ou
t c
om
pl
ic
at
io
ns
 (I
C
D
-9
/IC
D
-8
 c
od
es
); 
ot
he
r u
se
 =
 h
yp
og
ly
ca
em
ia
 +
 2
50
0B
/2
50
00
 +
 re
st
 o
f o
th
er
 u
se
 (a
ny
 in
pa
tie
nt
 u
se
 o
th
er
 th
an
 T
1D
M
-r
el
at
ed
); 
 
T1
D
M
 u
se
 =
 c
om
pl
ic
at
io
ns
 to
ta
l +
 2
50
0B
/2
50
00
 
 
 
102
 
 
  
0
10
0
20
0
30
0
40
0
50
0
60
0
70
0
80
0
90
0
1,
00
0
1,
10
0
1,
20
0
1,
30
0
1,
40
0
1,
50
0
CERV
ASC
CARV
ASC
PERV
ASC
NEUR
OL
RENA
L
ENDO
CRIN
OPHT
HALM
IC
OTHE
R com
plicat.
COMA
Compl
ication
s total
Hypog
lycaem
ia
2500B
/25000
Rest o
f other
 
use
OTHE
R use
T1DM
-
use
TOTAL
 
use
C
os
ts
 p
er
 p
at
ie
nt
  T
1D
M
 
9.
5 
yr
s 
C
os
ts
 p
er
 p
at
ie
nt
 T
1D
M
 1
6.
5 
yr
s
 
   
   
   
   
   
   
   
   
   
   
Fi
gu
re
 2
3.
   
A
ve
ra
ge
 a
nn
ua
l c
os
ts
 (€
) p
er
 p
at
ie
nt
 in
 th
e 
co
ho
rt 
by
 c
om
pl
ic
at
io
n 
gr
ou
p 
an
d 
du
ra
tio
n 
of
 T
1D
M
 
103
  
 
Cost by sex  
Yearly costs of hospital care per female patient are presented in Table 13. When T1DM had 
lasted 9.5 years, total costs per female patient were over 1,642 €. T1DM-related costs were 1,264 
€ and costs of all complications were slightly over 236 €. Of all complications, treatment costs of 
ophthalmic and other complications were clearly the highest. 
When the duration of T1DM was 16.5 years, total hospital costs per female patient decreased by 
22.1%, while those of all complications almost 2.5-folded (to 586 €). Costs of all complication 
groups (except those of coma), increased considerably. Costs due to renal complications 4.5-
folded, those due to peripheral vascular complications 4.4-folded, those due to neurological 
complications 3.2-folded and those due to ophthalmic complications 2.5-folded as the duration 
of T1DM increased. Treatment costs due to ophthalmic complications clearly remained the 
highest (234 €), followed by costs due to other and renal complications.  
Annual hospital costs per male patient are presented in Table 13. When T1DM had lasted 9.5 
years, total hospital costs per male patient were over 1,198 €. T1DM-related costs were slightly 
over 873 €, and costs of all complications exceeded 167 €. Of all complications, treatment costs 
of other complications were clearly the highest, followed by those of ophthalmic complications.  
When the duration of T1DM increased to 16.5 years, total annual hospital costs per male patient 
decreased by 19.4%, while those of all complications over 2.6-folded (to 441 €). Costs of many 
complication groups increased substantially. Costs due to peripheral vascular complications 6.8-
folded, those due to renal complications 4.8-folded and those due to ophthalmic complications 
3.2-folded as duration of T1DM increased. Now treatment costs of ophthalmic complications 
became the highest (159 €), followed by those of other complications.  
Table 13, and Figures 8 and 9 in Appendix 2 present the sex differences in average annual 
hospital costs per patient by duration of T1DM. Women dominated in almost every cost 
category. When T1DM had lasted 9.5 years, total hospital costs in women were 37% higher, 
those due to T1DM were almost 45% higher and those due to all complications were over 41% 
higher than the respective figures for men. Treatment costs of ophthalmic and renal 
complications and coma per person were 65%- 98% higher in women. Costs due to neurological 
complications were over two times higher in men.  
As the duration of T1DM increased to 16.5 years, the cost differences somewhat narrowed but 
nevertheless persisted in most cost categories. The sex difference in costs per patient diminished 
around 10 percentage points in T1DM-related hospital costs and in costs of all complications 
combined. Women had distinctly higher costs in renal, ophthalmic and neurological 
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complications than men (around 50% higher). Treatment costs due to peripheral vascular 
complications were over 50% higher in men.  
5.4.3.  Total costs of inpatient care in the cohort  
Total annual costs of inpatient care in the whole cohort are presented in Table 14 by duration of 
T1DM and by sex. Total costs of inpatient care dropped from 7.2 million to 5.6 million euros, 
and those of care related to T1DM dropped from 5.4 million to 3.4 million euros when the 
duration of T1DM was longer. Conversely, treatment costs of all complications combined 
increased from around 1 million to slightly over 2.5 million euros. Treatment costs of 
ophthalmic, other and renal complications rose approximately to 1 million, 0.7 million and 0.6 
million euros, respectively, when the duration of diabetes increased; treatment costs due to 
ophthalmic complications alone were now almost as high as those of all complications combined 
when T1DM had lasted 9.5 years.  
Yearly total treatment costs due to inpatient care, care of all complications, other hospital use 
and care of many complications were higher in women than in men, although there were 
approximately 20% more men in both cohorts. 
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5.4.4. Costs of inpatient care per hospital user 
Total population 
Annual treatment costs per hospital user by duration of T1DM are presented in Table 15, and 
Figure 10 in Appendix 2. When the duration of T1DM was 9.5 years, total hospital costs per 
hospital user were little over 7,881 € and those of all complications 5,361 €. Of all 
complications, treatment costs per hospital user for ophthalmic complications were highest 
(5,758 €), followed by those for other, cerebrovascular and renal complications.  
 
Table 15. Annual costs (€) per inpatient hospital user by complication group and duration   
of T1DM, and changes in costs with increased duration of diabetes 
        
 Cost per Cost per Change in 
 hospital user hospital user costs (%) 
  T1DM 9.5 yrs T1DM 16.5 yrs 9.5/16.5 yrs. 
CERVASC 4,735 5,361 13.2 
CARVASC 1,044 6,024 476.8 
PERVASC 3,341 3,808 14.0 
NEUROL 3,280 2,474 24.6 
RENAL 4,712 6,131 30.1 
ENDOCRIN  1,044  
OPHTHALMIC 5,758 5,796 0.7 
OTHER complicat. 4,913 6,437 31.0 
COMA 3,335 2,179 34.7 
Complications total 5,361 7,255 35.3 
Hypoglycaemia  1,864  
2500B/25000 6,089 2,832 53.5 
OTHER use 7,327 4,842 33.9 
TOTAL use 7,881 6,991 11.3 
        
    
cervasc = cerebrovascular disease; carvasc = cardiac disease; pervasc = peripheral vascular disease; 
neurol = neurological complications; renal = renal complications; endocrin = endocrine complications;  
ophthalmic = ophthalmic complications; 2500B/25000 = T1DM without complications (ICD-9/ICD-8 codes); 
other use = hypoglycaemia + 2500B/25000 + rest of other use (any inpatient use other than T1DM-related);  
 
 
When duration of T1DM increased to 16.5 years, total costs of inpatient care per hospital user 
decreased slightly, while those of all complications increased by one-third (to 7,255 €). The costs 
of treating a patient with diabetes without complications (2500B) dropped by over 50%. Treatment 
costs due to other, renal, cardiovascular and ophthalmic complications produced the highest costs 
per hospital user (around 6,000 €) when the duration of T1DM increaced by 7 years. 
The numbers of cerebrovascular and cardiovascular patients were, however, very small. 
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By sex 
Annual treatment costs per hospital user by duration of T1DM and by sex are presented in Table 
16, and in Appendix 2 in Figure 11. When T1DM had lasted 9.5 years, total hospital costs per 
female hospital user were 8,447 € and those of all complications 5,567 €. Of all complications, 
treatment costs of ophthalmic complications per female hospital user were clearly the highest 
(6,214 €), followed by costs of other and renal complications.  
When the duration of T1DM increased to 16.5 years, total costs of inpatient care per female user 
decreased by almost 15%, while those of all complications increased by almost one-third (to 
7,208 €). Treatment costs due to cardiovascular (almost 9,000 €), cerebrovascular, other, 
ophthalmic and renal complications produced the highest costs per female hospital user. 
When T1DM had lasted 9.5 years, total hospital costs per male hospital user were 7,327 € and 
those of all complications 5,140 €. Of all complications, treatment costs per male hospital user 
for cerebrovascular, ophthalmic, other and renal complications were the highest.  
When the duration of T1DM increased to 16.5 years, total hospital costs per male user decreased 
slightly, while those of all complications increased by over 42% (to 709 €). Treatment costs due 
to renal complications increased by 45% (to 7,009 €), and these costs were now the highest of all 
complications, followed by those of other, ophthalmic and peripheral vascular complications 
(which increased by over 50%), as the duration of T1DM increased. Treatment costs per male 
user due to coma dropped by over one-third. 
The sex differences in yearly treatment costs per hospital user by duration of T1DM are 
presented in Table 17, and in Appendix 2 in Figure 11. When T1DM had lasted 9.5 years, total 
hospital costs in women were somewhat higher (+15.3%) and those due to all complications per 
person were a little higher (+8.3%) than the respective costs in men. Treatment costs of 
ophthalmic complications were over 20% higher in women, while those due to neurological 
complications were 69% higher in men.  
As the duration of T1DM increased to 16.5 years, the sex difference in treatment costs per 
hospital user narrowed in total hospital costs, and in all complications combined the difference 
was negligible. Women had over double the treatment costs of men for cardiovascular and renal 
complications, while treatment costs due to peripheral vascular complications per user were now 
two times higher in men, as the duration of T1DM increased.  
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5.4.5. Costs per treatment period  
Total population 
Annual costs per treatment period by duration of T1DM are presented in Table 18, and in 
Appendix 2 in Figure 12. When the duration of T1DM was 9.5 years, total inpatient costs per 
treatment period were slightly in excess of 3,472 €, those of T1DM-related costs were somewhat 
less and those of all complications were almost 3,500 €. Costs per treatment period of 
ophthalmic complications were highest (4,435 €), followed by those of cerebrovascular and other 
complications.  
 
Table 18. Annual cost (€) per treatment period by complication group and duration  
                 of T1DM and changes (%) in costs, with increased duration of diabetes 
        
 Costs per Costs per Change in 
 treatment period, treatment period, costs (%) 
   T1DM 9.5 yrs.  T1DM 16.5 yrs 9.5/16.5 yrs 
CERVASC 3,946 4,874 23.5 
CARVASC 855 3,012 252.5 
PERVASC 2,562 2,531 1.2 
NEUROL 2,320 1,621 30.1 
RENAL 3,195 2,670 16.4 
ENDOCRIN  1,044  
OPHTHALMIC 4,435 3,315 25.3 
OTHER complicat. 3,537 2,922 17.4 
COMA 2,587 1,651 36.2 
Complications total 3,494 2,900 17.0 
Hypoglycaemia 0 1,313  
2500B/25000 3,392 1,710 49.6 
Rest of other use 3,659 2,919 20.2 
OTHER use 3,466 2,423 30.1 
T1DM use 3,409 2,460 27.9 
TOTAL use 3,472 2,622 24.5 
        
    
cervasc = cerebrovascular disease; carvasc = cardiac disease; pervasc = peripheral vascular disease; 
neurol = neurological complications; renal = renal complications; endocrin = endocrine complications;  
ophthalmic = ophthalmic complications; 2500B/25000 = T1DM without complications (ICD-9/ICD-8 codes); 
other use = hypoglycaemia + 2500B/25000 + rest of other use (any inpatient use other than T1DM-related);  
T1DM use = complications total + 2500B/25000 
 
As the duration of T1DM was 16.5 years, total inpatient costs per treatment period decreased by 
almost 25% (to 2,622 €) and those of all complications by 17%. Costs per treatment period of 
T1DM-related use and those of other hospital use dropped notably. There was also a marked 
decrease (-49.6%) in costs due to treating diabetes without complications (2500B). Costs per 
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treatment period of all complication groups decreased, except those of cerebrovascular and 
cardiovascular complications. Costs per treatment period of cerebrovascular complications were 
the highest, followed by those of ophthalmic, cardiovascular and other complications.  
Again, it should be born in mind that the numbers of cerebrovascular and cardiovascular patients 
were small. 
By sex  
Costs per treatment period by duration of T1DM and sex are presented in Table 19, and in 
Appendix 2 in Figure 13. The changes in costs per treatment period by the duration of T1DM 
were very similar in both sexes in total use, T1DM-related use, other use and use due to 
complications combined. In women, the costs per treatment period of coma and renal, 
ophthalmic and peripheral vascular complications had a clear drop, as the duration of T1DM 
increased. In men, the costs per treatment period of neurological complications, coma and 
ophthalmic complications dropped most when the duration of diabetes increased. 
The sex differences in the costs per treatment period by duration of T1DM are presented in 
Appendix 1 in Table 4, and in Appendix 2 in Figure 13. As for total costs and costs due to all 
complications, the differences were very small. When T1DM had lasted 9.5 years, costs per 
treatment period due to neurological complications in men were over 43% higher than in women, 
those due to peripheral vascular complications were over 58% higher and those due to renal 
complications were nearly 22% higher when T1DM had lasted on average 16.5 years.
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5.5. Inpatient care of T1DM in 1998 by sex 
In 1998, T1DM had lasted on average 25 years (18-33 years; SD 4.3), and the average age of the 
study population was 35.3 years (19-51 years; SD 6.1). The average age at diagnosis was 10.2 
years (males 10.4 years; females 9.9 years).  
5.5.1.  Numbers of hospital users 
The numbers of hospital users in 1998 are presented in Table 5 in Appendix 1. The total 
number of hospital users due to any cause was 566, accounting for 12% of the whole cohort 
(N=4701). Around 9% (412 persons) of the cohort used hospital treatment due to complications. 
There were 17% more men than women in the cohort in 1998. There were over 14% more males 
than females using inpatient care due to complications. 
Of the complications, renal, ophthalmic and other complications showed a clear dominance, 
forming 93% of hospital users due to all complications and two-thirds of hospital users due to 
any cause. The proportion of hospital users due to any complication was 73% of all hospital 
users in 1998. Only a few patients used inpatient care due to cerebrovascular complications or 
hypoglycaemia, and no patient needed treatment due to endocrine complications.  
5.5.2. Discharges  
The proportions of discharges due to complications by diagnostic group and sex are depicted in 
Table 20. The majority of discharges were due to treatment of complications. The share of 
discharges due to all complications was over 70%, and the share of T1DM-related discharges 
(complications + diabetes without complications ICD 2500B) was over three-quarters of all 
hospital discharges. 
By this measure of hospital use, renal complications was the biggest group of complications, 
forming over 44% (women 51.4%, men 39%) of discharges due to complications and almost 
one-third (women 35.4%, men 28.9%) of all discharges. Discharges due to other, ophthalmic and 
peripheral vascular complications were the next most common groups. 
Table 6 in Appendix 1 shows the numbers of hospital discharges per 1,000 patients by sex in 
1998. Men had around 11% more discharges due to all complications combined and 3% more 
total hospital discharges than women. By complication groups, men had more discharges related 
to peripheral vascular complications (98% more), coma (95% more) and other complications 
(around 22% more) than women. Women had around 18% more renal discharges than men. 
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Discharges per hospital user in 1998 are depicted in Table 7 in Appendix 1. Peripheral vascular 
complications (3.0 visits; females 1.8, males 4.2) and renal complications (2.7 visits) caused the most 
frequent hospital use per user. Overall, men used hospital somewhat more frequently than women. 
5.5.3. Bed-days  
Table 21, and Figure 14 in Appendix 2 show the distributions of bed-days due to complications 
and all bed-days by diagnostic group and sex in 1998. The bed-days of all complications 
combined formed around 72% of total hospital bed-days. The share of bed-days due to renal 
complications was overwhelming; its share of bed-days of all complications was 52.7% (women 
60%, men 46.7%) and of all bed-days 38% (women 42. 6%, men 34. 2%). 'Other complications' 
was clearly the second biggest group, followed by peripheric vascular and ophthalmic 
complications.  
 
Table 21. Shares (%) of bed-days due to complications and all bed-days in 1998 by sex 
       
 Shares (%) of bed-days due to 
complications 
Shares (%) of all bed-days 
  
Total 
(fem + male) females males 
Total 
(fem + male) females males 
CERVASC 2.7 5.3 0.5 1.9 3.7 0.4 
CARVASC 3.6 4.7 2.8 2.6 3.3 2.0 
PERVASC 9.3 7.1 11.1 6.7 5.0 8.1 
NEUROL 1.5 0.1 2.6 1.1 0.1 1.9 
RENAL 52.7 60.0 46.7 38.0 42.6 34.2 
ENDOCRIN 0.0 0.0 0.0 0.0 0.0 0.0 
OPHTHALMIC 6.7 5.8 7.4 4.8 4.1 5.4 
OTHER complications 21.2 15.7 25.7 15.3 11.1 18.8 
COMA 2.4 1.5 3.2 1.7 1.0 2.3 
Complications total 100.0 100.0 100.0 72.1 70.9 73.1 
Hypoglycaemia    0.0 0.0 0.0 
2500B    4.4 4.2 4.7 
Rest of other use    23.5 24.9 22.2 
Other use    27.9 29.1 26.9 
T1DM use    76.5 75.1 77.8 
TOTAL use    100.0 100.0 100.0 
              
       
cervasc = cerebrovascular disease; carvasc = cardiac disease; pervasc = peripheral vascular disease; 
neurol = neurological complications; renal = renal complications; endocrin = endocrine complications;  
ophthalmic = ophthalmic complications; 2500B = T1DM without complications (ICD-9 code); 
other use = hypoglycaemia + 2500B + rest of other use (any inpatient use other than T1DM-related);  
T1DM use = complications total + 2500B; total use = complications total + other use  
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Table 8 in Appendix 1 and Figure 15 in Appendix 2 show the bed-days per 1,000 patients in 
1998. Men had slightly more bed-days than women measured by either bed-days due to 
complications, bed-days related to T1DM or all bed-days. By groups of complications, women 
had 24% more bed-days due to renal and 62% more bed-days due to cardiovascular 
complications than men (the number of all cardiovascular complication patients was, however, 
rather small, n=22). Men had 70% more bed-days due to other complications, 62% more bed-
days due to peripheric vascular complications, 33% more bed-days due to ophthalmic 
complications and 123% more bed-days due to coma than women.  
Table 22, and Figure 16 in Appendix 2 show the bed-days per hospital user in 1998. In general, 
men had a little more bed-days than women. Of the complication groups, renal and peripheric 
vascular complications had led to a distinctly biggest amount of bed-days per user, the peak 
figure being 21.6 days for peripheric vascular complications in men (note, however, the presence 
of an outlier, which increased the mean of male patients). Men clearly also had more bed-days 
per user related to other and to neurological complications (the latter group contained only two 
female patients). The number of bed-days per user was high for patients with cerebrovascular 
complications, but this group contained only one female and two male patients.  
 
Table 22. Number of bed-days per hospital user in 1998 by complication group and sex 
        
 Bed-days Bed-days Bed-days 
 per hospital user, per hospital user, per hospital user, 
  total females males 
CERVASC 50.3 136.0 7.5 
CARVASC 9.4 10.0 8.7 
PERVASC 16.5 11.4 21.6 
NEUROL 6.4 1.0 7.4 
RENAL 20.1 21.2 19.2 
ENDOCRIN 0.0 0.0 0.0 
OPHTHALMIC 4.4 3.6 5.2 
OTHER complications 8.1 6.2 9.7 
COMA 3.8 3.2 4.1 
Complications total 13.8 13.6 14.0 
Hypoglycaemia 1.0 0.0 1.0 
2500B 6.6 6.3 6.9 
Other use 9.0 8.9 9.2 
TOTAL use 14.0 13.5 14.4 
        
    
cervasc = cerebrovascular disease; carvasc = cardiac disease; pervasc = peripheral vascular disease; 
neurol = neurological complications; renal = renal complications; endocrin = endocrine complications;  
ophthalmic = ophthalmic complications; 2500B = T1DM without complications (ICD-9 code); 
other use = hypoglycaemia + 2500B + rest of other use (any inpatient use other than T1DM-related);  
total use = complications total + other use  
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5.5.4. Length of stay  
Table 23 presents the LOS (and SD) in 1998. LOS of all treatment periods was rather similar to 
that for the treatment of complications. These figures were slightly higher for women than for 
men. Patients with cardiovascular (7.7 days) and renal (7.4 days) complications appeared to have 
the longest LOS, but the variances (SD) of these figures were also larger than those of the other 
complication groups, especially in women. The shortest LOS was for patients with ophthalmic 
complications and coma (2.9-3.7 days). 
 
Table 23. Length of stay (LOS) and standard deviations in hospital in 1998  
                  by complication group and sex  
              
       
 LOS SD LOS SD LOS SD 
  total total females females males males 
CERVASC 50.3 74.2 136.0  7.5 2.1 
CARVASC 7.7 9.2 9.2 11.3 6.2 6.8 
PERVASC 5.5 7.7 6.3 5.0 5.1 8.7 
NEUROL 4.0 6.1 1.0  4.3 6.4 
RENAL 7.4 12.3 7.6 15.0 7.2 8.9 
ENDOCRIN 0.0  0.0  0.0  
OPHTHALMIC 3.2 3.1 2.9 3.1 3.5 3.1 
OTHER complications 5.9 5.7 4.8 4.0 6.7 6.5 
COMA 3.5 4.0 3.2 3.1 3.7 4.4 
Complications total 6.2 10.3 6.5 13.1 6.0 7.5 
Hypoglycaemia 1.0  0.0  1.0  
2500B 5.5 6.1 4.7 3.7 6.2 7.7 
Rest of other use 6.3  6.1  6.5  
Other use 6.2 8.7 5.9 8.9 6.4 8.6 
T1DM use 6.2  6.4  6.0  
TOTAL use 6.2 9.9 6.3 12.0 6.1 7.8 
              
       
SD= standard deviation 
cervasc = cerebrovascular disease; carvasc = cardiac disease; pervasc = peripheral vascular disease; 
neurol = neurological complications; renal = renal complications; endocrin = endocrine complications;  
ophthalmic = ophthalmic complications; 2500B = T1DM without complications (ICD-9 code); 
other use = hypoglycaemia + 2500B + rest of other use (any inpatient use other than T1DM-related);  
T1DM use = complications total + 2500B; total use = complications total + other use  
 
5.5.5. Single diagnoses causing the most inpatient care 
Table 9 in Appendix 1 lists the bed-days, discharges and LOS of the diagnoses/diseases, that 
caused the most inpatient use in 1998, sorted by the number of bed-days. The table shows that in 
terms of total hospital use, 'nephropathy' (belonging to renal complications) caused three times 
119
  
 
 
more bed-days than number two on the list ('other defined complication'), 13 times more than 
number five ('ketoacidosis') and 37 times more than number 15 ('atherosclerosis'). By the end of 
1998, around every sixth person in the cohort had used hospital due to nephropathy.  
5.6. Inpatient costs of T1DM in 1998 by sex 
5.6.1. Structure of costs of inpatient care 
Table 24 shows the structure of hospital costs by complications and sex, and Figures 17 and 18 
in Appendix 2 show the same graphically. The costs of treatment due to complications 
accounted for around 70% of total costs, and other hospital use around 30% (consisting of 
treatment periods for hypoglycaemia, diabetes without complications 2500B and the rest of other 
use). All costs related to the treatment of T1DM (complications total + ICD code 2500B) 
accounted for 73.6% of total costs. A clear majority of costs was due to renal complications; the 
share was half of the complication treatment costs (women 57.3%, men 44.1%) and over one-
third of total hospital costs (women 39%, men 31.2%). The next most costly were other 
complications, ophthalmic complications and peripheral vascular complications. The rest of the 
complication groups accounted for a rather small share of costs.  
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5.6.2. Costs of inpatient care per patient 
Table 25, and Figure 19 in Appendix 2 show the costs per patient in 1998 by diagnostic groups 
and sex. Hospital costs due to renal complications were 2.5-fold those of other complications, 
4.3-fold those of ophthalmic complications and 5.7-fold those of peripheral vascular 
complications. Costs for treating renal complications alone were 14% higher than the costs due 
to other hospital use (hypoglycaemia + diabetes without complications + rest of other use), and 
formed almost half of the costs of all T1DM-related hospital use.  
 
Table 25. Mean cost (€) of inpatient care per patient in 1998 by complication group and sex 
          
 Cost Cost per Cost per Difference in 
 per female male costs (%) 
  patient patient patient between sexes 
CERVASC 11.2 21.8 2.1 959.3 
CARVASC 15.3 19.3 12.0 61.2 
PERVASC 39.0 29.2 47.4 62.2 
NEUROL 5.8 0.3 10.5 3,366.4 
RENAL 222.3 248.1 200.3 23.9 
ENDOCRIN  0.0 0.0  
OPHTHALMIC 51.3 43.5 57.9 33.3 
OTHER complications 89.3 64.9 110.2 69.9 
COMA 10.1 6.1 13.6 123.0 
Complications total 444.4 433.2 454.0 4.8 
Hypoglycaemia 0.1 0.0 0.1  
2500B 25.9 24.2 27.4 12.8 
Rest of other use 169.1 178.8 160.7 11.3 
Other use 195.0 203.1 188.0 8.0 
T1DM use 470.3 457.5 481.3 5.2 
TOTAL use 639.4 636.3 642.0 0.9 
     
          
     
cervasc = cerebrovascular disease; carvasc = cardiac disease; pervasc = peripheral vascular disease; 
neurol = neurological complications; renal = renal complications; endocrin = endocrine complications;  
ophthalmic = ophthalmic complications; 2500B = T1DM without complications (ICD-9 code); 
other use = hypoglycaemia + 2500B + rest of other use (any inpatient use other than T1DM-related);  
T1DM use = complications total + 2500B; total use = complications total + other use  
  
 
Generally, the hospital costs of all complications and the total hospital costs per patient were 
slightly higher for men than for women. The costs due to renal complications per patient were 
almost 24% higher for women than for men. The costs for treating cardiovascular complications 
were also higher in women. Treating other complications and peripheral vascular complications 
had accounted for higher costs in men. The number of users due to cerebrovascular (total 3 
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persons) and neurological complications (2 women) was small, and thus the differences (%) 
between sexes showed huge percentages.  
5.6.3. Total costs of inpatient care in the cohort 
The total costs in the whole cohort by complication group and sex are presented in Table 26. Total 
inpatient costs in the cohort (4,701 patients) in 1998 were a little over 3 million euros, of which 
costs due to treating complications accounted for over 2 million euros and those due to treating 
renal complications over 1 million euros. The costs of whole T1DM-related use totalled 2.2 million 
euros, and the costs of hospital use for other diseases than diabetes were 0.9 million euros. 
 
Table 26. Total costs (€) of inpatient care in the cohort in 1998 by complication group  
                 and sex 
        
 Costs in  Costs in  Costs in  
 1998 1998 1998 
   (per 4,701 patients) (per 2,168 females) (per 2,533 males) 
CERVASC 52,574 47,351 5,223 
CARVASC 72,071 41,780 30,291 
PERVASC 183,486 63,367 120,119 
NEUROL 27,223 656 26,567 
RENAL 1,045,207 537,923 507,284 
ENDOCRIN 0 0 0 
OPHTHALMIC 240,954 94,231 146,723 
OTHER complic. 419,893 140,661 279,232 
COMA 47,699 13,230 34,469 
Complications total 2,089,106 939,200 1,149,907 
Hypoglycaemia 348 0 348 
2500B 121,860 52,574 69,286 
Rest of other use 794,761 387,730 407,031 
Other use 916,621 440,304 476,317 
T1DM use 2,210,966 991,773 1,219,192 
TOTAL use 3,005,727 1,379,504 1,626,223 
        
    
cervasc = cerebrovascular disease; carvasc = cardiac disease; pervasc = peripheral vascular disease; 
neurol = neurological complications; renal = renal complications; endocrin = endocrine complications;  
ophthalmic = ophthalmic complications; 2500B = T1DM without complications (ICD-9 code); 
other use = hypoglycaemia + 2500B + rest of other use (any inpatient use other than T1DM-related);  
T1DM use = complications total + 2500B; total use = complications total + other use  
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5.6.4. Costs of inpatient care per hospital user 
Costs per hospital user in 1998 are presented in Table 27, and graphically in Figure 20 in 
Appendix 2. Apart from treating cerebrovascular complications (very few patients), treatment of 
renal complications formed the highest costs calculated per hospital user (7,015 €), followed by 
treatment of peripheral (5,734 €) and cardiovascular (3,276 €) complications. The costs of 
treating renal complications were 38% higher than the costs of treating of all kinds of 
complications. The mean costs for hospital use due to all complications were 5,071 €, and for the 
total inpatient cost the figure was 5,310 €.  
 
Table 27. Costs (€) of inpatient care per hospital user in 1998 by complication group  
                  and sex 
          
  Cost per Cost per Difference 
 Cost per hospital user, hospital user, in costs (%) 
  hospital user females  males  between sexes 
CERVASC 17,525 47,351 2,611 1,713.3 
CARVASC 3,276 3,482 3,029 14.9 
PERVASC 5,734 3,960 7,507 89.6 
NEUROL 2,094 328 2,415 636.4 
RENAL 7,015 7,369 6,675 10.4 
ENDOCRIN  0 0  
OPHTHALMIC 2,802 2,298 3,261 41.9 
OTHER complications 2,837 2,164 3,364 55.5 
COMA 1,325 1,103 1,436 30.3 
Complications total 5,071 4,943 5,180 4.8 
Hypoglycaemia 348 0 348  
2500B 2,299 2,191 2,389 9.1 
Other use 3,757 3,700 3,811 3.0 
TOTAL use 5,310 5,128 5,475 6.8 
          
     
cervasc = cerebrovascular disease; carvasc = cardiac disease; pervasc = peripheral vascular disease; 
neurol = neurological complications; renal = renal complications; endocrin = endocrine complications;  
ophthalmic = ophthalmic complications; 2500B = T1DM without complications (ICD-9 code); 
other use = hypoglycaemia + 2500B + rest of other use (any inpatient use other than T1DM-related);  
total use = complications total + other use  
 
 
There were notable differences in costs between sexes in 1998. In general, costs per hospital user 
were slightly higher in men than in women. The costs per male hospital user due to peripheral 
vascular complications were almost 90% higher than those for the corresponding female group. 
The costs per male user were 55% higher than those per female user in treating other 
complications and 42% higher in treating ophthalmic complications. The costs due to renal 
complications calculated per hospital user were around 10% higher in women than in men. The 
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numbers of hospital users due to cerebrovascular and neurological complications were too small 
to allow comparisons between sexes.  
5.6.5. Costs of inpatient care per treatment period 
Table 28, and Figure 21 in Appendix 2 show the costs per treatment period (discharge) in 1998. 
The mean costs of a treatment period for all kinds of diseases (total costs) and for that of all 
kinds of complications were around 2,300 euros. Hospital use due to the rest of other use (where 
2500B is excluded) and cardiovascular and renal complications accounted for the highest costs 
per treatment period.  
Table 28. Costs (€) of inpatient care per treatment period in 1998 by complication group 
and sex 
 Cost per Cost per Cost per Difference  
 treatment treatment period,  treatment period,  in costs (%) 
  period females males between sexes 
CERVASC 17,525 47,351 2,611 1,713.3 
CARVASC 2,669 3,214 2,164 48.5 
PERVASC 1,911 2,185 1,793 21.9 
NEUROL 1,296 328 1,398 326.3 
RENAL 2,581 2,637 2,524 4.5 
ENDOCRIN 0 0 0 0 
OPHTHALMIC 2,042 1,812 2,223 22.7 
OTHER complications 2,058 1,675 2,327 39.0 
COMA 1,223 1,103 1,277 15.8 
Complications total 2,288 2,366 2,229 6.2 
Hypoglycaemia 348 0 348  
2500B 1,904 1,643 2,165 31.8 
Rest of other use 2,703 2,638 2,769 5.0 
Other use 2,560 2,460 2,661 8.2 
T1DM use 2,261 2,312 2,221 4.1 
TOTAL use 2,365 2,395 2,340 2.4 
          
cervasc = cerebrovascular disease; carvasc = cardiac disease; pervasc = peripheral vascular disease; 
neurol = neurological complications; renal = renal complications; endocrin = endocrine complications;  
ophthalmic = ophthalmic complications; 2500B = T1DM without complications (ICD-9 code); 
other use = hypoglycaemia + 2500B + rest of other use (any inpatient use other than T1DM-related);  
T1DM use = complications total + 2500B; total use = complications total + other use  
Generally, the costs per treatment period in 1998 were slightly higher in women than in men for 
all kinds of complications of T1DM and for total hospital costs. Measured by this variable, costs 
due to renal complications were quite similar between the sexes. Men had higher costs per 
treatment period than women due to other (+39%) and ophthalmic (+22.7%) complications and 
due to diabetes without complications (+31.8%), while women's costs were more prominent for 
treating cardiovascular complications (+48.5%).  
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6. DISCUSSION 
6.1. General limitations of the study 
There was no non-diabetic control group. Such a control group would have given comparison 
data relating to hospital use, also in different age groups. Standardisation by sex and age would 
also have given added value to the results.  
The results of this study are valid only in the Finnish population and the Finnish health care 
system, and certain caution is needed when generalising them to other populations and health 
care systems. 
The main focus of this longitudinal study was to describe only inpatient hospital care and to 
calculate its costs, as in many studies they have proved to form a dominant share of the total 
treatment costs of persons with diabates. Registers were used, and according to previous studies 
their reliability, validity and coverage can be considered very good. Costs and use of outpatient 
care were omitted, as this data would have been difficult (or impossible) to get, especially during 
the long follow-up for this population. By conducting a survey, complimentary data of inpatient 
and outpatient hospital care could have given more value to the study and given more detailed 
information. Though, administering a survey  might have required a large sample size, and it 
would have been more expensive and time-consuming to conduct (Keskimäki et al 1997).  
Transfer payments (e.g. costs of sick leave and disability, costs of Social Insurance Institute) 
were omitted, as the perspective of the study was societal. Also, the costs of drugs for patients 
were not included in the calculations (cost of bed-day includes the costs of treatment that 
happens in hospital, as well as out-of-pocket payments of patients). 
Indirect costs (productivity losses due to mortality and morbidity) were not included, as they are 
very seldom included in similar studies and are difficult to calculate, and raise debate and 
controversy between researchers. 
In a section 6.10 of the discussion, though, costs of outpatient care and drugs were included in 
the national estimates of health care costs of T1DM and persons with T1DM in Finland in 2001. 
Complications of pregnancies, which were excluded from this study, might have caused an 
excess use of hospitals for diabetic women compared with non-diabetic women. This possible 
incremental effect was not examined because no control group was used. Hospital use during 
pregnancy in diabetic women would be an interesting subject for a separate assessment. In this 
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study, the exclusion of complications of pregnancies may have caused an underestimation of 
hospital use in women. This might have partly contributed to the higher hospital use in female 
patients than in male patients. On the other hand, women with T1DM have been recommended 
to be referred to hospital for clinical evaluation while planning their pregnancies; these were 
included in this current assessment. 
6.2. Methodological aspects 
6.2.1. Finnish hospital discharge register (FHDR) and T1DM 
Drug treatment for diabetes is free of charge in Finland. Patients receive reimbursement from the 
Social Insurance Institution after the institution has approved the patient’s application based on a 
certificate from the treating physician. Only occasionally do the parents of a diabetic child fail to 
seek reimbursement for insulin costs, and would thus not be included in the nationwide Central 
Drug Registry. The ascertainment rate of childhood T1DM (based on the Central Drug Register) 
in Finland is therefore almost 100% (Tuomilehto et al 1991).  
In Finland, there are better possibilities to conduct register-based health studies than in most 
countries, as the coverage is good and the quality for research purposes is usually excellent. It is 
also possible to link registers with a personal identification code (Keskimäki et al 1997). The 
accuracy and quality of the FHDR data for epidemiological research purposes have been 
estimated in a number of studies (Keskimäki and Aro 1991;  Keskimäki et al 1997, Mähönen 
1997, Nikiforov 1984; Salmela and Koistinen 1987, Niemi and Winell 2005). In a comparison of 
coded diagnoses with hospital records during the corresponding hospital stay, 95% of the 
principal diagnoses and 96% of the dates of admission and discharge were found to be correct in 
1986, though the accuracy of the FHDR data was moderate concerning recording procedures, 
whereas accident types (in addition to accident location and nature) and secondary diagnoses 
were more often underreported (Keskimäki and Aro 1991). Virtually all hospitals in Finland are 
owned by communities or federations of communities and are primarily funded by local and 
governmental taxes. Patients only pay a fixed nominal fee for any hospitalisation. Thus, hospital 
charges are not an obstacle in seeking hospital care in Finland. 
All persons in this study were ascertained to be patients with diabetes, as all were dependent on 
insulin. Thus no patients were missed. Only the main diagnoses of hospital discharges were 
compared, which means that the inferior accuracy of the secondary diagnoses in FHDR had no 
relevance. The use of primary diagnosis also prevented double counting, that can happen when 
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multiple diagnoses are used. All patients identified in the Finnish T1DM register were also found 
in the FHDR, i.e. every patient had been hospitalized at least once during the study period. 
6.2.2. Inpatient care and costs 
Hospitalisations after T1DM durations of 9-11 and 16-18 years were compared in both sexes. 
The inpatient treatment took place during 1973-1998. The inpatient treatment was considered in 
three-year periods to obtain steadier frequencies across years and to damp fluctuations. These 
three-year numbers were then divided by three to get yearly figures and to demonstrate how 
hospital use differs in various complication groups when T1DM has lasted on average 9.5 years 
compared with 16.5 years. Yearly inpatient care was calculated per 1,000 patients to adjust for 
different numbers of men and women and to take into account mortality during observation 
periods. Also, the numbers and shares of hospitalisations of each complication group were 
compared with the amount of hospitalisations of all complication groups, inpatient treatment due 
to other causes than diabetes and the amount of all hospitalisations.  
ICD-8 codes were converted to correspond to ICD-9 codes, because the coding changed in 
January 1st, 1987. The complication groups and complications were based on the criteria of the 
American Diabetes Association (1998), which was considered the best 'authority' for this 
purpose. Cerebrovascular complications was presented as a group of its own, as was diabetic 
coma. Ketoacidosis and hypoglycaemia have ICD-9 codes, but they do not have ICD-8 codes, so 
their inclusion in complication grouping would have distorted the comparison between 
complication groups; they were thus excluded from the main groupings. 
The length of stay (LOS) in hospital was calculated based on real treatment periods, to obtain the 
actual average time in hospital in each complication group. Simply diving bed-days by treatment 
periods would have given a slight underestimate because if a person was admitted to hospital 
before the calculation period (duration of diabetes 9-11 or 16-18 years), these days would have 
been omitted, and if a person stayed in hospital after the calculation period, these days would 
also have been disregarded.  
In the hospitalisation data related to complications, no treatment periods had lasted longer than 
365 days. This means that very long hospital periods (“outliers”) did not affect the means of the 
variables. 
Acute hypoglycaemia was considered separately using an ICD-9 code to assess its approximate 
occurrence. It was not included in the complications as a group because there was no specific 
code for it before January 1st, 1987 (ICD-8). Had it been included, the basis for calculations 
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would have been somewhat different, and in this study, due to the ICD coding, there were most 
likely less cases due to hypoglycaemia than there were in reality. For many patients, their 
hospitalisations due to hypoglycaemia would not have been diagnosed as hypoglycaemia; 
instead, they could have been coded into complication group “other”, causing an overestimation 
of hospital use for that group and an underestimation of inpatient hospital use due to 
hypoglycaemia in the younger observation group.  
The validity of inpatient costs used in this study can be considered good because the average unit 
costs used are based on cost data from all Finnish general hospitals providing specialised somatic 
care. These unit costs are recommended for use in health economic cost analyses and evaluations 
in Finland by the National Research and Development Centre for Welfare and Health 
(STAKES). 
Inpatient hospital care and the corresponding costs were calculated separately for patients aged 
under 16 years since this patient group is typically treated in paediatric wards in Finland, and the 
costs of treatment in these wards are higher than in many other hospital wards. 
Statistical methods 
This study was population based, as the study population consisted of all Finnish T1DM patients 
diagnosed before the age of 18 years (between 1965-1979). The rather large cohort (the number 
of patients was 5166) was not a random sample of T1DM patients. Thus, no statistical methods 
were used to test the differences. The study type was designed to be descriptive, not predictive or 
explanatory, and the main objective was to describe how hospital use and costs of numerous 
complications of T1DM changed during a long period of follow-up time by sex. The data was 
formed by linking registers. The register data included only few variables about the population, 
and the possibilities to perform multivariate analyses to control possible confounding variables 
were small. This is why statistical methods were not used or considered mandatory, as  they 
might be better suited for different kind of study set-ups, variables and content, with perhaps a 
separate control group of non-diabetic patients. 
6.3. Inpatient care of a cohort of T1DM patients during 1973-1997  
The total rate of hospitalisations clearly dropped after 1987, especially among women. Since 
1992, the total use remained at the same level, with 19-22% of the cohort using hospital yearly, 
and the difference between the sexes levelled off. The drop in the total rate after 1987 was 
caused by a steep decrease in diabetes-related hospitalisations. The number of yearly hospital 
129
  
 
 
bed-days dropped by 50% during 1979-1997, the LOS decreased by 42% (from 9.3 to 5.4 days), 
but the yearly number of discharges only dropped slightly.  
Men stayed in hospital on average slightly longer than women. Twice as many male patients as 
female patients became deceased during the follow-up (308/157). This higher mortality may also 
have supported the need for a longer hospital stay in male patients since they may have had more 
severe problems than female patients. As a general trend, the yearly numbers of hospital bed-
days and discharges dropped clearly after 1987, especially among women. At the end of 1987, 
the mean age of the cohort was 25.6 years (min 9.1; max 40.7) and the mean duration of diabetes 
15.3 years (min 8; max 23.0).  
There are evidently several reasons for the decrease of hospitalisations after 1987. No changes in 
the national policy for hospital care (in general or for diabetic patients) took place in the late 
1980s, but a new reimbursement system from government funds to local communities to cover 
part of the health care costs was implemented. At the same time, but largely independently of the 
former, many regional diabetes care programmes were implemented to organise diabetes care 
within local communities. In 1986, an experiment was started in Finland to examine the effect of 
the length of initial treatment hospital stay on the treatment balance of children with diabetes 
(Simell et al 1993). The results encouraged efforts to shorten the initial treatment time and may 
have affected the prevailing treatment practices even more widely. Human insulin was adopted 
in Finland nationwide in 1986-1987. To what extent the change to human insulin in the late 
1980s, which required several additional contacts between patients and treating physicians, 
actually improved outpatient care of T1DM patients (and as a consequence reduced unnecessary 
hospitalisations and the LOS) cannot be determined from this study or from other data.  
Any comparison of the results of this subsection of the study with those from other countries is 
difficult because only a few hospital utilisation studies of diabetes exist and these have generally 
concentrated on inpatient care due to diabetes mellitus, rather than specifically investigating 
patients with T1DM. In particular, population-based and longitudinal studies of T1DM-related 
hospital use are lacking. The different methods and study designs also make comparisons difficult. 
The proportion of yearly hospital users was reported to be around 25% by Moss et al (1991) for 
diabetic patients diagnosed under 30 years of age. Donnan et al (2000) also reported a similar 
hospital admission rate (mean age 34 years, SD 15 years). In a German study, around 18% of 
diabetic patients were hospitalised at least once (Icks et al 2001). In a recent Finnish cross-
sectional study, over 26% of T1DM patients (all ages included) used somatic hospital care in 
1997 (Kangas 2001). These findings from that study are in line with the results of this study.  
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Aro et al (1994) examined the inpatient care of drug-treated diabetic patients in Finland in 1989. 
The percentage of hospital users per year with diabetes as the principal diagnosis was related to 
age, and it dropped first from 41% (age 0-14 years) to 24% (age 15-24 years), to 18% (age 25-44 
years) and finally to 10% (age 55-64 years). Among children aged 0-14 years, the ratio of bed-
days of diabetic children compared with that of children without diabetes was 10 to 1. In this 
cohort, the proportions of hospital users were somewhat different, averaging 23% from 1973 
(mean age of patients 15 years, min/max age 2/27 years) to 1987 (mean age 25 years) and 
dropping after this to 9% in 1997 (mean age 36 years). One reason for the higher proportion of 
hospital users in the youngest group in the study by Aro et al (1994) compared with this study 
might be that the hospital visits related to the diagnosis of the disease (visits during the month 
following diagnosis, in 1973-1979) were excluded. In comparison, an Australian study reported 
that 5.5% of diabetic patients (excluding newly diagnosed cases) aged 0-19 years were 
hospitalised at least once in 1987 (Sutton et al 1989).  
The LOS of diabetic patients varies between different studies, depending on the year, methods 
applied, patients’ age, types of complications, country and initial treatment (Green and Solander 
1984; Fishbein 1985; Sutton et al 1989; Jacobs et al 1991; ADA 1993a; Aro et al 1994; Hirasing et al 
1996; Simell et al 1996; Icks 2001; Kangas 2001). In most studies, T1DM and T2DM are not 
separated. Treatment practices and funding of hospital costs differ between countries and years. 
Therefore, comparisons should be made with caution. On the other hand, such differences observed 
can be used in the evaluations of the management of diabetes between countries and over time.  
In a study by Aro et al (1994) the LOS of diabetic children (0-14 years) was 5.1 days and the 
LOS of non-diabetic children 0.5 days in 1987. In a German study, the mean hospital stay in 
1997 (excluding hospitalisations at the onset of diabetes) was seven days for diabetic patients 
aged under 20 years (Icks 2001). For the same age group in a Dutch study, the LOS decreased 
from 14.5 days to 11.9 days between 1980 and 1991 (Hirasing 1996). In this study, the LOS (due 
to any cause) was 6.5 days for 1987 and 5.4 days for 1997. 
The length of the initial treatment and patient education, the latter in most countries starting for 
childhood-onset T1DM patients in hospital, varies markedly between countries (Simell et al 
1996). In an Australian study, the median duration of hospital stay for diabetic patients aged 0-19 
years was 12 days at the time of diagnosis and seven days after other admissions in 1987. The 
average LOS was four days (Sutton et al 1989). A study carried out in all hospitals in Finland in 
1985 indicated that for diabetic children aged under 15 years, the overall mean initial LOS in 
hospital was 24 days, and that for the other admissions seven days (Simell 1994; Simell et al 
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1996). The length of the initial treatment affects the costs, but not necessarily the effectiveness of 
treatment. In a Finnish study, 4-week and 1-week initial hospital treatment periods were 
compared with each other, and the conclusion was that a shorter period is more cost-effective 
than a longer one because the effectiveness in both periods was similar (Simell et al 1993). In the 
present longitudinal study, the first hospital visits for diagnosing diabetes were excluded for 
purposes of comparison. 
According to the Finnish inpatient and day surgery statistics in 1997, 15.5% of the Finnish 
general population used hospital services yearly and the mean LOS was 11.1 days (83% of the 
treatment periods were less than 10 days). For the treatment of diabetes (both T1DM and T2DM 
included), the average LOS was 13.0 days. The structure of resource utilisation among diabetic 
patients (due to diabetes) indicated that they had 75% of their bed-days and 50% of their 
treatment periods in wards of primary health care centres. The corresponding figures for 
specialised hospital use were 23% (bed-days) and 48% (treatment periods). The general 
population had 41% of their bed-days and 73% of their treatment periods in specialised hospitals, 
and 54% and 21% in primary health care centre wards (Pelanteri and Nenonen 1998). 
Discharges (treatment periods) per user and bed-days per user have very rarely been reported in 
previous studies. In a Finnish study, T1DM patients were observed to have 2.2 discharges and 
13.7 inpatient days per user and LOS of 6.2 (Kangas 2001). These figures are in accordance with 
the results of this study.  
The amount of resources used for particular diseases can form a useful basis for cost calculations 
and cost-benefit comparisons of alternatives for treating the disease. This study shows interesting 
trends in inpatient resource use for a population-based cohort of T1DM patients during 25 years 
longitudinally. Hospitalisation costs constitute 60-80% of direct costs of diabetes, and diabetic 
patients clearly use more hospital services than the general population. A US study (Moss et al 
1999) reported, that by reducing glycosylated haemoglobin level by just 1%, hospital days could 
be reduced by 14-20%, which would result in 4-5 billion dollars savings in direct costs alone in the 
US nationwide. Hypertension and especially glycosylated haemoglobin level were the most 
important predictors for hospitalisation. In Finland, over 50% of T1DM patients had poor average 
glycaemic control in the mid-1990s (Valle et al 1999). That the situation was likely even worse in 
the past. It is difficult to assess the extent to which improved glycaemic control and active self-
monitoring of blood glucose might have influenced hospital admissions over time in this study.  
In the future, it would be interesting to explore the relationships between duration of diabetes, 
patient’s age and hospitalisation in more detail, and to investigate the effect of other 
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demographic variables and the presence of various diabetic complications on inpatient care and 
costs of care.  The cost structure of T1DM should be calculated in more detail, incorporating 
direct, indirect (productivity) and intangible costs (e.g. loss of quality of life), to obtain a more 
complete description of the costs and the effects of diabetes. Most studies have not distinguished 
between the costs related to T1DM and T2DM diabetes, although their treatment costs do differ 
(Stern and Levy 1994).  
6.4. Use of inpatient care by T1DM patients due to diabetes (main diagnosis 
250) or other causes during 1973-1997 
The proportion of patients hospitalised with diabetes as the main diagnosis (main diagnosis 250) 
decreased from 26% and 21% per year (1987) to 8% and 10% per year (1997) in females and 
males, respectively. However, when the main diagnosis was some other than diabetes-related 
(other than 250), the proportion of hospital users in both sexes increased steadily from 6% to 
14% in 25 years, exceeding the diabetes-related use in 1992. During the entire 25-year study 
period, diabetes-related bed-days comprised 67% of all bed-days, and there were twice as many 
bed-days and hospital discharges due to diabetes-related causes than due to other causes. During 
the first years from 1973 to 1989, hospital use due to diabetes was three to four times more 
common than the use due to other causes. Bed-days due to diabetes decreased markedly towards 
the end of the study period, i.e. during 1980 to 1997 by 66%, while bed-days due to other causes 
increased, exceeding the number of diabetes-related bed-days in these patients in 1993. 
Discharges due to other causes than diabetes increased by 106%, the number of patients using 
hospital annually increased by 73% and discharges per hospital user increased from 1.3 to 1.6 
between 1979 and 1997. This indicates that more patients tended to use hospital more frequently 
due to causes other than diabetes as the years elapsed and the patients became older.  
The average LOS due to other causes than diabetes was longer than that due to diabetes (during 
the entire follow-up 7.9 days and 7.4 days, respectively), but there was marked variation in LOS 
between the years and the sexes. During the 25-year study period, the average number of yearly 
discharges due to diabetes increased from 1.3 to 2.0 per hospital user. However, the number of 
yearly discharges dropped distinctly after 1987; in female patients it decreased by 70% and in 
male patients by 59% during 1988-1997. Thus, fewer patients used hospital, but those who did, 
used it more frequently.  
Females used hospital care more than males; females had 21% more bed-days, 26% more 
discharges due to diabetes, and 25% more bed-days and 15% more discharges due to other 
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causes than diabetes than males during the 25-year period. The difference in hospital use due to 
diabetes between female and male patients levelled off during the last 10 years. 
After 1987, diabetes-related hospital use began to drop steeply. One reason for this might be that 
human insulin was taken into use at that time in Finland, which may have reduced the need for 
inpatient care. Treatment practices may also have changed in a way that encouraged outpatient 
care. An economic recession in Finland started in 1990-1991, resulting in the cutting of funds 
allocated to health care and most likely reducing diabetes-related inpatient hospital use. During 
the follow-up, however, the yearly number of hospital discharges and the percentage of hospital 
users due to reasons other than diabetes as the main diagnosis doubled in this cohort. The 
increase in hospital visits may be explained by the greater incidence of various chronic illnesses 
with advancing age and the emergence of diabetic complications. 
Any comparison of the results with the findings to the results of other studies is difficult because, 
to my knowledge, no equivalent studies have been carried out earlier. Previous studies on 
utilisation of inpatient care by diabetic patients have focused on hospital use among all diabetic 
patients, not among T1DM patients separately. Longitudinal studies of T1DM-related hospital 
use are almost non-existent. Furthermore, the different methods and study designs applied in 
earlier studies make comparisons difficult. In a Dutch study, Hirasing et al (1996) reported a 
dramatic decrease in diabetes-related hospital bed-days (by 55%) between 1980 and 1991. In this 
study here, the decrease for this period was 36%.  
In a study by the ADA, the LOS attributable to diabetes itself was 6.2 days (4.6 days for patients 
under 44 years of age). The LOS attributable to chronic complications of diabetes was 8.2 days, 
and the LOS due to other co-morbid conditions in diabetic patients was 9.5 days. Depending on 
age, the LOS attributable to different chronic complications ranged from 2.5 to 15.3 days. The 
LOS attributable to complications and other co-morbid conditions together among diabetic 
patients was 2.8 days longer than the LOS among non-diabetic patients (American Diabetes 
Association 1993a). These results indicate that hospital use by diabetic patients due to other 
causes than diabetes itself warrants a more detailed analysis. 
There may be some underestimation of the inpatient care attributed to diabetes in this subsection 
of the study. Diabetes often contributes to the development or is a cause of other illnesses, which 
are coded as the main diagnosis for hospital admission. A recent evaluation of drug treatments 
for other diseases in Finnish T1DM patients showed that virtually all treatments were more 
common in diabetic patients than in non-diabetic control subjects (Reunanen et al 2000). When 
only the main diagnosis is taken into account in exploring the use of hospital care, as was done in 
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this analysis, the real effect of diabetes on inpatient use will be underestimated. In Sweden, it 
was observed that the number of discharges from somatic hospitals with diabetes as any 
diagnosis was 2.5 times higher than the number of discharges with diabetes as the primary 
diagnosis (Jönsson 1983). Furthermore, some co-morbid diseases attributed to diabetes, e.g. 
pneumonia, may cause more hospital days for diabetic patients than for a non-diabetic 
population (American Diabetes Association 1993a). In this study, such excess in hospital use 
related to diabetes was included in the hospital use due to other reasons than diabetes, also 
causing some underestimation of hospital use due to diabetes. However, it is difficult to 
determine which other diseases are predisposed to or caused by diabetes and which hospital 
admissions are longer because of diabetes.  
In the future, it would be interesting to examine more closely the effect of various T1DM-related 
complications on the utilisation of inpatient care and costs as well as to identify the heavy users 
of inpatient care. By targeting interventions to these risk groups as early as possible, hospital 
resources and costs could be saved, not to mention the alleviation of human suffering. 
6.5. Inpatient care of T1DM patients by duration of diabetes (9.5 years vs. 16.5 
years) and sex 
The results indicated that for hospital use due to complications, the numbers of hospital users 
doubled, the annual number of discharges increased 3-fold and the annual number of bed-days 
increased 2.8-fold when the duration of diabetes increased from an average of 9.5 to 16.5 years.  
The yearly number of discharges due to other causes than complications dropped markedly (-
28%), but the drop was smaller than the increase in discharges due to complications, so the total 
number of discharges due to any cause increased somewhat for both sexes when diabetes lasted 
longer. A remarkable finding is anyway that the yearly number of total discharges was 7.1-fold 
that of the number of discharges due to complications in the group having suffered from diabetes 
on average 9.5 years, but 2.4-fold in the group whose diabetes had lasted on average 16.5 years. 
The yearly number of bed-days due to other causes than complications dropped considerably (-
41%) when diabetes lasted longer. This figure compared with the number of bed-days due to 
complications was 5.8-fold when the duration of diabetes was 9.5 years, but only 1.2-fold in the 
older group. The drop was bigger than the increase in bed-days due to complications, causing a 
decline of the total number of bed-days (-10%). Notable is the increase in the share of bed-days 
for the treatments of complication groups, as calculated from the total numbers of bed-days 
(14.7% to 44.6%). 
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One reason for the considerable drop in the yearly number of discharges and bed-days due to 
other causes than complications was a prominent decrease in hospitalisations due to ICD code 
25000/2500B, diabetes without complications, which dropped over 70% when diabetes lasted on 
average 7 years longer. More diabetic patients without complications may have been treated in 
outpatient care and at home as a result of a change in treatment practices. Patients may also have 
learned better self-management of the disease as they got older. However, hospitalisations of 
many complications increased manifold with the increasing duration of diabetes. 
Regarding discharges, the biggest complication groups were other, ophthalmic and renal 
complications and coma when diabetes had lasted 9-11 years. When the duration of diabetes 
increased, the biggest groups were ophthalmic, other and renal complications, while the relative 
increase was biggest in the discharges of peripheral vascular, renal, cardiovascular and 
ophthalmic complications. Regarding bed-days, the biggest complication group was other 
complications, followed by ophthalmic and renal complications and coma. When the duration of 
diabetes lasted longer, the biggest groups were other, renal and ophthalmic complications, and 
the biggest relative increase in the amount of bed-days occurred in the treatment of 
cardiovascular, peripheral vascular and renal complications. A distinct drop was seen in the 
number of bed-days for treating coma, which may indicate better self-management of blood 
glucose levels as patients became older. 
The length of stay decreased in all complication groups, except in cerebro-, cardio-, and 
peripheral vascular complications. Although the LOS in hospital generally decreased, the 
number of discharges per user increased, especially for the big complication groups (other, renal, 
ophthalmic complications); thus, patients were clearly more frequently in hospital as diabetes 
lasted longer. As a result, the number of bed-days per user for complication groups increased 
because the drop of the LOS was offset by the increase in the frequency of hospital visits. 
A comparison between sexes demonstrated notable differences. Generally, women clearly used 
more inpatient treatment than men. By using discharges in the assessment (complications 
combined, other causes than diabetes, total hospital use, diabetes without complications), women 
used hospital around 36-55% more than men, and by using bed-days the corresponding figures 
showed 30-50% more inpatient treatment for women. As the duration of diabetes increased, the 
sex differences for these figures narrowed, but the sex difference still remained bigger for shares 
of discharges than for bed-days. 
The finding that women used hospital so much more than men was surprising. This result may be 
explained, at least partly, by the fact that women may seek health care more readily than men 
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when a disease occurs. This kind of health behaviour has been reported earlier in Finland in a 
study by Kokko (1988), according to which women visited health centres 1.5 times more than 
men. Mens' attitude towards disease and symptoms seem to be different compared with womens', 
and that leads to mens' slower reaction to seek health care when they notice symptoms of a 
disease (Kivelä 1990). 
Another Finnish study (Hujanen et al 2004) reflects this same phenomenon that women, at least in 
certain age groups, seem to use hospitals more than men. According to that study, per capita 
municipal somatic specialised care treatment costs in women aged 16-52 years were 11% higher than 
those in men, and costs in women aged 18-40 years were almost twice the costs in men in 2002. 
As diabetes lasted longer, men had a slightly bigger increase than women in the hospital use due 
to all complications and in the total hospital use, as measured by number of discharges, and in 
the hospital use due to all complications, as measured by the number of bed-days. Women’s total 
number of bed-days dropped slightly more than that of men (-12% vs. -7%). Women visited 
hospitals slightly more frequently than men, when total hospital use and hospital use due to other 
causes than diabetes were observed. Men, however, generally stayed during their treatment 
periods a bit longer in hospital than women, especially considering the group of complications 
combined, other hospitalisations than those due to diabetes and total hospital use, when diabetes 
had lasted 9.5 years or 16.5 years; the LOS decreased for both sexes by about the same amount. 
The yearly numbers of bed-days and discharges per user considering all complications combined 
increased for both sexes clearly as the duration of diabetes lasted longer. 
An increase in the proportion of yearly discharges due to renal complications was notably bigger 
for women than for men as the duration of diabetes increased, but for ophthalmic complications, 
men had a clearly bigger increase. The sex difference in yearly discharges was about the same 
(8% points higher for women) in the 9.5-year cohort for ophthalmic complications as in the 16.5-
year cohort for renal complications. Thus, women seemed to use hospital relatively more 
frequently due to ophthalmic causes than men when diabetes had lasted on average 9.5 years, but 
they visited hospital relatively more often for renal causes than men when diabetes had lasted 
16.5 years. The yearly number of discharges due to other complications dropped about 10% 
points for both sexes. 
The biggest differences between the sexes in the absolute number of discharges per 1,000 patients 
per year were that women had twice as much ophthalmic and over 50% more renal complication 
discharges when diabetes had lasted 9.5 years, and almost 40% more ophthalmic and twice as much 
renal complication discharges compared with men, when diabetes had lasted longer.  
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There were huge increases in the number of yearly discharges due to certain complications as 
diabetes lasted longer. For women, those due to renal complications increased 6-fold, peripheral 
vascular complications 5.7-fold and ophthalmic complications 3.3-fold. For men, yearly 
discharges due to peripheral vascular complications increased 5.8-fold, renal complications 5-
fold and ophthalmic complications 4.6-fold.  
The variable "discharges per user" showed that renal, ophthalmic, cardiovascular and other 
complications caused clearly more frequent hospital use in both sexes when the duration of 
diabetes increased. The number of discharges per male patient was higher than that for women in 
the case of peripheral vascular and other complications, but smaller due to coma, when diabetes 
had lasted longer. The latter finding was attributed to a notable drop in the number of women 
using hospital due to coma, for some unknown reason (n=45/18 women). This may indicate a 
better self-management of blood glucose levels as female patients became older. 
The proportion of yearly bed-days of the complication group “other” dropped clearly, especially 
among men, but other complications still remained the biggest single complication group as the 
duration of diabetes was longer. In both sexes, the share of renal complications showed a 
considerable increase, replacing ophthalmic ones as the second biggest group with the increase in the 
duration of diabetes. The share of yearly bed-days of ophthalmic complications dropped in women 
but rose in men. Thus, the relative structure of the shares of bed-days indicated that women used 
clearly more bed-days for ophthalmic causes than men when diabetes had lasted on average 9.5 
years, but the difference seemed to level off when diabetes had lasted on average 16.5 years. 
In terms of bed-days and discharges, men had a higher proportion in the complication group 
“other” than women also as diabetes had lasted longer. This suggests that men were more prone 
to be given diagnoses "other defined" (25008/2507B) or "non-defined" complications 
(25009/2508B) and exact diagnoses were for some reason more seldom for men than for women.  
The most striking sex differences considering the absolute number of bed-days per 1,000 patients 
per year were that women had twice as many ophthalmic and 60% more renal complication 
discharges when diabetes had lasted 9.5 years, and around 50% more ophthalmic and renal 
complication bed-days compared to men when diabetes had lasted longer.  
There were vast increases also in the yearly number of bed-days due to certain complications as 
diabetes had lasted longer. For women, the number of renal complications increased 4.8-fold, 
peripheral vascular complications 4.3-fold, neurological complications 3.2-fold, ophthalmic 
complications 2.5-fold and other complications 2.3-fold. For men, the number of peripheral 
vascular complications increased 6.9-fold, renal complications  5-fold, ophthalmic complications 
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3.4-fold and other complications 2.2-fold. These figures stress the importance of good metabolic 
control and management, as these considerable increases in hospital use happened in only 7 
years on average, and most of these complications can be life-threatening and can reduce the 
quality of life immensely. 
It was checked that no hospital periods exceeding a duration of 365 days existed in hospital use 
for any complication group during the two 3-year observation periods. Certain single shorter 
“outliers” were observed, which raised the means of bed-days in certain groups and observation 
periods. On the other hand, they increase use of resources and generate costs.  
In the observation period with duration of diabetes from 9 to 11 years, there were 445 male bed-
days due to renal complications (n=33), one person being in hospital for 155 days . If these bed-
days were disregarded, bed-days due to renal complications for men would have 7.6-folded as 
diabetes lasted longer, and 7-folded if also the biggest number of bed-days produced by a single 
male in the latter observation period (167 of 2,154 bed-days, n=107) was disregarded.  
A big percentual rise of women’s bed-days for the treatment of cardiovascular complications was 
partly attributed to one person, who used half of the bed-days as the duration of diabetes 
increased (n=8, 206 days in the cohort of 16-18 years duration), causing also an elevation in the 
LOS and bed-days per user.  
Men had more bed-days and bigger LOS regarding the treatment of peripheral vascular disease 
than women as diabetes increased. A contributory factor for this was that one male patient used 
17% of the bed-days in the latter 3-year observation period (n=53; 798 bed-days).  
Hospital use due to endocrine complications was practically non-existent in this study (3 bed-days 
for hyperkalaemia). Intriguing is, why the American Diabetes Association classified this as a group 
of its own. The reason may be that endocrine complications evolve at a later age. Also surprising 
was the small number of cerebrovascular patients and their bed-days (0.3-1.4% of bed-days due to 
complications). It is evident, though, that their numbers increase as diabetes lasts longer. 
The number of bed-days due to neurological complications increased in women, but decreased in 
men, as the duration of diabetes increaced. That is partly explained by the fact that the number of 
female users 3-folded while the number of male users increased by around 40%. It is odd why a 
larger number of men had less hospital days than women; this might be explained by the rather 
small number of patients. 
Men had clearly more bed-days for the treatment of peripheral vascular complications as 
calculated per user (15.1 days vs. 7.3 days) and male patients with peripheral vascular 
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complications visited hospital more frequently than women (discharges per user 1.7 vs. 1.3) as 
diabetes lasted longer. Also women's LOS due to peripheral vascular complications was clearly 
shorter than that of men, which was the reason for the smaller hospital use of women.  
Men had more bed-days per user due to renal complications than women when diabetes lasted 
longer. The reason was that LOS in women decreased distinctly. The frequency of visits was 
similar for both sexes as the duration of diabetes prolonged.  
In comparison, the amount of bed-days due to hypoglycaemia was about the same as bed-days 
due to cerebrovascular complications, and the amount of discharges due to hypoglycaemia was 
similar to that due to cardiovascular complications (in the 16.5-year cohort). Its share of the total 
number of bed-days was only 0.4%, and if it was included in the complications, its share would 
have been 0.9% of the bed-days of all complications. Men visited hospital more frequently, but 
women had a longer stay in hospital due to hypoglycaemia (in the 16.5-year cohort).  
Certain common diagnoses of complications of T1DM, that caused many hospitalisations 
according to ICD-9 codes did not have specific ICD-8 codes, e.g. ketoacidosis (ICD-9: 2501B) 
and microangiopathy (ICD-9: 2506B), and this may have caused an underestimation of 
hospitalisations in the younger observation group. The lack of ICD-8 code for microangiopathy 
may have caused an underestimation of peripheral vascular complications in the younger group, 
and therefore an overestimation of the marked growth of that group as diabetes lasted longer. 
Patients with microangiopathy or ketoacidosis may have been diagnosed before 1987 as non-
defined complications (ICD-8: 25009), and this coding may partly explain the 2.7-fold drop in 
that diagnosis (non-defined complications) when diabetes had lasted 16-18 years. Also, after the 
year 1987, some diseases earlier classified as non-defined complications may have been 
classified as other defined complications, as their share 3-folded as the diabetes lasted longer. 
The primary diagnosis of hospital use was used to avoid double counting. This may have caused 
an underestimation of hospital use, as diabetes is often a contributory cause to the main disease 
causing hospital use and is marked as a secondary diagnosis in hospital records. 
Using a control group would have allowed the incremental effect of diabetes on hospitalisations 
to be shown and would have increased the value of the study. Due to difficulty in obtaining a 
valid and reliable control group, and due to limited resources and the scope of the study, the use 
of a control group was omitted.  
The main reasons for these notable increases in hospitalisations (in 7 years) are evidently 
metabolic and indicate the severe nature of T1DM and its complications; it should be 
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remembered that, in addition to chronic complications,  acute complications (hypoglycaemia, 
ketoacidosis, coma) of the disease can result in death.  
There were considerable increases in bed-days for the treatment of certain complications, while 
bed-days for the treatment of some other complications dropped markedly when the duration of 
diabetes lasted longer. Generally,  in the 7-year period, hospital use due to complications 
increased, while hospital use due to diabetes without complications dropped dramatically (e.g. 
bed-days: +175% vs. –72%). This was one of the major findings in this study, demonstrating a 
clear structural change in hospital use as diabetes lasts longer. Bed-days for treatment of 
nephropathy 7-folded, that for ophthalmic disorders 3-folded (glaucoma 8-folded) and for that 
for personality disorders doubled.  
According to the findings of this study, there is really a great need for effective intervention 
programmes for T1DM, at least in Finland. By preventing and delaying complications, part of 
the resources devoted to treating persons with T1DM could be allocated to treatment of other 
diseases, not to mention the extra life-years and quality-of-life gains achieved for diabetic 
patients. The results of this study may also be relevant rather long, as there are no effective 
intervention methods yet available for preventing T1DM and its complications, as compared 
with T2DM and associated complications (e.g. interventions related to exercise, smoking, eating 
saturated fat, nutrition, diet).  
6.6. Costs of inpatient care of T1DM by duration of diabetes 
Numerous notable changes were discovered in costs of inpatient care as duration of T1DM 
increased on average by 7 years, from 9.5 to 16.5 years. When the duration of T1DM was 9.5 
years, the share of costs of treatment of all complications was 14% and the share of costs of 
treatment of diabetes without complications (ICD codes 25000 and 2500B) was 60% of total 
costs of inpatient care. As the duration of T1DM increased to 16.5 years, the share of treatment 
costs of complications was almost half of the total costs, but the share of treatment costs of 
diabetes without complications had dropped to 16% of total treatment costs. Inpatient care of 
ophthalmic complications had become clearly more costly than hospital treatment of other 
complication groups. It was followed by inpatient care of other and renal complications; these 
groups incurred the vast majority of the costs of treating complications. The share of treatment 
costs due to ophthalmic diseases was clearly higher in women than in men when T1DM had 
lasted 9.5 years. This finding implies that women get eye problems at an earlier age than men.  
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Combined treatment costs of all complications per patient had a notable increase, as they 2.5-
folded in 7 years. On the other hand, total treatment costs (all costs combined) and total T1DM-
related costs per patient decreased because there was a considerable drop related to treatment 
costs due to diabetes without complications.  
When T1DM had lasted 16.5 years, average treatment costs per patient increased substantially in 
all complication groups (except coma). Costs due to peripheral vascular complications diseased 
5.7-folded, and those due renal and ophthalmic complications 4.6- and 2.8-folded. Ophthalmic, 
other and renal complications were clearly the most expensive complication groups in terms of 
average inpatient costs per patient, followed by peripheral vascular complications, neurological 
complications, cardiovascular complications, coma, cerebrovascular complications and 
endocrine complications, in that order.  
It should be emphasised that these considerable increases in costs due to hospitalisations took 
place in an average of only 7 years. Complications of T1DM are typically severe in nature and 
often lead to premature death. Besides the growing costs to patients, the health care system and 
the whole society, human suffering may be immense, especially when a person with T1DM has 
several complications simultaneously. In this cohort, when T1DM had lasted 9.5 years, one of 
every eight patient had two or more complications at the same time, but when T1DM duration 
increased to 16.5 years, every fourth patient had two or more complications.  
The comparison of average treatment costs between sexes for certain complications also yielded 
some intriguing findings as T1DM duration increased from 9.5 to 16.5 years. In men, treatment 
costs of ophthalmic and peripheral vascular complications increased clearly more than those in 
women, but generally, women's treatment costs predominated in practically every complication 
group and cost category. Women's treatment costs due to ophthalmic complications were twice 
those of men (T1DM 9.5 years), but as T1DM lasted longer (T1DM 16.5 years) they were still 
1.5-fold. The cost difference related to treatment of renal complications remained around the 
same as duration of T1DM increased (i.e. women's costs were 1.5-fold those of men). In the 
main cost categories (complications combined, other inpatient use, T1DM use, total inpatient 
use) women's costs distinctly prevailed (33% - 45% bigger), regardless of wheather T1DM lasted 
9.5 or 16.5 years. The cost differences between sexes remained notable as T1DM had lasted  an 
average of 16.5 years, although they somewhat diminished. Also, it is known that when females 
develop diabetes, either T1DM or T2DM, their relative risk of CVD is increased more steeply 
than that of diabetic males (Tuomilehto et al 2004). 
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Total inpatient treatment costs in the cohort were 7.2 million euros (T1DM 9.5 years), but they 
dropped to 5.6 million euros (T1DM 16.5 years). The main contributor to this was the decrease 
in the treatment costs of diabetes without complications (-3.5 million €). On the other hand, as 
the costs of all complications combined increased by 1.5 million euros, costs due to T1DM 
declined by 2 million euros when T1DM duration increased to 16.5 years. Remarkably that 
treatment costs of ophthalmic complications (T1DM 16.5 years) became almost as high as the 
costs of all 9 complication groups combined when T1DM had lasted 9.5 years, around one 
million euros. It is evident that special attention should be paid to preventing especially eye 
complications by administering effective care, as the treatment costs of ophthalmic 
complications alone contributed to over 40% of the growth of costs of all complications with 
T1DM increased by 7 years. Naturally, loss of vision also causes numerous problems in 
everyday life (at work and home, in leisure) and may cause other health problems.  
A comparison of treatment costs per hospital user gives different kinds of results. As the duration 
of T1DM increased, inpatient treatment costs of all complications increased by one-third because 
treatment costs and number of bed-days 2.5-3.5-folded, but at the same time the number of users 
(due to complications) increased by 'only' 85%. Many patients (around every fourth) had more than 
two complications simultaneously, when T1DM had lasted 16.5 years; thus, the severity and 
treatment costs of T1DM obviously can vary notably between patients. In the future, complications 
in these patients, their treatment costs and hospital use should be further followed up, and 
preventive interventions targeted to these patient groups, before complications start to evolve. 
As T1DM duration increased to 16.5 years, the most expensive treatments per hospital user were 
due to other, renal and cardiovascular complications. The equivalent costs per user due to 
ophthalmic complications remained the same (5,800 €) since the treatment costs and number of 
users both 2.8-folded as T1DM duration increased in that group. Treatment costs per user due to 
neurological complications dropped by one-quarter; the costs rose by 50%, but this was offset by 
the fact that the number of users doubled. Treatment costs per user due to peripheral vascular 
complications rose slightly, as the costs of treatment 6-folded and the number of users 5-folded. 
Treatment costs related to renal costs per user increased by almost one-third since although the 
number of users 3.5-folded, the equivalent treatment costs 4.6-folded. Generally, the rise in both 
costs of treatment and numbers of users that occurred in an average in 7 years of increased 
T1DM was remarkable. 
Costs of treatment due to cardiovascular complications became clearly the most expensive 
complication group in women (around 9,000 €/user/year) as the duration of T1DM increased to 
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16.5 years; however, number of users was small (n=8). In men, renal complications became the 
most expensive complication group (7,000 €/user/year) and the costs per user increased more in 
men than in women (+45% vs. +21%). In general, treatment costs per user related to all 
complications increased somewhat more in men than in women as T1DM lasted on average 7 
years longer.  
In terms of inpatient costs per treatment period, certain consistent changes seemed to occur. As 
the duration of T1DM increased to 16.5 years, costs per treatment period in every 'cost group' 
(except for cerebrovascular, cardiovascular and peripheral vascular complications) decreased 
around 17%-50%. The main reason for this was the distinct drop in LOS in hospital. In addition, 
as patients got older, use of the paediatric ward, which has higher bed-day costs than e.g. the 
internal medicine ward, naturally diminished. Changing treatment practices and improved 
medical treatments (e.g. treatments of ophthalmic complications) most likely contributed to the 
decline in costs per treatment period.  
When the duration of T1DM increased to 16.5 years, costs per treatment period due to renal 
complications in women dropped by one-quarter, while in men the costs remained at the same 
level. An explanation for this is that women visited hospital more frequently, but stayed there 
shorter periods than men, whose costs per treatment period were now 22% higher than those of 
women (T1DM 16.5 years).  
Moreover, the costs per treatment period due to peripheral vascular complications clearly 
became higher in men than in women as duration of T1DM increased to 16,5 years, the reason 
being that men had more bed-days and longer LOS in hospital. 
Hospital use of patients under 16 years of age had a different effect on the costs in certain 
complication groups, when T1DM had lasted on average 9.5 years (Table 13 in Appendix 1). 
Every third bed-day due to complications, every sixth bed-day due to total hospital use and half 
of the bed-days due to diabetes without complications were caused by patients aged under 16 
years, but there were no bed-days due to cerebrovascular, cardiovascular, peripheral vascular and 
neurological complications in this younger patient group. The percentages of bed-days due to 
other, ophthalmic and renal complications and coma were 27, 9, 6 and 18, respectively. Female 
patients had more bed-days than men due to ophthalmic and renal complications and coma when 
T1DM had lasted 9.5 years and the patients were under 16 years of age. In conclusion, 
ophthalmic and renal complications (and naturally coma) emerge earlier in life than the rest of 
the complications, especially in female patients, and this affects the costs, as paediatric care is 
more expensive than hospital care in many other wards.  
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6.7. Inpatient care of T1DM in 1998 
In 1998, when the duration of T1DM was on average 25 years, there were 566 hospital users due 
to any cause. This represents 12% of the whole cohort (N=4,701). Due to complications of 
T1DM, around 9% (412 persons) of the cohort used hospital. Of the complications, renal, other 
and ophthalmic complications were clearly the dominating ones. Patients with these 
complications formed 93% of hospital users due to all complications and two-thirds of all 
hospital users. Users due to renal and other complications alone formed almost 75% of all users 
due to complications in 1998.  
In terms of hospital discharges, the share of discharges due to renal complications was 
considerable, accounting for around 45% of all complication discharges and almost one-third of 
total discharges. Of total discharges, the share of all complications was slightly over 70%, but 
diabetes without complications (ICD code 2500B) formed only 5% of all discharges.  
There were on average 2.2 discharges per hospital user in 1998 due to all complications and due 
to total hospital use (in renal complications, the figure was 2.7). Generally, men used hospital 
slightly more frequently than women.  
Regarding bed-days in 1998, the share of bed-days due to renal complications turned out to be 
predominant compared with other complication groups (over half of bed-days of all complications 
and almost 40% of total bed-days). Interesting also is that the number of bed-days due to ophthalmic 
complications was now at about the same level as that of diabetes without complications, ICD code 
2500B (5% of total bed-days). In addition, the number of bed-days due to peripheric vascular 
complications was higher than that of ophthalmic complications (in both sexes). 
In women, the share of bed-days due to renal complications was noteworthy (60% of bed-days of 
all complications and over 40% of total bed-days). Women also had 25% more renal bed-days 
than men per 1,000 patients. On the other hand, men had 33% more bed-days due to ophthalmic 
complications, twice the amount of bed-days due to coma and distinctly more bed-days due to 
peripheric vascular and other complications than women per 1,000 patients in 1998. The reason 
for these differences is unclear; perhaps women have better glycaemic control and self-
monitoring of blood sugar than men, leading to a smaller risk of these complications. Also, in 
earlier stages of T1DM, women may have been more active in seeking health care, and thus, may 
have had different health behaviour than men (e.g. relating to smoking, exercise, nutrition). 
However, women seem to be more sensitive to developing renal complications than men at this 
stage of the disease. In general, men had more bed-days than women in 1998, but the difference 
was very small. 
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In terms of LOS in hospital in 1998, besides cerebrovascular complications (only a few patients), 
LOS due to cardiovascular and renal complications was longest (7.7 and 7.4 days), but their 
standard deviations (SD) were widest. The SD of renal complications in women was notably 
larger than in men (15 vs. 8.9), which was reflected as a wider variation in total LOS (all 
complications and total use). In general, the average LOS in 1998 was 6.2 days.  
In 1998, diabetic nephropathy was the single diagnosis causing overwhelmingly the most hospital 
use. Of all diagnoses, diabetic nephropathy caused over 7 times more bed-days than diabetes 
without complications (ICD code 2500B) or diabetic microangiopathy (which ranked 3rd and 4th, 
respectively, on the 'top diagnoses' list), and 15 times more bed-days than e.g. diabetic retinopathy 
(6th on the 'top diagnoses' list). This stresses the importance of good glycaemic self-control and 
regular check-ups by physicians and nurses to avoid and postpone especially renal disease, which 
is a common cause of hospital use and mortality among T1DM patients. 
6.8. Costs of inpatient care of T1DM in 1998 
In 1998, T1DM-related treatment costs accounted for almost three-quarters of total costs of 
hospital use. The share of costs due to the treatment of complications was approximately 70%. 
Costs for treating renal complications caused half of the treatment costs of all complications 
(women 57%, men 44%), and over one-third of total inpatient treatment costs. Treatment costs 
due to other complications (20% of treatment costs of all complications), ophthalmic (11.5%) 
and peripheral vascular complications (around 9%) were the next highest.  
In 1998, treatment costs due to renal complications per hospital user were highest (over 7,000 
€/hospital user). This cost was around 33% higher than the cost of total use and 2.5-fold that of 
e.g. ophthalmic complications. Men had over 40% higher treatment costs per hospital user than 
women due to ophthalmic complications, but in renal complications the cost difference between 
sexes was small. The numbers of hospital users due to hypoglycemia (n=1) and cerebrovascular 
(n=3), neurological (n=13) and cardiovascular (n=22) complications were quite small. 
In terms of costs per treatment period in 1998, (apart from those due to cerebrovascular 
complications, where the number of patients was very small), costs per treatment period due to 
cardiovascular and renal complications were the highest (about 2,600 €). Men's costs per 
treatment period due to ophthalmic complications were again somewhat higher than those of 
women (20% higher), but in renal complications the difference was negligible. 
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The average inpatient treatment costs due to renal complications were 222 € per patient in 1998, 
and they totalled over one million euros in the whole cohort. These costs were 4-6 fold those of, 
for instance, ophthalmic and peripheral vascular complications. In general, men's treatment costs 
per patient were slightly higher than those of women, but the difference was negligible. Women's 
treatment costs due to renal complications were around 25% higher than those of men, while 
men, in turn, had higher treatment costs due to other, peripheral vascular and ophthalmic 
complications and coma. Women's treatment costs due to cardiovascular and cerebrovascular 
complications were higher than those of men, but the number of patients was quite small.  
In 1998, the total average inpatient treatment costs per patient with T1DM were 640 € (636 € 
women, 642 € men), and due to complications of T1DM they were 444 €. To put these figures 
into wider perspective and to estimate the size of the burden of treatment costs of T1DM on 
society, a comparison with the national treatment costs may be enlightening. The average 
inpatient cost of municipal somatic specialised care per person in Finland in 1998 was 345 € 
(Hujanen et al 2004). The costs for men aged 18-40 years were 117 € and for men aged 41-64 
years 332 €. The corresponding costs for women were 243 € (in age group 18-40) and 302 € (in 
age group 41-64). These costs were inflated from the original 2002 price level to the 1998 price 
level by using the price index of municipal health services (Hujanen 2003; 
www.tilastokeskus.fi/tk/hp/kui_kust.html).  
In 1998, the average age of persons in this study was 35 years (min 19, max 51), and around two-
thirds of persons were aged from 18-40 years. Thus, the younger age group in the study by 
Hujanen et al (2004) forms a better comparison group than the older one (41-64 years) when 
comparing with the national inpatient costs. Inpatient treatment costs per male T1DM patient in 
1998 were 5.5 times higher than the average costs of somatic specialised inpatient care of men 
aged 18-40 years in Finland (642 € vs. 117 €). Those costs were double the average equivalent 
costs of inpatient care of all age groups of men in Finland (642 € vs. 326 €). Respectively, inpatient 
treatment costs per female T1DM patient in 1998 were 2.6 times higher than the average costs of 
somatic specialised care of women aged 18-40 years in Finland (636 € vs. 243 €). Those costs 
were 1.7-fold the average equivalent costs of inpatient care of all age groups of women in Finland 
(636 € vs. 364 €). Inpatient treatment costs per T1DM patient in 1998 were almost twice as high as 
than the average costs of somatic specialised care in Finland (640 € vs. 345 €). 
As mentioned earlier, the youngest patients in 1998 were 19 and the oldest 51 years of age. Thus, 
the treatment costs do not contain the initial treatment costs, costs related to the period shortly 
after T1DM was diagnosed and treated in the paediatric department, and when the patient and 
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his/her parents were counselled about treatment of T1DM. Many patients had not yet developed 
complications, especially complications involving the most expensive treatments.  
Generally, comparing costs between different studies is often impossible or very difficult 
because different methods have been used, and patients, their ages, severity of diseases, follow-
up periods differ and studies have been conducted in different years. Countries also differ in 
respect to age structure, incidence of various diseases, availability and relative prices of health 
care resources and medicines, price levels, clinical practices and incentives to health care 
professionals and institutions (Drummond and McGuire 2001). 
Comparison of treatment costs presented in different studies in Finland can also be really 
difficult. In a recent study, Punnonen (2005) explored the costs of 27 common treatments in 
specialised care. All central hospitals and almost all local hospitals participated and provided 
their pricing information of various treatments. The results revealed that there was large cost 
variation in treatments of the same diseases across hospitals. The costs of treatment of the same 
disease were often manyfold depending on the hospital. For example, the ‘packet price’ for the 
treatment of T1DM varied between 1,457 € and 2,520 € (in 17 hospitals using DRG pricing).  
6.9. Comparison of costs of inpatient care of T1DM patients when duration of 
T1DM was on average 9.5 years vs. 16.5 years vs. 25 years 
Various complications of T1DM develop at a differing pace over time. It is therefore essential to 
study hospitalisations and costs longitudinally to determine the use of physical and monetary 
resources required to treat complications of T1DM. Apart from this study, few longitudinal 
studies have thus far been conducted on hospital use and costs of T1DM complications.  
Interesting and considerable changes were discovered when the costs of treatment of T1DM 
having lasted on average 9.5 years (range 9-11 years) or 16.5 years (range 16-18 years) were 
compared with the costs of treatment of T1DM in 1998, when T1DM had lasted on average 25 
years (range 19-33 years). It should be taken into account, though, that the basis of cost 
calculations (and hospital use) in 1998 was cross-sectional. This may have caused some bias.  
Costs per patient 
In terms of average annual costs per patient by duration of T1DM (Table 10 in Appendix 1 and 
Figures 22 and 23 in Appendix 2), there was a marked increase in treatment costs due to renal 
complications. When the duration of T1DM increased from 9.5 years to 16.5 years, the costs of 
treating renal complications 4.5-folded, and when the duration increased to 25 years (16.5 to 25 
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years), these costs doubled. Thus, in around 15 years (T1DM duration 9.5 years vs. 25 years) the 
costs of treating renal complications 9-folded. It would be interesting to see how these costs 
develop over an even longer duration of T1DM. Would they still continue to rise and at what 
speed? As the average age in the cohort in 1998 was 35 years (min 19, max 51) and the average 
age at diagnosis was 10 years, the treatment costs due to renal complications would presumably 
continue to rise, but perhaps not at the same speed as before 25 years of T1DM duration. 
Generally, as the duration of T1DM increased from 9.5 years to 16.5 years, all treatment costs 
due to complications, except those due to coma, rose clearly. When these costs were compared in 
the next duration range (16.5 vs. 25 years), there was an increase in treatment costs due to 
cerebrovascular, cardiovascular, peripheral vascular and renal complications and coma. Notably, 
treatment costs of ophthalmic complications first had an almost 3-fold increase (9.5 vs. 16.5 
years), but dropped almost three-quarters as diabetes lasted longer (16.5 vs. 25 years). One 
reason for this may have been the increasing use of outpatient hospital care and the 
developments in treatment practices and medical technology. For example, laser 
photocoagulation has proved to be an effective treatment for diabetic retinopathy, and retinal 
photography is a cost-effective screening method to prevent visual impairment (Pajunpää 1999). 
Also, many ophthalmic patients had most likely become blind, and this fact naturally would have 
decreased hospital use and treatment costs in that complication group. As the duration of T1DM 
increased by 7 years (from 16.5 to 25 years), the treatment costs of all complications combined 
had a slight decrease, but those of total hospital use and especially diabetes without 
complications (code 2500B) had a clear drop. In around 15 years (T1DM duration 9.5 vs. 25 
years), treatment costs due to code 2500B had a considerable drop, well over 90%. This was the 
single main contributor to treatment costs of total hospital use dropping around over 50% in that 
period, as did the costs due to T1DM-related use. During the same period, the treatment costs of 
all complications combined more than doubled.  
Costs per treatment period 
The average annual costs per treatment period for separate complication groups in differing 
durations of T1DM (9.5/16.5/25 years) are compared in Table 11 in Appendix 1 and in Figures 
24 and 25 in Appendix 2. The costs per treatment period due to total use, T1DM-related use, renal 
complications, coma and especially those due to T1DM without complications dropped more in 
the earlier duration period of T1DM (9.5/16.5 years) than in the later one (16.5/25 years).  
In general, despite a few exceptions, average annual costs per treatment period dropped when 
9.5/16.5/25 years of T1DM duration were compared. Comparing the costs when duration of 
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T1DM increased by around 15 years (9.5 to 25 years) is most interesting, as costs per treatment 
period dropped notably (by 20%-50%) in each cost category (except for cerebrovascular, 
cardiovascular and endocrine complications, where the numbers of patients were rather small). 
Costs per treatment period due to total use, T1DM-related use and all complications combined 
declined by one-third as the duration of T1DM increased by 15 years.  
Striking was the decline in costs per treatment period due to ophthalmic complications. When 
T1DM had lasted 9.5 years, the costs due to ophthalmic complications per treatment period were 
the highest of all groups (4,400 €/period), but when T1DM lasted on average 15 years longer, the 
costs per period dropped by over one-half. The reason for this was the marked decreases in bed-
days, LOS and numbers of hospital users. These decreases were obviously due to the reasons 
mentioned earlier (development of treatment practices, technical advancement).  
Costs per hospital user 
Another picture is obtained when average annual treatment costs per hospital user in each 
complication group are compared between different durations of T1DM (9.5/16.5/25 years). 
These figures are presented in Table 12 in Appendix 1 and in Figure 26 in Appendix 2. Total 
costs per user due to all hospitalisations decreased continuously as the duration of T1DM 
increased (by one-quarter between 9.5/16.5 years and 16.5/25 years) because total costs 
diminished more than did the number of hospital users. On the other hand, costs per user due to 
all complications combined first increased by around one-third (between 9.5 and 16.5 years of 
T1DM duration), and then decreased by about the same amount as T1DM lasted on average 25 
years (range 16.5/25 years). Thus, these costs remained at the same level of over 5,000 € per user 
during a 15-year period (9.5/25 years of T1DM).  
A lot of fluctuation was observed in the costs per user in different complication groups, as 
T1DM lasted longer. Treatment costs per hospital user due to ophthalmic complications were the 
highest of all treatment costs for  complications when T1DM had lasted 9.5 years (5,800 € per 
user). When the T1DM duration increased from 16.5 to 25 years, these costs dropped by 50%, 
and the costs per user were now the 6th highest of the 9 complication groups. The main reasons 
for this drop were the considerable decline in hospital bed-days and the decrease in LOS (from 
5.4 to 3.2 days). Again, not surprisingly, costs per user due to treatment of renal complications 
continued to rise as the duration of T1DM increased from 9.5 to 25 years (increase around 50%). 
These costs became the second highest of treatment costs of all complication groups (7,000 
€/user). Although LOS of renal complications declined somewhat when the duration of T1DM 
increased from 9.5 to 25 years (9.1 to 7.4 days), the frequency of hospital visits (discharges/user 
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1.5 to 2.7) and the number of hospital users increased at the same time. Because the increase in 
bed-days, and thus, the increase in treatment costs of renal complications, was bigger than the 
increase in hospital users, costs per hospital user due to renal complications rose clearly.  
Treatment costs per user due to peripheral vascular complications also increased as T1DM 
duration increased to 25 years. An essential reason for this was growth in the amount of use due 
to microangiopathy (ICD 2506B), which in 1998 ranked fourth of all diagnoses causing bed-days 
(at the same level as diabetes without complications, ICD 2500B). A direct comparison of the 
treatment costs of peripheral vascular complications over time is impossible because 
microangiopathy did not have a specific ICD code before 1987. This means that the treatment 
costs due to peripheral vascular complications when T1DM had lasted 9.5 years were 
underestimated. Treatment costs due to other complications of T1DM were most likely 
somewhat overestimated as microangiopathy was possibly coded in that group.  
6.10. Health care costs of persons with T1DM and of T1DM in Finland in 2001 
Costs of inpatient hospital care of T1DM are notable. In this study, the costs of outpatient care 
and medicines were not included. To give a wider picture of this disease, the following 
calculations are informative:     
 
Health care costs of persons with T1DM in Finland 
Health care costs (all) for a person with T1DM were 22,095 FIM (3,717 €) in Helsinki in 1997 
(Kangas 2002). The total cost was over four times higher than for the control group (22,095 FIM 
vs. 5,315 FIM). As the health care costs were 10.4% higher in Helsinki in 1997 than in Finland 
overall (Kangas 2002), the costs for a person with T1DM in Finland would be: 
• 22,095 FIM / 1.104=20,013 FIM (3,366 €).  
This figure is next inflated to the 2001 price level using the price index of municipal health care 
(Hujanen 2003, www.tilastokeskus.fi/tk/hp/kui_kust.html):  
• 2001 index 116.4 / 1997 index 104.6 =1.113 
• 20,013 FIM* 1.113 = 22,375 FIM (3,764 €), which is the total cost of a person with 
T1DM in 2001.  
There were around 45,000 persons with T1DM in Finland in 2000 (Reunanen 2006), so when 
multiplied: 45,000 * 22,375 FIM = 1,007 billion FIM, or 169 million euros. 
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• In 2001, the health care costs of all persons with T1DM in Finland were around 170 
million euros. 
Health care costs of T1DM in Finland 
The excess cost of a person with T1DM compared with the cost of a person without T1DM in 
Helsinki in 1997 was 16,780 FIM (2,823 €) (Kangas 2002). Using the same methodology as 
above, the excess costs of a person with T1DM in Finland in 2001 would be:  
• 16,780 / 1.104 = 15,199 FIM (2,557 €).  
• 15,199 FIM* 1.113 = 16,916 FIM (2,845 €), which is the (excess) cost of T1DM per 
person in 2001.  
• 45,000 * 16,916 = 761 million FIM, or 128 million euros  
• In 2001, the health care costs of T1DM in Finland were around 130 million euros. 
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7. CONCLUSIONS 
1. The length of stay in inpatient care and the total number of yearly bed-days of T1DM 
patients decreased notably with ageing of the patients from 1973 to 1997, but hospital 
visits became more frequent. In nearly all stages of diabetes, women used more hospital 
bed-days than men.  
2. The use of bed-days of T1DM patients due to diabetes (main diagnosis ICD-9 code 
250.xx) was 3- to 4-fold that due to other diagnoses (main diagnosis other than 250), as 
shown by the results during the period from 1973 to 1987. After this period, the use due to 
diabetes decreased steadily, while the use due to other diagnoses increased, reaching the 
level of use due to diabetes in the early 1990s. Increases in the numbers of hospital users 
and discharges contributed to this increase. During the total follow-up period of 25 years, 
the use of bed-days due to diabetes was twice as high as the use due to other diagnoses.  
3. When the duration of T1DM increased on average from 9.5 to 16.5 years with ageing of 
patients, the yearly numbers of bed-days due to all complications of diabetes increased 
almost 3-fold, while the yearly numbers of bed-days due to T1DM without complications 
dropped considerably. The number of bed-days due to renal complications, peripheral 
vascular diseases and ophthalmic complications in particular increased markedly. At this 
stage of diabetes, women consumed clearly more bed-days than men, especially due to 
renal and ophthalmic complications.  
 In 1998, when T1DM had lasted on average 25 years, the proportion of bed-days due to 
renal complications constituted almost 40% of total bed-days, while the share of bed-days 
due to ophthalmic complications was now only 5% of total bed-days. Among the T1DM 
patients having suffered from diabetes for 25 years, male patients used slightly more total 
bed-days and bed-days due to diabetes than female patients.  
 It can be concluded that women use inpatient care more than men during the earlier stages 
of T1DM and obviously get many complications earlier than men, but as T1DM lasts 
longer, male patients catch up to female patients in terms of bed-days consumed.  
4. As the duration of T1DM increased from 9.5 to 16.5 years with ageing of the patients, the 
yearly costs of inpatient care due to diabetic complications 2.5-folded and their share of the 
costs rose to almost half of total costs of inpatient care. Average treatment costs per patient 
for all complication groups (except coma) increased substantially; a vast majority of these 
costs were incurred due to ophthalmic and renal complications and complications 
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classified as other complications. Women's treatment costs were higher than those of men 
in practically every complication group and cost category, although the differences 
between sexes somewhat diminished as duration of T1DM increased (by these 7 years). 
Treatment costs of ophthalmic complications contributed almost half of the growth of costs 
of treatments of all complications at this stage of diabetes.  
 In 1998 (T1DM duration on average 25 years), the yearly costs for treating renal 
complications accounted for half of the treatment costs of all complications of diabetes, 
and the costs of treating renal complications were higher in female patients. At this stage of 
diabetes, the total yearly treatment costs per patient were about the same for both sexes. In 
comparison with the average inpatient costs of municipal somatic specialised care per 
person in Finland in 1998, the inpatient treatment costs per T1DM patient were 
considerably higher (roughly 1.7-5.5 times higher, depending on age and sex).  
5. Besides the notable inpatient costs of T1DM calculated in this study, T1DM obviously 
causes considerable outpatient costs as well as loss of quality and lenght of life. These 
costs and losses should be addressed in future studies. 
6. The results of this study showed that in the early phases of T1DM, T1DM without 
complications causes a considerable amount of inpatient bed-days. The use of inpatient 
care increases with ageing of patients; an important cause of this increase is the 
development of complications of diabetes. These results combined with the high incidence 
of T1DM in Finland indicate that the economic burden of inpatient care of T1DM is 
substantial. Measures to prevent T1DM and its complications and treatments focused on 
complications of T1DM should be developed.  
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Table 1. Number of bed-days and discharges, and mean length of stay (LOS) of diseases (by diagnoses) causing 
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Table 2. Shares (%) of the annual costs of complication groups of total inpatient costs and 
shares (%) of the annual costs of complication groups of the costs of all 
complications, by duration of T1DM 
 
 Shares (%) of total costs Shares (%)  of complication costs 
  T1DM 9.5 yrs.  T1DM 16.5 yrs.  T1DM 9.5 yrs.   T1DM 16.5 yrs.  
CERVASC 0.1 0.3 0.8 0.7 
CARVASC 0.0 0.8 0.3 1.8 
PERVASC 0.4 2.6 2.5 5.6 
NEUROL 0.4 0.8 3.1 1.9 
RENAL 1.8 10.3 12.4 22.5 
ENDOCRIN 0.0 0.0 0.0 0.0 
OPHTHALMIC 4.8 17.4 34.2 38.1 
OTHER complicat. 5.3 12.7 37.7 27.9 
COMA 1.3 0.7 9.1 1.4 
Complications total    
Hypoglycaemia 0.0 0.3 0.0 0.8 
2500B/25000 60.9 15.7 428.7 34.4 
Rest of other use 25.0 38.6 175.8 84.4 
OTHER use 85.8 54.3 604.5 118.8 
T1DM use 75.0 61.4 528.7 134.4 
TOTAL use     
          
 
cervasc = cerebrovascular disease; carvasc = cardiac disease; pervasc = peripheral vascular disease; 
neurol = neurological complications; renal = renal complications; endocrin = endocrine complications;  
ophthalmic = ophthalmic complications; 2500B/25000 = T1DM without complications (ICD-9/ICD-8 codes); 
other use = hypoglycaemia + 2500B/25000 + rest of other use (any inpatient use other than T1DM-related);  
T1DM use = complications total + 2500B/25000 
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14.2 45.7 100.0 100.0
100.0 100.0 704.5 218.8
   
Table 3. Average annual costs (€) per patient in the cohort by complication group and by 
duration of T1DM and changes (%) in costs with the increased duration of 
diabetes. 
 
        
 Costs per Costs per Change in 
 patient patient costs (%) 
   T1DM 9.5 yrs  T1DM 16.5 yrs 9.5/16.5 yrs 
CERVASC 1.5 3.6 131.4 
CARVASC 0.6 9.2 1406.4 
PERVASC 5.0 28.6 472.2 
NEUROL 6.2 9.4 51.5 
RENAL 24.5 114.2 365.4 
ENDOCRIN 0.0 0.1  
OPHTHALMIC 67.8 193.2 184.8 
OTHER complicat. 74.8 141.3 88.8 
COMA 18.0 7.3 59.8 
Complications total 198.6 506.9 155.2 
Hypoglycaemia  3.8  
2500B/25000 851.4 174.5 79.5 
Rest of other use 349.2 427.6 22.5 
OTHER use 1,200.6 602.1 49.9 
T1DM use 1,050.1 681.3 35.1 
TOTAL use 1,399.2 1,109.0 20.7 
        
 
cervasc = cerebrovascular disease; carvasc = cardiac disease; pervasc = peripheral vascular disease; 
neurol = neurological complications; renal = renal complications; endocrin = endocrine complications;  
ophthalmic = ophthalmic complications; 2500B/25000 = T1DM without complications (ICD-9/ICD-8 codes); 
other use = hypoglycaemia + 2500B/25000 + rest of other use (any inpatient use other than T1DM-related);  
T1DM use = complications total + 2500B/25000 
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Table 5.  Numbers of hospital users in 1998 by complication group and sex 
 
 Number of Number of Number of 
 users, users, users, 
  total females males 
CERVASC 3 1 2 
CARVASC 22 12 10 
PERVASC 32 16 16 
NEUROL 13 2 11 
RENAL 149 73 76 
ENDOCRIN 0 0 0 
OPHTHALMIC 86 41 45 
OTHER complications 148 65 83 
COMA 36 12 24 
Complications total 412 190 222 
Hypoglycaemia 1 0 1 
2500B 53 24 29 
Other use 244 119 125 
TOTAL use 566 269 297 
    
        
Total N in the cohort 4,701 2,168 2,533 
 
cervasc = cerebrovascular disease; carvasc = cardiac disease; pervasc = peripheral vascular disease; 
neurol = neurological complications; renal = renal complications; endocrin = endocrine complications;  
ophthalmic = ophthalmic complications; 2500B = T1DM without complications (ICD-9 code); 
other use = hypoglycaemia + 2500B + rest of other use (any inpatient use other than T1DM-related);  
total use = complications total + other use  
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Table 6. Number of inpatient discharges per 1000 patient in 1998 by complication group 
               and sex 
        
    
 Discharges per Discharges Discharges 
 1,000 patients, 1,000 patients, 1,000 patients, 
  total females males 
CERVASC 0.6 0.5 0.8 
CARVASC 5.7 6.0 5.5 
PERVASC 20.4 13.4 26.5 
NEUROL 4.5 0.9 7.5 
RENAL 86.2 94.1 79.4 
ENDOCRIN 0.0 0.0 0.0 
OPHTHALMIC 25.1 24.0 26.1 
OTHER complications 43.4 38.7 47.4 
COMA 8.3 5.5 10.7 
Complications total 194.2 183.1 203.7 
Hypoglycaemia 0.2 0.0 0.4 
2500B 13.6 14.8 12.6 
Rest of other use 62.5 67.8 58.0 
Other use 76.2 82.6 70.7 
T1DM use 208.0 197.9 216.7 
TOTAL use 270.4 265.7 274.4 
        
    
cervasc = cerebrovascular disease; carvasc = cardiac disease; pervasc = peripheral vascular disease; 
neurol = neurological complications; renal = renal complications; endocrin = endocrine complications;  
ophthalmic = ophthalmic complications; 2500B = T1DM without complications (ICD-9 code); 
other use = hypoglycaemia + 2500B + rest of other use (any inpatient use other than T1DM-related);  
T1DM use = complications total + 2500B; total use = complications total + other use  
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Table 7.  Number of discharges per hospital user in 1998 by complication group and sex 
        
 Discharges Discharges Discharges 
 per user, per user, per user, 
  total females males 
CERVASC 1.0 1.0 1.0 
CARVASC 1.2 1.1 1.4 
PERVASC 3.0 1.8 4.2 
NEUROL 1.6 1.0 1.7 
RENAL 2.7 2.8 2.6 
ENDOCRIN 0.0   
OPHTHALMIC 1.4 1.3 1.5 
OTHER complications 1.4 1.3 1.4 
COMA 1.1 1.0 1.1 
Complications total 2.2 2.1 2.3 
Hypoglycaemia 1.0 0.0 1.0 
2500B 1.2 1.3 1.1 
Other use 1.5 1.5 1.4 
TOTAL use 2.2 2.1 2.3 
        
    
cervasc = cerebrovascular disease; carvasc = cardiac disease; pervasc = peripheral vascular disease; 
neurol = neurological complications; renal = renal complications; endocrin = endocrine complications;  
ophthalmic = ophthalmic complications; 2500B = T1DM without complications (ICD-9 code); 
other use = hypoglycaemia + 2500B + rest of other use (any inpatient use other than T1DM-related);  
total use = complications total + other use  
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Table 8.  Number of bed-days per 1000 patients in 1998 by complication group and sex 
        
    
 Bed-days per Bed-days per Bed-days per 
 1,000 patients, 1,000 patients, 1,000 patients, 
  total females males 
CERVASC 32.1 62.7 5.9 
CARVASC 44.0 55.4 34.3 
PERVASC 112.1 83.9 136.2 
NEUROL 17.7 0.9 32.0 
RENAL 638.6 712.6 575.2 
ENDOCRIN 0.0 0.0 0.0 
OPHTHALMIC 81.0 68.7 91.6 
OTHER complications 256.5 186.3 316.6 
COMA 29.1 17.5 39.1 
Complications total 1,211.2 1,188.2 1,231.0 
Hypoglycaemia 0.2 0.0 0.4 
2500B 74.5 69.6 78.6 
Rest of other use 394.2 417.0 374.7 
Other use 468.6 486.6 453.2 
T1DM use 1,285.9 1,257.8 1,309.9 
TOTAL use 1,679.9 1,674.8 1,684.2 
        
    
cervasc = cerebrovascular disease; carvasc = cardiac disease; pervasc = peripheral vascular disease; 
neurol = neurological complications; renal = renal complications; endocrin = endocrine complications;  
ophthalmic = ophthalmic complications; 2500B = T1DM without complications (ICD-9 code); 
other use = hypoglycaemia + 2500B + rest of other use (any inpatient use other than T1DM-related);  
T1DM use = complications total + 2500B; total use = complications total + other use  
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Table 9.  Single diagnoses causing most inpatient care (bed-days, discharges, LOS's) 
               in 1998, when duration of T1DM was on the average 25 years (19-33 years) 
          
 Number of Number of   
ICD-9 code bed-days discharges LOS Diagnosis 
     
Total hospital use    
2503A,B 2,917 389 7.5 Nephropathia diabetica 
2507A,B,X 972 175 5.6 Complicatione alia (definita) 
2500A,B 405 77 5.3 Diabetes, sine complicatione 
2506A,B 394 76 5.2 Microangiopathia diabetica 
2501A,B 232 44 5.3 Ketoacidosis 
3620A,B 194 64 3.0 Retinopathia diabetica 
2961A 142 2 71.0 Depressio mentis gravis  
2502A,B 137 39 3.5 Coma diabeticum 
4340A 136 1 136.0 Thrombosis cerebri 
2504A 126 29 4.3 Cum complicatione oculi 
2508A,B 120 20 6.0 Complicatione non descripta, NUD 
5678X 103 12 8.6 Peritonitis alia definita 
5672A 99 16 6.2 Peritonitis suppurativa diffusa  
4140X, 
4148B,X 82 8 10.3 Morbi cordis ischaemici alii.  
4402A 79 11 7.2 Atherosclerosis 
6951C 67 2 33.5 Casus erythematodes syndroma Lyell  
2505A,B 66 10 6.6 Neuropathia diabetica 
4100B,X 65 5 13.0 Infarctus myocardii acutus.  
2961E 60 1 60.0 Depressio mentis gravis  
0388X 58 3 19.3 Septichaemia alia definita  
3101A 55 1 55.0 Perturbatio mentis per laesionem cerebri  
6819X 54 2 27.0 Cellulitis 
7870A 53 12 4.4 Symptomata organorum digestionis. 
     Nausea et emesis 
0350X 47 6 7.8 Erypipelas alia definita seu NUD  
3000A 37 3 12.3 Neuroses  
     
     
     
 Number of Number of   
ICD-9 code bed-days discharges LOS Diagnosis 
     
Cerebrovascular complications   
4340A 136 1 136.0 Thrombosis cerebri 
4318X 9 1 9.0 Haemorrhagia intracerebralis 
4360A 6 1 6.0 Morbus cerebrovascularis alius sive non  
    definitus.  
     
Cardiovascular 
complications    
4140X 44 5 8.8 Morbi cordis ischaemici alii.  
4100B 40 2 20.0 Infarctus myocardii acutus  
4100X 25 3 8.3 Infarctus myocardii acutus 
4148B 24 2 12.0 Morbi cordis ischaemici alii.  
4289X 21 1 21.0 Insufficientia cordis.  
4148X 14 1 14.0 Morbi cordis ischaemici alii.  
4254A 12 2 6.0 Cardiomyopathia 
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Peripheral vascular complications   
2506B 356 65 5.5 Microangiopathia diabetica 
4402A 79 11 7.2 Atherosclerosis 
2506A 38 11 3.5 Microangiopathia diabetica 
4518X 24 2 12.0 Phlebitis, thrombophlebitis et trombosis  
    phlebarum  
4438X 20 2 10.0 Alii morbi vascularis peripherici.  
     
     
Neurological complications    
2505A 37 2 18.5 Neuropathia diabetica 
2505B 29 8 3.6 Neuropathia diabetica 
7135A 9 8 1.1 Arthropathia reactiva alia cum morbo  
    systematis nervosi.  
     
     
 Number of Number of   
ICD-9 code bed-days discharges LOS Diagnosis 
     
Renal complications    
2503B 2,214 294 7.5 Nephropathia diabetica 
2503A 703 95 7.4 Nephropathia diabetica 
5901A 36 8 4.5 Infectio renis 
5850B 21 2 10.5 Insufficientia renis chronica.  
     
Endocrine complications    
…     
     
Opthalmic complications    
3620B 173 59 2.9 Retinopathia diabetica 
2504A 116 24 4.8 Cum complicatione oculi 
3664A 37 21 1.8 Cataracta diabetica 
3620A 21 5 4.2 Retinopathia diabetica 
3682A 16 1 16.0 Diplopia.  
2504B 10 5 2.0 Cum complicatione oculi 
     
Other complications    
2507B 896 160 5.6 Cum complicatione alia 
2508B 88 17 5.2 Cum complicatione non descripta 
2507A 59 12 4.9 Cum complicatione alia 
6819X 54 2 27.0 Cellulitis 
2508A 32 3 10.7 Cum complicatione non descripta 
6829X 27 2 13.5 Cellulitis 
2507X 17 3 5.7 Cum complicatione alia 
6828X 17 2 8.5 Cellulitis 
5589X 16 3 5.3 
Gastroenteritis seu colitis alia 
noninfectiosa  
     
Coma     
2502B 129 36 3.6 Coma diabeticum 
2502A 8 3 2.7 Coma diabeticum 
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APPENDIX 2. FIGURES IN APPENDIX 2 
Figure 1.  Mean number of yearly discharges per 1000 patients by complication group, duration of T1DM and sex 
Figure 2.  Proportional change (%) in mean yearly discharges and bed-days during the follow-up (9,5 to 16,5 years ) 
by complication group and sex 
Figure 3.  Mean number of yearly discharges per hospital user in each complication group and for other use and 
total use by duration of T1DM and sex 
Figure 4.  Percentages of yearly bed-days due to complications out of all bed-days due to complications by 
complication group, duration of T1DM and sex 
Figure 5.  Mean number of yearly bed-days per 1000 patients by complication group, duration of T1DM and sex 
Figure 6.  Mean yearly number of bed-days per hospital user in each complication group and for other use and total 
use by duration of T1DM and sex 
Figure 7.  Mean length of stay (LOS) in hospital in each complication group and for other use and total use by 
duration of T1DM and sex 
Figure 8.  Average annual costs (€) per person by complication group, duration of T1DM and sex 
Figure 9. Average annual costs (€) per person by duration of T1DM and sex for all complications, T1DM without 
complications, other inpatient use, T1DM-related use and total use 
Figure 10. Annual costs (€) per inpatient hospital user by complication group and duration of T1DM 
Figure 11. Annual costs (€) per inpatient hospital user by complication group, duration of T1DM and sex 
Figure 12. Annual costs (€) per treatment period by complication group and duration of T1DM 
Figure 13. Annual costs (€) per treatment period by complication group, duration of T1DM and sex 
Figure 14. Shares (%) of bed-days due to complications in 1998 by complication group and sex 
Figure 15. Number of bed-days per 1000 patients in 1998 by complication group and sex 
Figure 16. Number of bed-days per hospital user in 1998 by complication group and sex 
Figure 17. Shares (%) of the costs of inpatient care due to complications in 1998 by sex 
Figure 18. Shares (%) of the costs of total inpatient care in 1998 by sex 
Figure 19. Mean cost (€) of inpatient care per patient in 1998 by complication group and sex 
Figure 20. Costs (€) of inpatient care per hospital user in 1998 by complication group and sex 
Figure 21. Costs (€) of inpatient care per treatment period in 1998 by complication group and sex 
Figure 22. Average annual inpatient costs of complications per patient, when duration of T1DM is 9.5, 16.5 or 25 years 
Figure 23. Average inpatient costs of per patient, when duration of T1DM is 9.5, 16.5 or 25 years 
Figure 24. Average annual inpatient costs per treatment period due to complications, when duration of T1DM is 9.5, 
16.5 or 25 years 
Figure 25. Average annual inpatient costs per treatment period, when duration of T1DM is 9.5, 16.5 or 25 years 
Figure 26. Average annual inpatient costs per hospital user, when duration of T1DM is 9.5, 16.5 or 25 years 
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